{"title": "PDF", "author": "PDF", "url": "http://www.arecibo.inter.edu/wp-content/uploads/portal/pdf/inter_scientific_06.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "Inter  Scientific\nInqu Iry \u2022 nature  \u2022 technology  \u2022 evolut Ion \u2022 research\nvol. 6 - a ugust  2019\nINTER  SCIENTIFIC  \n \n \nCONTENIDO  \nCONTENTS \n \n \nMENSAJE DEL RECTOR / MESSAGE FROM THE CHANCELLOR \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..1  \n  \nMENSAJE DE LA DECANA DE ASUNTOS ACAD\u00c9MICOS / MESSAGE FROM THE  \nDEAN OF ACADEMIC AFFAIRS \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u20261  \n \nDESDE EL ESCRITORIO DE LA EDITORA / FROM THE EDITOR \u2019S DESK\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026... .2 \n \nINVESTIGACI\u00d3N / RESEARCH ARTIC LES\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026... ..3-22 \n \n\uf0b7 Evaluation of phenolic compounds from ginger, curcuminoids and EHop -16 to activate \ncaspases and induce apoptosis in adenocarcinoma of the panc reas \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...3 \n \nEvaluaci\u00f3n de compuestos fen\u00f3licos del jengibre, curcuminoides y EHop -16 para la activaci\u00f3n de \ncaspasas y la inducci\u00f3n de apo ptosis en adenocarcinoma pancre\u00e1tico \n Acevedo, Natalia, Marrero, Cristopher, Ongay, Kevin, Ortiz, Joshua, Torres, Joaneliz, Woolcock, Karen   \n \n\uf0b7 Adaptations in the vocalizations of Margarops fuscatus  and Turdus plumbeus  in urban \nenvironments \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 .\u2026\u2026\u2026\u2026\u2026.. 10 \n \nAdaptaciones en las vocalizaciones de Margarops fuscatus  y Turdus plumbeus  en ambientes urbanos  \n Aparicio Massanett, Julissa , Fern\u00e1ndez P\u00e9rez, Tatiana \n \n\uf0b7 Estudio sobre la evoluci\u00f3n de la seguridad en la tecnolog\u00eda de la nube en los pasados cinco a\u00f1os \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.. ..\u202614 \n Study on the evolution of security in cloud technology in the last five years \n Nieves-M\u00e9nd ez, Alexander  \n \nART\u00cdCULOS DE REVISI\u00d3N / REVIEW ARTICLE S\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...\u2026.. .23-42 \n \n\uf0b7 Methicillin-resistant Staphylococcus aureus  and the effectiveness of vancomycin in hospitals \nand nursing homes \u2026\u2026\u2026.\u2026\u2026\u2026 \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.... 23  \n \nStaphylococcus aureus resistente a la meticilina y l a efectividad de la v ancomicina en hospitales y \nhogares de ancianos  \n \nSoto- Balseiro, Romina, P\u00e9rez -Albino, Ileanmarie, Mel\u00e9ndez -Vel\u00e1zquez, Daziury, Torres -Bugar\u00edn, \nOlivia  \n  \n INTER  SCIENTIFIC  \n \n \n  \n  \n \n  \n\uf0b7 Adherencia terap\u00e9utica en el adulto mayor que vive con VIH: barreras y facilitadores  \n\u2026\u2026\u2026\u2026\u2026.. \u2026\u2026..\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...\u2026\u2026.. ..35 \n \nTherapeutic adherence in the elderly living with HIV: barriers and facilitators  Cabrera Montero, Isaida \n \n \nOTRAS  INVESTIGACIONES  EN EL CAMPUS / OTHER R ESEARCH  ON C AMPUS  \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 43 \n \nResumen de otras investigaciones realizadas por nuestros estudiantes en el R ecinto durante el a\u00f1o \nacad\u00e9mico 2018-2019 en los campos de farmacolog\u00eda y  bioqu\u00edmica , ecolog\u00eda y qu\u00edmica. \n \nSummary of other r esearch conducted on campus by our students  during the academic year of 2018 -2019  in the fields of \npharmacology  and biochemistry , ecology and chemistry . \n                                                           \nFARMACOLOG\u00cdA -BIOQU\u00cdMICA / PHARMACOLOGY -BIOCHEMISTRY  \n \n1-A Time -course analysis of PANC -1 cells viability after exposure to phytochemicals and evaluation of \nthe pharmacological interactions with synthetic compounds \n \n1-B  Apoptosis induction and detection of E -cadherin expression on PANC -1 cells after treatment with \nEHop- 16 and 6-shogaol \n \nECOLOG\u00cdA / ECOLOGY  \n \n2-A Bacterial (16S) and Symbiodiniaceae (ITS2) metagenomic analyses in the endangered coral \nDendrogyra cylindrus  (Scleractinia: Meandrinidae) from north central and southwes tern Puerto \nRico. \n \nQU\u00cdMICA / CHEMISTRY  \n \n3-A S\u00edntesis de nanopart\u00edculas de plata, caracterizaci\u00f3n y efectos bactericidas \n \n3-B  Obtenci\u00f3n de biodiesel por medio de aceite de cocina usado \n \nPOL\u00cdTICAS EDITORIALES / EDITORIAL POLICIES\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026. 46 \n \n  \n \n  INTER  SCIENTIFIC  \n \n \n \n  \nM\nENSAJE DEL RECTOR  \nDR. RAFAEL RAM\u00cdREZ RIVERA  \n \nReiteramos nuestra f elicitaci\u00f3n  a la facultad y  a sus estudiantes por continuar desarrollando proyectos de \ninvestigaci\u00f3n de envergadura y vanguardia. En este sexto volumen de Inter Scientific  se presentan trabajos \ndel campo de la farmacolog\u00eda, ecolog\u00eda , ciencias de computadoras , microbiolog\u00eda y enfermer\u00eda . Extendemos \nnuestra felicitaci\u00f3n al Decanato de Asuntos Acad\u00e9micos por promover la investigaci\u00f3n y el apoyo incondicional \na esta publicaci\u00f3n.   \n \nM\nESSAG E FROM THE CHANCELLOR  \nDR. RAFAEL RAM\u00cdREZ RIVERA  \n \nCongratulations to the faculty and students for continuing to develop  research projects of scope, span and vanguard. In this \nsixth volume of Inter Scienti fic there are projects in the fields of  pharmacolog y, ecology, computer sciences, microbiology \nand nursing. We extend our congratulations and thanks to the Dean of Academic Affairs for promoting research and the \nunconditional support for this publication.  \n \n \nMENSAJE DE LA  \nDECANA DE ASUNTOS ACAD\u00c9MICOS  \nDRA. ANNETTE VEGA \n \nEn esta edici\u00f3n nos complce presentar una diversidad de \u00e1reas tem\u00e1ticas en las investigaciones. Una vez \nm\u00e1s, la comunidad estudiantil y la facultad aportando nueva informaci\u00f3n a trav\u00e9s de la investigaci\u00f3n. \nAgradecemos a todos los que de una manera u otra aportan al desarrollo y publicaci\u00f3n de la revista cient\u00edfica del Recinto de Arecibo.\n \n  M\nESSAGE FROM THE  DEAN OF ACADEMIC AFFAIRS  \nDR. ANNETTE VEGA \n \nIn this edition we are pleased to present a diversity of thematic areas in the research projects. O nce again, students and \nthe faculty providing new information through research. We thank all those who in one way or another contribute to the \ndevelopment and publication of the scientific journal of the Arecibo Campus.  \n \n \n  \n \n  \n \n \n1 Vol. 6 - 2019Vol. 6 - 20192INTER  SCIENTIFIC  \n \n \n  \n  \n \n \nDESDE EL ESCRITORIO DE L A EDITORA  \nDRA. LIZBETH ROMERO -P\u00c9REZ  \n \nQueremos presentarle nuestro sexto volumen de Inter Scientific . En este compartimos tres art\u00edculos de \ninvestigaci\u00f3n y dos art\u00edculos de revisi\u00f3n de estudiantes en diversas universidades. \n La primera investigaci\u00f3n nos presenta compuestos naturales y sint\u00e9ticos siendo evaluados por su efecto en \nadenocarcinoma pancre\u00e1tico. Este trabajo fue realizado por estudiantes del programa de bachillerato en \nBiotecnolog\u00eda de nuestro Recinto, dirigidos por la Dra. Karen Woolcock. El segu ndo trabajo tiene como objetivo \nevaluar las adaptaciones en vocalizaciones en el zorzal pardo y el zorzal patirrojo en ambientes urbanos. Este \nfue realizado por estudiantes de la Universidad de Puerto Rico en Mayaguez, bajo la mentor\u00eda del Dr. Alberto \nPuen te. La tercera investigaci\u00f3n es en el campo de las ciencias de computadoras y recoge la evaluaci\u00f3n de la \ntecnolog\u00eda de la nube en los pasados cinco a\u00f1os. El primer art\u00edculo de revisi\u00f3n presenta el problema de \ninfecci\u00f3n por una bacteria resistente a antibi\u00f3 ticos en hospitales. Este manuscrito fue d esarrollado por \nestudiantes de Medicina de la Universidad Aut\u00f3noma de Guadalajara, M\u00e9xico. El segundo art\u00edculo de revisi\u00f3n \nnos plantea la adherencia a tratamiento en una poblaci\u00f3n espec\u00edfica con el Virus de Inmunodeficiencia Humana \n(VIH). En la secci\u00f3n Otras Investigaciones en el Campus , encontrar\u00e1 res\u00famenes de otros trabajos que se han \nestado realizando en nuestro Recinto en los campos de farmacolog\u00eda y bioqu\u00edmica, ecolog\u00eda y qu\u00edmica.\n \n \n \nFROM THE EDITOR \u2019S DESK \nDR. LIZBETH ROMERO -P\u00c9REZ  \n \nWith great pride, we present our sixth volume of Inter Scientific . In this occasion we are sharing five excellent manuscripts; \nthree research articles and two review articles.  \n \nThe first research presents the evaluation of natural and synthetic compounds and their effect on pancreatic adenocarcinoma. This project was developed by Biotechnology students in our Campus directed by Dr. Karen Woolcock. The objective of the second research is to evaluate the adaptations in the vocalizations of the brown thrush and the red -\nfooted thrush in urban environments. This research was done by students at the University of Puerto Rico in Mayaguez \nmentored by Dr. Alberto Puente. The third research presented is in the computer sciences field and it evaluates the ev olution \nof cloud technology in the past five years. The first review article states the problem of antibiotic -resistant bacteria in \nhospitals. This manuscript was developed by students at the Universidad Aut\u00f3noma de Guadalajara in Mexico, School of \nMedicine. The second article raises the concern on treatment adherence in a particular population infected with the Human \nImmunodeficiency Virus (HIV). In the section Other Research on Campus  you will find abstracts for other research projects \nworked in  the fields of pharmacology and biochemistry, ecology and chemistry.  \n \n \n \n \n  \n \n \n  Vol. 6 - 20193INTER  SCIENTIFIC  \n \n \n   Evaluation of phenolic compounds from ginger, curcuminoids and \nEHop -16 to activate caspases and induce apoptosis  \nin adenocarcinoma of the pancreas  \n \nEvaluaci\u00f3n de compuestos f en\u00f3licos del jengibre, curcuminoides y EHop -16 para la activaci\u00f3n de \ncaspasas y la inducci\u00f3n de apoptosis en adenocarcinoma pancre\u00e1tico \n \nAcevedo, N. , Marrero , C., Ongay , K., Ortiz, J. , Torres , J., and Woolcock, K.    \n \nInter American University of Puerto Ric o, Arecibo Campus, Science and Technology Department  \n \nABSTRACT \n \nPancreatic ductal adenocarcinoma is a highly aggressive type of cancer that is commonly treated with a wide range of \nchemotherapeutic drugs, but a major drawback is that is highly resistant to  the pharmacological action of these drugs. \nTherefore, it is important to evaluate alternate approaches to improve patient prognosis. Since natural products derived from  \nCurcuma longa  and Zingiber officinale  are known to induce apoptosis in several type of  malignant cells, the effect of zingerone, \n6-shogaol , curcumin and bisdemethoxycurcumin to induce a regulated dead process in PANC -1 cells was evaluated. Also, the \neffect of synthetic compounds such as gemcitabine, the current ly approv ed pharmacological th erapy, and Ehop -16 a novel \ncompound were  studied. Among the natural compounds , curcumin followed by 6-shogaol  were the most effective for activating \nmultiple caspases and for inducing apopto tic mechanisms. The activation of caspases was dose dependent and time dependent \nfor both compounds. Although EHop -16 produced activation of caspase, after 48 hours only 25% of the caspase activity was \nimplicated in cell death, therefore it is possible that activated caspases are not all related to a regulated cell death  process.  \n \nRESUMEN \n \nEl adenocarcinoma ductal pancre\u00e1tico es un tipo de c\u00e1ncer muy agresivo cuyo tratamiento envuelve  quimioterapias con  una amplia \nvariedad de f\u00e1rmacos . Una desventaja que presenta , es su alta resistencia  a la acci\u00f3n de dichas terapias.  Por lo tanto, es importante \nevaluar distintos enfoques o alternativas para mejorar el pron\u00f3stico del paciente . Se conoce que productos naturales derivados de \nCurcuma longa y Zingiber officinale  inducen apoptosis en varios tipos de c\u00e9lulas malignas. En este estudio evaluamos el efecto de \nzingerone, 6-shogaol , curcumina y bisdimethoxycurcumina en la inducci\u00f3n de un proceso de muerte regulada en c\u00e9lulas PANC -1. \nTambi\u00e9n estudiamos el efecto de compuestos sint\u00e9ticos incluyendo  gemcitabina, que es el f\u00e1rmaco aprobad o como terapia y Ehop -16. \nEntre los compuestos naturales, curcumina seguido por 6-shogaol fueron los mas efectivos para activar m\u00faltiples caspasas e inducir \napoptosis. La activaci\u00f3n de caspasas fue dependiente de dosis y de tiempo para ambos compuestos. En  cuanto a los compuestos \nsint\u00e9ticos, Ehop -16 provoc\u00f3 activaci\u00f3n de caspasas a las 48 horas, pero solamente 25% de dicha actividad fue implicada en muerte \ncelular. Es posible que la activaci\u00f3n de caspasas no este toda relacionada a un proceso  de muerte celular. \n \nKEYWORDS pancreatic adenocarcinoma, apoptosis, caspase activity, ginger, curcuminoids, EHop -16, gemcitabine, regulated cell \ndeath  \n \nPALABRAS CLAVE  adenocarcinoma pancre\u00e1tico , apoptosis, actividad de caspasa, jen gibre, curcuminoides, Ehop -16, gemcitabi na, \nmuerte celular regulada \n \nINTRODUCTION  \n \nPancreatic cancer is a type of disease in which the healthy cells of \nthe pancreas stop working properly and grow out of control. As of \ntoday, there are two types of pancreatic cancers: the \nneuroendocrine tumor  and pancreatic ductal adenocarcinoma, the \nlatter being the most common. Pancreatic ductal adenocarcinoma is a highly aggressive epithelial cancer with a 5 -year survival rate of less than 5% and a median survival of approximately 6 -8 months \nfrom the time of diagnosis (Samulitis  et al., 2015). Since a high \nproportion of patients with this type of cancer are diagnosed at late -\nstages, only 10 \u201320% of pancreatic cancer patients are suitable for \nsurgical resection of the cancer. Current chemotherapy and radiother apies are largely ineffective in treating this type of cancer.  Vol. 6 - 20194INTER  SCIENTIFIC  \n \n \n Advanced pancreatic cancer still has a poor prognosis, even with \nthe approval of several new drugs, like gemcitabine (Zhou et al., \n2014) which is one of the most frequently used drugs to treat  this \ncondition. After cellular uptake, gemcitabine is phosphorylated \ninside the cell by deoxycytidine kinase (dCK) and converted to \ngemcitabine di - and triphosphate by deoxycytidine kinase (dCK) \nproducing termination of DNA elongation (Mini,  Nobili, Cacia gli, \nLandini, & Mazzei,  2006). Unfortunately, a downside of \ngemcitabine is its toxicity to normal tissues and the acquisition of \nresistance by tumor cells (Zhou et al., 2014). Studies has shown \nthat natural compounds derived from ginger have a variety of  \npharmacological properties including antioxidant, anti -\ninflammatory, and anticancer activities being the most significant \nthe inhibition of  angiogenesis during tumor progression (Bae,  \nChoi, Kim, Park, & Jeong, 2016). Other promising natural \ncompound s are th ose derived from Curcuma longa  commonly \nknown as turmeric (Shah et al., 2018). The extract of turmeric contains 77% curcumin, 17% demethoxycurcumin, and 3% bisdemethoxycurcumin, collectively named curcuminoids (Chin,  \n2016). Curcumin has been shown to posse ss anticancer activity \nagainst pancreatic cancer through its effect on NF \u03ba\u03b2 (Huang et al., \n2017). Another approach that can be considered for treating pancreatic cancer is the synthetic compound  EHop-16, a GTPase \nRac inhibitor that blocks Rac who has been shown to regulate \nbreast cancer cell migration, survival, and proliferation (Montalvo -\nOrtiz et al., 2012).  \n A hallmark of malignant cells is their ability to evade the \nmechanisms of regulated cell death, producing dysregulated \ncellular proliferation. Apopt osis is a regulated cell death process \nthat occurs in two different pathways; the extrinsic and intrinsic. \nThis mechanism is highly organized and depends on cysteine rich \naspartates known as caspases. Among these are the initiator \ncaspases (8 and 9) that will eventually lead to the activation of the effector caspases (3 and 7) that play a key role in the final demise of the cell. Since both, synthetic and natural compounds have the ability to induce apoptosis, it is possible that either components can \nimpro ve the apoptotic pathways in pancreatic cancer. Since \nmalignant cells can be resistant to apoptosis, the objective of this \nstudy was to evaluate the efficacy of natural compounds derived from ginger ( zingerone, 6-shogaol ), curcuminoids and the \nsynthetic co mpound EHop -16 for inducing apoptosis on the human \npancreatic adenocarcinoma cell line PANC -1, in comparison with \ngemcitabine, the main current treatment for pancreatic cancer.  \n \nMATERIALS AND METHODS \n \nMaterials  \n \nZingerone, 6-shogaol , gemcitabine, DMSO (Hy briMax), \ncurcumin, b isdemethoxycurcumin (BDMC), staurosporine and \nEHop- 16 where purchased from Sigma/Millipore (MA, USA). \nStock solutions of the treatments where prepared at a concentration \nof 100  mM and stored as small aliquots at -20\u00b0C. 6-shogaol  was prepared at 74.4  mM. Further dilution of the treatments was done \nwith cell culture media. The Multicaspase assay was purchased from Sigma/Millipore (MA, USA).  \n \nCell line and maintenance  \n \nThe human pancreatic adenocarcinoma cell line, PANC -1 was \nobtained fro m the American Type Culture Collection Manassas \nVA, USA (ATCC\u00ae CRL1469\u2122). The cells were maintained in a \nhumidified incubator (Galaxy 170R New Brunswick) at 37\u00b0C with \n5% carbon dioxide. Cells were fed every other day with Dulbecco\u2019s Modified Eagle\u2019s medium  (DMEM) supplemented \nwith 10% fetal bovine serum and with streptomycin (0.1 mg/mL) and penicillin (100 U). Cell concentration and viability was determined manually counting cell with the hemocytometer, using \ntrypan blue to exclude dead cells.  \n \nMultiCaspase Assay  \n \nThe detection of caspase activation on PANC -1 cells was \ndetermined using the MultiCaspase kit, obtained from \nSigma/Millipore (MA, USA), according to manufacturer\u2019s \ninstructions (EMD Millipore Corporation, 2013). Cell confluence was observed previou sly to determine the preferable flask to \nperform the assay. The seeding of cells was done at a density of 5x10\n5 cells/well. Cells were exposed in duplicates to each \ntreatment ( 6-shogaol , zingerone, gemcitabine, c urcumin, BDMC \nand EHop -16) diluted previousl y in DMEM at concentrations of \n10, 25, 50, and 100  \u03bcM. DMSO and staurosporine were used as \ncontrols for the assay. The exposure time of the treatments was 24 and 48 hours. Cells were analyzed using the Muse Cell Analyzer. The range of evaluated events (total cells) were between 5 x 10\n4 \ncells/mL up to 2 x 1 05 cells/mL. \n \nData analysis  \n \nAll graphs were constructed using Graph Pad Prism 8.1.2  software. \nMicrosoft Excel was used to organize quantitative data.  \n RESULTS  Study of activation of multiple caspase and caspase mediated cell death  \n \nThe activation of mul tiple caspases (1, 3, 4, 5, 6, 7, 8, and 9) was \nevaluated by flow cytometry after treating PANC -1 cells during \n24 and 48 hours with ginger derivates (zingerone and 6-shogaol ), \ncurcuminoids (curcumin and b isdemethoxycurcumin), EHop -16 \nor gemcitabine, at 10,  25, 50 and 100  \u03bcM, using DMSO (0.0001, \n0.01, 0.05, 0.025 and 0.1%) or cell culture media as a control.  \nAlso, staurosporine (1, 20, 100 and 1000  nM) was used as a \npositive control for apoptosis.  Figure 1 shows representative dot plots obtained for the an alysis of multicaspase activation, after \ntreating cells during 24 hours.  The obtained dot plot shows the Vol. 6 - 20195INTER  SCIENTIFIC  \n \n distribution of the evaluated cells at four different stages: live, \ndead, caspase/dead and caspases.  \n \n \n \n \n  \n \nFigure 1. Effect of chemical compounds isolated from ginger \nand turmeric or synthe tic compounds on the activation of \nmulticaspase in PANC -1 cells  (A, B). After 24 hours  of \ntreatments with A) zingerone B) 6-shogaol C) \nbisdemethoxycurcumin D) curcumin E) EHop -16 and F) \ngemcitabine at shown concen trations. The activation of caspases \nwas determined by labelling the cells with VAD -FLICA. Dots \nplots show the cells sorting in four populations (live cells, cells \nVol. 6 - 20196INTER  SCIENTIFIC  \n \n \n with activated caspase, caspase mediated dead cells, and dead \ncells), produced by the Muse\u2122 Cell Analyzer.  Fluorescence \nintensity for multi -caspase is indicated on the x -axis and that of \n7-AAD incorporation, a death cell marker, is indicated on the y -\naxis. The range of evaluated events (total cells) were between 5 \nx 104 cells/mL up to 2x105 cells/mL.  \n As shown in the summary of results in Table 1, it was observed that the tested compounds have unique ways to induce caspase \nactivation alone or induce both caspase activation and cell death. \nAmong the ginger derivates 6-shogaol  induced caspase medi ated \ncell death after 24 hours and the effect was increased two -fold \nafter 48 hours, and zingerone produced a slight activation of multiple caspases. Among the compound derived from turmeric, it was observed that curcumin produced multiple caspase s \nactivat ion and caspase mediated cell death, but the effect was not \ntime dependent. However, treatment with BDMC only increased multiple caspase activity but did not induce caspase mediated cell death during the tested periods. It was observed that EHop -16 had \na dramatic increase in multiple caspase when the exposure time \nwas increased from 24 to 48 hours, but the caspase mediated cell \ndeath was reduced almost by half when the exposure time was \ndoubled. Finally, gemcitabine treatment increased both multiple caspase  activity and caspase mediated cell death, but only after \n48 hours of treatment.  \n \nTable 1 . Summary of caspase activation and caspase induced cell \ndeath in PANC -1 cells produced after exposure during 24 and 48 \nhours to natural and chemical compounds .  \n \nTrea tment  \n(100 \u03bcM)  \n24 hours  48 hours  \nA B A B \nZingerone  4.9 2.9 12.3 4.6 \n6-shogaol  13.1 34.6 19.6 63.9 \nBDMC  26.3 6.4 6.0 6.8 \nCurcumin  32.6 62.4 32.6 64.8 \nEHop -16 27.3 44.7 56.8 27.1 \nGemci tabine  3.6 4.7 20.7 24.3 \nBDMC: Bisdemethoxycurcumin  \nA: % of cell with m ultiple caspase activation \nB: % of cell death mediated by caspase  \n \nFigure 2 shows the response of PANC -1 cells to staurosporine, a \npositive control for apoptosis. The highest activation (up to 42%) of total caspase activity was observed after exposing PANC -1 \ncells to 1  \u03bcM staurosporine for 48 hours. However, the highest \ncaspase mediated cell death (31%) was observed after 24 hours of treatment. These results show that there are adequate intracellular pathways that elicit activation of caspase that will eventually cause apoptosis, and therefore further evaluation of other \ncompounds, as an apoptotic inductor can be used.  \n \nAfter establishing the apoptotic induction capacity of staurosporine in PANC -1 cells, it was evaluated the ability of chemicals derived from  ginger, turm eric or synthetic  compounds \nto activate multiple caspases and produce caspase mediated cell death.  Among the tested compounds it was found that, as shown in Figure 3, curcumin increased total caspase activity up to \n85.2%, after treating the cells for 24 hours, and was further \nincreased to 96.3% at 48 hours. Gemcitabine and 6-shogaol  \nrequired an exposure of 48 hours to increase PANC -1 cell caspase \nactivity while EHop -16, reduced its ability to increase total \ncaspase activity when the exposure period was inc reased from 24 \nhours to 48 hours. These results suggest that each tested compound have unique ways to activate and sustain caspase activity and is time dependent.  \n   \n \n     \n \n     \n \nFigure 2.   Staurosporine apoptotic profile. Total caspase \nactivation (A) and  caspase mediated cell death (apoptosis) \nactivation (B) induced by staurosporine after 24 and 48 hours of \ntreatmen t. \n The total percent of PANC -1 cell s undergoing apoptosis was \ndetermined after 24 and 48 hours of treatment. It was observed (see Figure 4) that among the tested compounds curcumin and \nEHop- 16 were the most potent for inducing apoptosis followed \nby 6-shogaol . When the incubation period was increased to 48 \nhours 6-shogaol  and curcumin apoptotic effect was slightly \nincreased while the apoptotic e ffect of EHop -16 was reduced.  \nA \nTotal % of caspase activation  \nConcentration (nM)  \n(24 hrs) Staurosporine  \n(48 hrs) Staurosporine  \nB \nConcentration (nM)  \n(24 hrs) Staurosporine  \n(48 hrs) Staurosporine  \nTotal % of  PANC -1 apoptotic cells  Vol. 6 - 20197INTER  SCIENTIFIC  \n \n  \n \nFigure 3.   Total caspase activation induced by natural and \nsynthetic chemical compounds.  Caspase activation was evaluated \nafter treatment with gemcitabine, 6-shogaol , curcumin, EHop -16 \nduring A) 24 hours and B) 48 hours.   \n In order to determine what proportion of activated caspase s are \nmediating regulated cell death,  a ratio of total apoptosis vs. total \ncaspase activity was done for 24 and 48 hours and is presented in Table 2. From the analysis it seem s that when cells are  treated for \n24 hours, almost  50% of activated caspase is devoted to regulated cell death for the most of the treatment, however for EHop -16 \nwhen the period of exposure was increased to 48 hours, it was observed that only 25% is devoted to regulated cell death. This \nsuggest s that this treatment may cause other effects mediated by \nthe non -apoptotic functions of caspase.  \n To determine the net caspase activation, the effect caused by DMSO was subtracted from the apoptosis reflected by the treatments. Table 3 shows the net caspase activation produced in \nPANC -1 cells when they were exposed to z ingerone, 6-shogaol , \ncurcumin, BDMC, EHop -16, and g emcitabine during 24 and 48 \nhours. Data demonstrate s that when cells were treated for 24 \nhours curcumin and EHop -16 we re able to induce net apoptosis \nbut neither ginger derived compounds nor gemcitabine produced such effect. When the incubation period was increased to 48 hours curcumin apoptotic effect was reduced,  and ginger derived \ncompounds and gemcitabine had a modest  apoptotic effect. Table \n4 summarizes the net apoptosis induced by the tested compound s. \n \n \n \nFigure 4.   Total caspase mediated cell death (apoptosis) by \nnatural and synthetic  compounds.  The total % of dead cells \nthrough caspase activation was determine d after treatment with \ngemcitabine, shogaol, curcumin, E -hop 16 during A) 24 hours and \nB) 48 hours.  \n \nDISCUSSION AND CONCLUSION \n \nThe diverse analysis performed on the activation of multiple \ncaspase in PANC -1 cells, shows that this model of pancreatic \nadenoc arcinoma conserved the ability to both activate caspases \nand induce regulated cell death. PANC -1 cells response to \nstaurosporine, was lower than the values reported in other \npublications for the same experimental model. For example, \nMolasy et al. , (2019) reported that exposure to 1 \u03bcM \nstaurosporine for 24 hours produced apoptosis in 65% of PANC -\n1 cells population using Annexin assay. When caspase mediated \ncell death was evaluated the highest amount of detected apoptotic cells was 42%, showing that have a functioning apoptotic \npathway .   \nA \nConcentration ( \u03bcM) \nGemcitabine  \nShogaol  \nTotal % of  caspase activation  \nCurcumin  \nE-Hop 16  \nB \nConcentration ( \u03bcM) \nTotal % of  caspase activation  \nGemcitabine  \nShogaol  \nE-Hop 16  \nCurcumin  \nA \nConcentration ( \u03bcM) \nTotal % of  apoptotic cells  \nGemcitabine  \nShogaol  \nE-Hop 16 \nCurcumin  \nB \nConcentration ( \u03bcM) \nTotal % of  apoptotic cells  \nGemcitabine  \nShogaol  \nE-Hop 16  \nCurcumin  Vol. 6 - 20198INTER  SCIENTIFIC  \n \n \n Curcumin (100  \u03bcM) was the natural compound that produced the \nhighest activation of multiple caspase s (-1, 3, 4, 5, 6, 7, 8, and 9), \nfollowed by EHop -16. Caspase mediated cell death (apoptosis) \nwas induced more effectively with curcumin and EHop -16. Bo th \neffects were time -dependent for EHop -16 since it was observed \nthat the activation of multiple caspase s was increased but the \napoptotic effect decreased when the exposure time was 48 hours. \nAlso, it was observed that 6-shogaol  increased lightly the activ ity \nof multiple caspase, but the population of apoptotic cells \nincreased up to 63% when the incubation period was 48 hours. \nThe activation of caspase and apoptosis induction was also dose -\ndependent for EHop -16, 6-shogaol  and curcumin, but not for \ngemcitabi ne. The least effective compound was found to be \nginger derivate z ingerone.  \n \nTable 2 . Total apoptosis and total caspase activity ratio in PANC -\n1 cells after a 24 -hour exposure to chemical compounds isolated \nfrom ginger and turmeric or synthe tic compounds.  \n \nConcentration \n(\u03bcM)  Percent of activated caspase \nproducing regulated cell death  \nGemcitabine  6-shogaol  \nIncubation period \n(hrs)  24  48  24 48  \n10 56% 59% 43% 51% \n25 80% 48% 69% 47% \n Curcumin  EHop -16 \n10 55% 46% 76% 26% \n25 26% 62% 71% 25% \n \nTable 3 . Analysis of net caspase activation in PANC -1 cells after \na 24 and 48 hours exposure to chemical compounds isolated from \nginger and turmeric or synthe tic compounds.  \n \nConcentration \n(\u03bcM)  Net caspase activation (%)   \nZingerone  6-shogaol  \nIncubation period  24h 48h 24h 48h \n100 ND ND 22.1 40 \n50 ND ND ND ND \n25 ND ND ND ND \n10 ND ND ND ND \n Curcumin  BDMC  \n100 30.3 23.2 15.9 ND \n50 14.3 12.7  2.2 ND \n25 11.6 ND  7.4 ND \n10  9.1 ND  6.0 ND \n EHop -16 Gemcitabine  \n100 23.7  46.3 ND 10.9 \n50 19.4  11.6 ND  4.9 \n25 10.3  ND ND  8.3 \n10 6.3 ND ND 5.9 \nND= Not detected  \nNet caspase activation= Total caspase activation induced by \ntreatment-Total caspase activation induced by DMSO  \n When the proportion of activated caspase devoted to induce apoptosis was evaluated (see Table 2) it was found that the most drastic transition was observed for EHop -16 (10 and 25 \u03bcM), \nsince during the first 24 hours approximately 75% of activated caspase are involved in apoptosis but when the exposure increased to 48  hours, only 25% of activated caspase were  \nmediating cell death. This observation suggests that EHop -16 \ninduces the activation of caspases that regulates other cellular \nprocess such as cell proliferation, cell migration or metastasis (Xu, Arthurton , & Baena-L\u00f3pez, 2018).  Regulation of caspase  8 \nactivation has been related to a regulated cell death process called \nanoiki s, produced by the detachment of epithelial cells from the \nextracellular matrix (Xu et al., 2018). Also, caspase 8 expression \nhas been implicated in the suppression of metastasis in neuroblastoma cells (Stupack et al ., 2006). Further evaluation of \nother ce llular effect produced by EHop -16 in PANC -1 cells is \nneeded.  \n \nTable 4 . Analysis of net caspase mediated cell death \n(apoptosis) in PANC -1 cells after 24 and 48 -hour exposure \nto chemical compounds isolated from ginger and turmeric or \nsynthe tic compounds.  \n \nConcentration \n(\u03bcM)  Net caspase mediated cell death \n(apoptosis)   \nZingerone  6-shogaol  \nIncubation period  24h 48h 24h 48h \n100 ND ND 22.1 40 \n50 ND ND ND ND \n25 ND ND ND ND \n10 ND ND ND ND \n Curcumin  BDMC  \n100 40.0  57.1 ND ND \n50 ND 8.3 ND ND \n25 ND ND ND ND \n10 ND ND ND ND \n EHop -16 Gemcitabine  \n100 40.3  20.4 6.3 19.8 \n50 ND 16.0 7.2 19.0 \n25 ND ND 9.2 19.0 \n10 ND ND 5.8 26.0 \nND= Not detected  \nNet apoptosis = Total apoptosis induced by treatment -Total \napoptosis induced by DMSO  \n Since the solvent DMSO used for exposing the cells to treatments, produces a slight increase in caspase activity and caspase induced \ncell death, the net effect for each treatment was determined.  It was \nfound that 6-shogaol , curcumin, BDMC, EHop -16 and \ngemcitabine reflect net caspase activation when cells were treated \nfor 24 hours. When the incubation period was increased to 48 \nhours BDMC lo st the caspase activation effect, gemcitabine had \ndose in dependent apoptotic effect, and 6 -shogaol and EHop -16 \ndoubled the capacity for activating caspases. Also, it was observed that net apoptotic activity  for EHop- 16 was reduced \nwhen the incubation period was increased. In contrast the net apoptotic effect for 6-shogaol  was doubled when the incubation \nperiod was increased from 24 hours to 48 hours. Th is Vol. 6 - 20199INTER  SCIENTIFIC  \n \n demonstrates that both caspase activation and the subsequent \nregulated death process is time dependent.  \n \nIn conclusion, both natural and synthetic  compounds ind uced \napoptosis in PANC -1 cells. Among the natural compounds \ncurcumin followed by 6-shogaol  were the most effective for \nactivating multiple caspase and for inducing apoptosis. The \nactivation of caspases was dose dependent and time dependent for both compoun ds. It is noteworthy the effect of EHop -16 in \nproducing activation of caspase s. After 48 hours only 25% of the \ncaspase activity is implicated in cell death, therefore it is proposed that not all activated caspases are related to regulated cell death and th at this effect may regulate the capacity of invasion and \naggressivity that is observed in pancreatic cancer cells.  \n \nACKNOWLEDGMENTS \n \nWe thank Jos\u00e9 Arce, Jes\u00fas Ramos and Kevin Ongay for the \ntechnical assistance. This study was funded by the Science and Technology Department, of the Inter American University of \nPuerto Rico Arecibo Campus. The equipment used for this work was acquired with funds from the US Department of Education, MSEIP Project, (Award number P120 A150082).  \n \nREFERENCES  \n \nBae, W. Y., Choi, J.  S., Kim, J. E., Park, C., & Jeong, J. W. \n(2016). Zingerone suppresses angiogenesis via inhibition of \nmatrix metalloproteinases during tumor development. \nOncotarget, 7 (30), 47232.  \n \nChin, K. Y. (2016). The spice for joint inflammation: anti -\ninflammatory role of curcumin in treating osteoarthritis. Drug \ndesign, development and therapy, 10 , 3029. \n \nHuang, F., Yao, Y., Wu, J., Liu, Q., Zhang, J., Pu, X., ... & Xia, L. (2017). Curcumin inhibits gastric cancer -derived \nmesenchymal stem cells mediated angiogenesis b y regulating \nNF-\u03baB/VEGF signaling. American journal of translational \nresearch, 9 (12), 5538.  \n Mini, E., Nobili, S., Caciagli, B., Landini, I., & Mazzei, T. (2006). \nCellular pharmacology of gemcitabine. Annals of Oncology, 17  \n(Suppl_5), V7 -V12. doi:10.1093/  annonc/mdj941  \n \nMontalvo-Ortiz, B. L., Castillo -Pichardo, L., Hern\u00e1ndez, E., \nHumphries-Bickley, T., De La Mota -Peynado, A., Cubano, L. A., \n... & Dharmawardhane, S. (2012). Characterization of EHop -016, \nnovel small molecule inhibitor of Rac GTPase. Journal o f \nBiological Chemistry, 287 (16), 13228 -13238.  \n Samulitis, B. K., Pond, K. W., Pond, E., Cress, A. E., Patel, H.,  \nWisner, L., ... & Landowski, T. H. (2015). Gemcitabine resistant   pancreatic cancer cell lines acquire an invasive phenotype with \ncollateral hy persensitivity to histone deacetylase inhibitors. \nCancer biology & therapy, 16 (1), 43 -51. \n Shah, D., Savaliya, R., Patel, P., Kansara, K., Pandya, A., Dhawan, A., & Singh, S. (2018). Curcumin Ag nanoconjugates for improved therapeutic effects in cancer. International journal \nof nanomedicine, 13,  75. \n \nStupack, D. G., Teitz, T., Potter, M. D., Mikolon, D., Houghton, \nP. J., Kidd, V. J., . . . Cheresh, D. A. (2006). Potentiation of neuroblastoma metastasis by loss of caspase -8. Nature, \n439(7072), 95 -99. doi:10. 1038/nature04323 . \n \nXu, D. C., Arthurton, L., & Baena -Lopez, L. A. (2018). Learning \non the Fly: The Interplay between Caspases and Cancer. BioMed \nResearch International ,1-18. doi:10.1155/2018/5473180  \n \nZhou, L., Qi, L., Jiang, L., Zhou, P., Ma, J., Xu, X., &  Li, P. \n(2014). Antitumor activity of gemcitabine can be potentiated in \npancreatic cancer th rough modulation of TLR4/NF -\u03baB signaling \nby 6-shogaol. The AAPS journal , 16(2), 246 -257.  \n \nAUTHORS /AUTORES  \n \nNatalia Acevedo, Christian Marrero, Kevin Ongay, \nJoshua Ortiz, Joaneliz Torres.  Biotechnology students at \nthe Inter American University of Puerto Ric o, Arecibo \nCampus .  \n \nEstudiantes del programa de Biotecnolog\u00eda de la Universidad \nInteramericana de Puerto Rico, Recinto de Arecibo.  \nKaren Woolcock. Professor in the Department of Science \nand Technology at the Inter American University of Puerto \nRico, Arecibo Campus. Earned a doctoral degree (Ph.D.) in \nPharmacology and an M.S. in Pharmacology/Toxicoloy from the University of Puerto Rico, Medical Sciences Campus. She has published many articles in peer -reviewed \njournals . May be contacted via email at: \nkwoolcock@arecibo.inter.edu  \nPosee el rango de Catedr\u00e1tica del Departamento de Ciencias y \nTecnolog\u00eda de la Universidad Interamericana de Puerto Rico, Recinto de Arecibo. Obtuvo un grado doctoral (Ph.D.) en \nFarmac olog\u00eda y una maestr\u00eda M.S. en Farmacolog\u00eda/Toxicolog\u00eda \nde la Universidad de Puerto Rico, Recinto de Ciencias M\u00e9dicas. \nHa publicado varios art\u00edculos en reconocidas revistas profesionales. Puede ser contactada a trav\u00e9s del correo electr\u00f3nico: kwoolcock@arecibo.inter.edu \n Vol. 6 - 201910INTER  SCIENTIFIC  \n \n \n   Adaptations in the vocalizations of Margarops fuscatus  and Turdus \nplumbeus  in urban environments  \n \nAdaptaciones en las vocalizaciones de Margarops fuscatus  y Turdus  \nplumbeus  en ambientes urbanos \n \nAparicio Massanett, J.M., Fern\u00e1ndez P\u00e9rez, T.I., Puente- Rol\u00f3n, A.  \n \nUniversity of Puerto Rico, Mayag\u00fcez Campus. Department of Biology  \n \nABSTRACT \n \nWith the continued expansion of urbanization,  it has become necessary for wildlife to adapt to its new environment. Birds are \njust one of many animals who depends on sound for communication, reproduction, defense, etc. Our interest was to study how \nthe pearly -eyed thrasher and the red -footed thrush were adapting to these challenges, if they had developed a different call. In \norder to study this we tested for significant differences across five variables: vocalizations per minute, duration, mean fre quency, \nmaximum frequency and minimum frequency. However,  significant differences were only detected i n the vocalizations per \nminute of the pearly -eyed thrasher in both the urban and rural environments, the vocalizations per minute in both species in \nrural environment and in the maximum frequency of the pearly -eyed thrasher in both environments. Future research in this \narea may use the same methodology but bigger sample sizes.   \n \nRESUMEN \n Con la expansi\u00f3n continua de las zonas urbanas se ha vuelto necesario que la vida silvestre se adapte a su nuevo ambiente. La s aves son \nuno de muchos animales que dependen  de sonido para comunicaci\u00f3n, reproducci\u00f3n, defensa, etc. Nuestro enfoque fue estudiar como el \nzorzal pardo y el zorzal patirrojo se adaptaba a estos retos, si habr\u00edan desarrollado otro canto. Para estudiar esto hicimos pruebas \nestad\u00edsticas para  determinar diferencias significativas a trav\u00e9s de cinco variables: vocalizaciones por minuto, duraci\u00f3n, frecuencia \npromedio, frecuencia m\u00e1xima y frecuencia m\u00ednima. Sin embargo,  solo se detectaron diferencias significativas en las vocalizaciones por \nminuto del zorzal  pardo en \u00e1reas urbanas y rurales, las vocalizaciones por minuto de ambas especies en zonas rurales y en la frecuencia \nm\u00e1xima del zorzal pardo en los dos ambientes. Estudios futuros  en esta \u00e1rea pueden utilizar la misma metodolog\u00eda, pero una muestra \nm\u00e1s gr ande.   \n KEYWORDS Anthropogenic noise, bird song, vocalization frequency, acoustic adaptation  \n PALABRAS CLAVE  Sonido antropog\u00e9nico, canto de  aves, frecuencia de vocalizaci\u00f3n, adaptaci\u00f3n ac\u00fastica \n \nINTRODUCTION   \nCities are growing at alarming rates and with this comes \nanthropogenic noise such as traffic and other day to day activities. This is not without consequence to local wildlife. A variety of \nanimals have sound as a vital component for communication, \nreproduction, etc. A study on avian and anuran co mmunities \nestablished that closeness to human activity affected bird community composition. When the background noise of traffic \nmasked the bird\u2019s vocalizations they moved away to areas of lower \nnoise (Herrera -Montes & Aide,  2011). This is common in bird s \nwith low frequencies who are only detected in quiet areas. Slabbekoorn in 2013, put forth the concern that this would lead to homogenization of avian communities where only those who had adapted to the new urban environment would flourish .  \n   A study by  Dooling and Popper  (2016) summarized these new \nstrategies for adapting to anthropogenic noise as long -term \nstrategies or shor -t term strategies. While both long and short -term \nincluded a change in location, short -term strategies include \nmodifying the dura tion of vocalization and chang ing the length, \nintensity and repetition. Long term changes include modifying the spectrum and singing time.  \n \nAs a preliminary study , we decided to focus on the short -term \nstrategies to answer how the vocalizations in these s pecies vary in \nurban versus rural environment and , whether or not , there is a \ndifference in the mechanisms for adaptations in these species. In \norder to answer these questions,  we will be using Margarops Vol. 6 - 201911INTER  SCIENTIFIC  \n \n fuscatus , the pearly -eyed thrasher , and Turdus plumb eus, the red -\nlegged thrush as our focal species.  \n \nMATERIALS AND METHODS  \n \nRecording sites and equipment  \n Focal species were recorded in five urban sites and two rural sites located in the municipalities of Mayag\u00fcez and Cabo Rojo. Of the \nurban sites, four were areas within the University of Puerto Rico \n(UPRM) campus and one was at the Parque de los Pr\u00f3ceres  \nlocated adjacent to the UPRM campus. Rural recordings took place at the Adrian H. Acevedo Cruz  recreational park at Las Mar\u00edas and \nat a residential area i n Boquer\u00f3n, Cabo Rojo  (Table 1) .  \n \nThe audio was obtained during December 2017 up until mid -\nJanuary 2018 at various hours within the 8 :00 am to 5 :00 pm range. \nTo avoid recording the same bird, each one was selected from a \ndifferent tree. When two birds of the same species were vocalizing \nat the same time, they were considered as one measure , as \ndescribed by Hu  and Cardoso  (2010). Vocalizations were recorded \nspontaneously each time the focal species were heard and approximately 6 to 16 m eters were kept to av oid any interference \nwith normal bird activity. The duration of the audio ranged from 3 to10 minutes because the recording was stopped when the bird flew \nto an area that was too far to locate  (Table 2) . After the audio was \nobtained, the best quality sample s were selected from the total of \nrecordings. These audio samples were recorded using a smart \nphone and the applications Voice Recorder 2.0.22, Recorder and \nVoice Memo. The microphone was oriented towards the focal \nspecies during vocalization.  \n \nFrequency measurements  \n  \nFrom the audio obtained, the samples with best quality were \nselected. The selected recordings were processed using the Audacity\u00ae Cross -Platform Sound Editor for noise reduction. After \nhaving filtered the recordings, total number of chirps wer e \nmeasured.  \n In order to obtain the duration, mean frequency, maximum frequency and minimum frequency, chirps were carefully chosen \nfrom each audio which had the best quality and the least \ninterference with vocalizations from other species  (Table 3) . Afte r \nthese vocalizations were selected, Sound Analysis Pro 2011 was \nused for the mentioned measurements. An average of the vocalizations that corresponded to each recording was \ndocumented.  \n  \nIntraspecific and Interspecific Statistical Analyses  \n  \nBy using t -test statistical analysis to determine significant \ndifferences among the studied species, five variables were \ncompared (vocalizations per minute, duration, mean frequency, max frequency and minimum frequency). Intraspecific \ncomparisons were made by calculat ing the t -values for these \nvariables between urban and rural pearly-eyed thrashers as well as \nurban and rural red -legged thrush. In terms of interspecific \ncomparisons and by using the same variables, t -values between \nurban pearly -eyed trashers and red -legg ed trush as well as between \nthe rural pearly -eyed thrashers and red -legged thrush were \ncalculated. \n \nTable 1.  Identification for study subjects.  \n \nBird \nnumber  Species  Environment \n1 Margarops f.  Urban  \n2 Margarops f.  Urban  \n3 Margarops f.  Urban  \n4 Margarops  f. Urban \n5 Margarops f.  Urban \n6 Margarops f.  Urban  \n7 Margarops f.  Urban  \n8 Margarops f.  Urban  \n9 Margarops f.  Urban  \n10 Margarops f.  Urban  \n11 Margarops f.  Urban  \n12 Margarops f.  Urban  \n13 Margarops f.  Urban  \n14 Margarops f.  Urban \n15 Margarops f.  Rura l \n16 Margarops f.  Rural  \n17 Turdus p.  Urban  \n18 Turdus p.  Urban  \n19 Turdus p.  Urban  \n20 Turdus p.  Rural  \n21 Turdus p.  Rural  \n   \n \nRESULTS \n \nVocalizations per minute  \n \nThe test between Margarops fuscatus  in both environments gave \nus a t= -13.5676, df= 13.97,  p-value= 1.954 x e( -9). Given the \nmagnitude of t and the value of p we can see a significant difference \nin the number  of vocalizations of the pearly -eyed thrasher in rural \nand urban environment.  The test between Turdus plumbeus  in both \nenvironments gave u s a t= 1.424, df= 1.9, p -value= 0.2972. These \nvalues however are not enough to assume a significant difference \nin the number  of vocalizations that a red -legged thrush may make \nin a rural and an urban environment. The test between both species in an urban environment gave us a t= 2.879, df= 14.67, p -value= \n0.01168. These values show some difference in the number  of \nvocalizations of both species in a rural environment but not to a \nsignificant amount .  The test between both species in a rural \nenvironment gave us a t= -31.5, df= 1.6, p -value= 0.003. We can Vol. 6 - 201912INTER  SCIENTIFIC  \n \n \n detect a significant difference for vocalizations of  both species in \nthe same environment.  \n \nTable 2 . Data for observation time, number of calls and calls per \nminute for sample group \n \nBird \nnumber  Observation \ntime (mins)  Numer of \ncalls  Calls per \nminute  \n1 6:00 0 0 \n2 10:00  15 1.5 \n3 10:00  0 0 \n4 2:44 40 14.6 \n5 10:51  49 4.5 \n6 10:00  2 0.2 \n7 10:00  82 8.2 \n8 6:10 33 5.4 \n9 7:00 12 1.7 \n10 8:05 29 3.6 \n11 9:00 155 17.2 \n12 6:58 140 20.1 \n13 8:13 14 1.7 \n14 10:13  39 3.8 \n15 1:09 36 31.3 \n16 1:13 37 30.4 \n17 20:00  0 0 \n18 10:00  0 0 \n19 3:11 5 1.6 \n20 4:33 5 1.1 \n21 12:00  32 2.7 \n \nDuration \n \nThe test between Margarops fuscatus  in both environments gave \nus a t= -1.026, df= 2.81, p -value= 0.385. No significant difference  \nwas detected  between the duration of calls for the pearly -eyed \nthrasher. The test between Turdus plumbeus  in both environments \ngave us a t= -2.1105, df= 1.46, p -value= 0.2141. In urban \nenvironments both species behave similarly in terms of call \nduration ( t= 1.839, df= 3.63, p -value= 0.147). The test between \nboth species in a rural environment gave us a t= -0.8202, df= \n1.2255, p -value= 0.5412. These values do not show a significant \ndifference in the duration of vocalization for both species in a rural \nenvir onment.  \n \nMean frequency  \n \nThe test between Margarops fuscatus  in both environments gave \nus a t= -0.8177,df= 3.11734, p -value= 0.4714. These values do not \nshow a significant difference in the mean frequency of pearly -eyed \nthrashers. The test between Turdus p lumbeus  in both environments \ngave us a t= -1.8512, df= 2.67, p -value= 0.1724. The values do not \nshow a significant difference in the mean frequency of red -legged \nthrush. For both species in an urban environment mean frequency \nwas not different (t= 0.6275, df= 2.3, p -value= 0.587). The test between both species in a rural environment gave us a t= -1.3416, \ndf= 1.47, p -value= 0.3499. These tests do not show a significant \ndifference between the mean  frequencies of both species in a rural \nenvironment.  \n \nMaximum frequency  \n \nFor Margarops fuscatus  in both environments, comparison of \nmaximum frequency was different (t= -3.1892, df= 13.37, p -\nvalue= 0.006895). However, for Turdus plumbeus in both \nenvironments there was not a difference (t= -1.8169, df= 0.1736, \np-value=  0.1736). The comparison between both species in an \nurban environment gave us a t= 1.0922, df= 2.668, p -value= \n0.3634. These tests do not show significant difference between the \nmaximum frequencies in an urban environment for both species. \nOn the other han d, comparison of both species in a rural \nenvironment gave us a t= -0.027, df= 1, p -value= 0.9828. These \nvalues do not show a significant difference for the maximum \nfrequency of both birds.  \n Table 3.  Data for duration, mean frequency, maximum frequency \nand minimum frequency for the sample group  \n \nBird #  Duration \n(ms)  Mean \nFrequency \n(kHz)  Maximum \nFrequency \n(kHz)  Minimum \nFrequency \n(kHz)  \n1 0 0 0 0 \n2 130.7  2 2.9 1 \n3 0 0 0 0 \n4 155.79  4.8 7.1 1.4 \n5 74.86  2.2 2.8 2 \n6 59.9 4.4 9.8 1.3 \n7 192.73  3.8 5.5 1.8 \n8 256.4  3.3 6.2 2 \n9 0 0 0 0 \n10 96.775  3.4 6.1 0.9 \n11 97.03  2.7 3.4 2.4 \n12 167.9  4.2 6.8 2.2 \n13 210.8  3.8 5.2 1.1 \n14 185.16  3.9 5.1 2.1 \n15 178.06  3.8 6.8 2.4 \n16 125.29  2.8 7 2 \n17 0 0 0 0 \n18 0 0 0 0 \n19 110.915  5 6 3.4 \n20 141.2  4.3 5.1 3.4 \n21 297.3 2 3.8 8.8 2.4 \n \nMinimum frequency  \n \nThe test between Margarops fuscatus  in both environments gave \nus a t= -2.9855, df= 4.6, p -value= 0.03406. These values show \nsome differences in the maximum frequencies but not that much. \nFor Turdus plumbeus  in both enviro nments gave us a t= -1.4262,  Vol. 6 - 201913INTER  SCIENTIFIC  \n \n df= 2.65, p -value= 0.2602. These values do not show significant \ndifferences. The comparison of both species in an urban \nenvironment showed not significant difference for the minimum  \nfrequency (t= 0.1442, df= 2.16, p -value= 0.89 77). \n \nDISCUSSION \n \nFor the variable of vocalizations per minute there was a significant difference in the vocalizations per minute in Margarops fuscatus  \nwith more vocalizations in a rural environment than in the urban environment. This could be due to one o f two reasons. One is that \nin urban areas, there is more competition between the vocalizations versus the ambient noise making the species prefer to not invest energy in vocalizations that might be ineffective. The second \npossible explanation is that the recordings of the two variables \nwere taken at different times throughout the day which means the \nobtained results might be affected by peak hours of activity. There was also a significant difference between both species in a rural environment with the pearl y-eyed thrasher doing more \nvocalizations. But these differences could be a result of traits that \nare particular to the pearl -eyed thrasher in which it differs from the \nred-legged thrush.  \n \nThe lack or the presence of significant differences may be owed to the irregular sample sizes. One demographic had an abundant \nsample while others had a few specimens and this proved to be a non-representative number of the population.  \n \nCONCLUSION \n \nMargarops fuscatus  shows preference for living in densely \npopulated urban areas and was generally absent in more quiet \nareas. Turdus plumbeus  was the opposite, being much more active \nin quiet rural areas and the specimens found in urban areas were flighty and difficult to find. As stated earlier, the sampled sizes were unreprese ntative of the true population and so a future study \nmust take into account the sample sizes. Another factor that might \nhave affected our results is that our data was recollected at different \npoints during the day which sometimes matched the active times of our focal species and sometimes did not. The calls per min may \nbe affected by different high -activity times. The quality of our \nrecordings and subsequent analysis was affected by the distance \nwe had to keep from the birds and the relatively poor resoluti on of \nour recording instruments.  \n \nAnd the distribution of our focal species may have been affected by Hurricane Maria which brought about various challenges. The first being the destruction of habitat and the access to resources for \nthese birds which may h ave been affected. Another consequence \nof the disaster was an increment of anthropogenic noise in the form \nof electric generators. This was especially noticeable in rural areas where the devastation remained much the same as the first week after the hurric ane. The generators were heard for miles and this \nwould affect the usually peaceful and quiet rural area for birds with  \nlow-frequency calls.  \n \nREFERENCES \nDooling, R.J. & Popper, A.N. (2016) . Some lessons from the \neffects of highway noise on birds. Proceedi ngs of Meetings on \nAcoustics, 2 ,7 (010004) 1 -12.  \nHerrera-Montes, M.I.  & Aide, T.M. (2011) . Impacts of traffic noise \non anuran and bird communities. Urban  Ecosystem, 14, 415-427. \ndoi: 10.1007/s11252 -011-0158 -7. \nHu, Y. & Cardoso , G.C. (2010) Wh ich birds ad just the frequency \nof vocalizations in urban noise? Animal Behaviour . 79,  863-867. \nSlabbekoorn, H. (2013) Songs of the city: noise -dependent spectral \nplasticity in t he acoustic phenotype of urban birds. Animal \nBehavior, 85. 1089 -109. \nAUTHORS /AUTORES  \n \nJulissa Aparicio Massannet, Tatiana Fern\u00e1ndez P\u00e9rez . \nBiology students at the University of Puerto Rico, \nMayaguez Campus.  \n \nEstudiantes del programa de Biolog\u00eda de la Universidad de Puerto \nRico, Recinto de Mayaguez.  \nAlberto Puente Rol\u00f3n. Investigador del Recint o de \nMayag\u00fcez de la  Universidad de Puerto Rico.  Obtuvo un \ngrado doctoral (PhD) en Ecolog\u00eda Tropical y una maestr\u00eda \n(M.S.) en Biolog\u00eda/ Ecolog\u00eda de la Universidad de Puerto Rico, Recintos de R\u00edo Piedras y Mayag\u00fcez , \nrespectivamente. Ha publicado varios art\u00edculos en \nreconocidas revistas profesionales. Su correo electr\u00f3nico: \napuente@arecibo.inter.edu  \nResearcher and professor at the University of Puerto Rico, \nMayaguez Campus. Earned a doctoral degree (Ph.D) in T ropical \nEcology and an M.S. in Biology / Ecology at the University of Puerto Rico, R\u00edo Piedras and Mayaguez Campus respectively. He \nhas published several articles in peer reviewed journals. May be \ncontacted via e mail:  apuente@arecibo.inter.edu \n \n \n \n  Vol. 6 - 201914INTER  SCIENTIFIC  \n \n \n Estudio sobre la evoluci\u00f3n de la seguridad en la tecnolog\u00eda de la nube \nen los \u00faltimos cinco a\u00f1os  \n \nStudy on the evolution of security in cloud technology in the past five years  \n \nNieves- M\u00e9ndez, A.  \n \n Universidad Internacional Iberoamericana , Puerto Rico \n \nRESUMEN \n Este estudio de investigaci\u00f3n exploratoria y cuantitativa tiene como prop\u00f3sito informar y determinar cu\u00e1nto ha evolucionado l a \nseguridad en la tecnolog\u00eda de la nube en los \u00faltimos cinco a\u00f1os. Se explica detalladamente la arquitectura y las tres plataformas \nque son utilizadas para la creaci\u00f3n de los servicios en la red: Infraestructura de Servicio (IaaS), Servicio de Software  (SaaS) y \nPlataforma de Servicio (PaaS). Se exploraron cuatro tipos de modelos que son  utilizados para la creaci\u00f3n de la arquitectura de \nla nube: privada, p\u00fablica, h\u00edbrida y comunitaria. Con los datos de la estructura y los modelos , los usuarios analizaron si los \nproveedores de los servicios de la nube est\u00e1n brindando la seguridad necesaria  para proteger la informaci\u00f3n. La poblaci\u00f3n en \nesta investigaci\u00f3n fueron sujetos que estaban brindando y recibiendo servicios en hospitales, universidades, bancos y comerci os \nen la Zona Norte de Puerto Rico. La poblaci\u00f3n fue seleccionada de forma aleatoria  en los pueblos de Arecibo, Hatillo y \nBarceloneta. La poblaci\u00f3n escogida ten\u00eda conocimientos b\u00e1sicos de c\u00f3mo la tecnolog\u00eda de la nube ha evolucionado en los \u00faltimo s \na\u00f1os y la seguridad que proporciona la empresa para la cual brindan y reciben sus servicios . La muestra estuvo constituida por \n113 sujetos a los que se administr\u00f3 un cuestionario dise\u00f1ado por el investigador.  \n \nABSTRACT  \n \nThis exploratory and quantitative research study aims to inform and determine how security has evolved in the cloud technolog y in the \nlast five years. It explains in detail the architecture of the cloud technology and the three platforms that are used for the creation of the \nservices in the network: Infrastructure as a Service (IaaS), Software  as a Service (SaaS) and Platform as a Service  (PaaS). We explored \nfour types of models that are used for the creation of cloud architecture: private, public, hybrid and community. With the da ta of the \nstructure and the models, the users analyzed whether the providers of the cloud services are providing the necessary security to protect \nthe information. The population in this research were subjects that are providing and receiving services in hospitals, univer sities, banks \nand businesses in the Northern Zone of Puerto Rico. The population was randomly selected in the towns of Arecibo, Hatillo and \nBarceloneta. The chosen population had basic knowledge of how cloud technology has evolved in recent years and the security p rovided \nby the company for which they provide and receive their services. The sample was obtained personally from the employees and clients who are providing and / or receiving services in banks in the Northern Zone of Puerto Rico. The sample consisted of 113 subje cts who \nwere administered a questionnaire designed by the researche r.  \n \nPALABRAS CLAVE  tecnolog\u00eda de la nube, evoluci\u00f3n, seguridad, y protocolos  \n \nKEYWORDS  cloud technology, evolution, security, and protocols  \n \nINTRODUCCI\u00d3N  \n   \nAndrew (2014) expone que en los \u00faltimos a\u00f1os la tecnolog\u00eda haevolucionado en forma eficiente como un recurso que la poblaci\u00f3n utiliza y cada vez depende m\u00e1s para lograr alcanzar las metas. Uno de esos recursos es la tecnolog\u00eda de la nube y es un  \nfactor determinante en la vi da de los usuarios. Para Furht y  \nEscalante (2010), con la tecnolog\u00eda de la nu be se puede acceder, \neditar u obtener cualquier documento, buscar, solicitar y/o comprar cualquier servicio profesional. Un beneficio de la tecnolog\u00eda de la nube es facilitar el desempe\u00f1o de las personas en sus labores diarias, personales y profesionales. Adem\u00e1s, es \nutilizada en la descripci\u00f3n de productos y compa\u00f1\u00edas en diferentes partes del mundo.  \n \nLa evoluci\u00f3n en la tecnolog\u00eda de la nube ha cambiado la manera \nen que se comunican las personas, empresas, organizaciones y negocios (Andrew, 2014). La tecnolog\u00eda de la nube provee todas las herramientas necesarias para la b\u00fasqueda de cualquier tipo de servicio y es parte del diario vivir de la poblaci\u00f3n mundial (Nepal  Vol. 6 - 201915INTER  SCIENTIFIC  \n \n y Pathan, 2014).  \n \nFearne (2015) explic\u00f3 que la tecnolog\u00eda de la nube es un modelo \nde la infor m\u00e1tica que ha evolucionado y se ha expandido sin \ncontrol. Con dicha tecnolog\u00eda se aprovechan las ventajas de la \nInternet al acceder informaci\u00f3n y datos personales en otros \ndispositivos electr\u00f3nicos. Seg\u00fan Paczkowski (2009), en el pasado los dispositivos electr\u00f3n icos se da\u00f1aban y eran reemplazados, por \nlo que la informaci\u00f3n se perd\u00eda. La tecnolog\u00eda de la nube ha \ncambiado dr\u00e1sticamente la forma en que los datos se guardan en \nlos servidores. Debido a estos cambios Paczkowski (2009) \npresenta varias preguntas a consid erar: \u00bfCu\u00e1ndo se acceden y \nguardan los datos en la tecnolog\u00eda de la nube?; \u00bfQu\u00e9 seguridad tienen?; \u00bfQui\u00e9n tiene acceso a la informaci\u00f3n?, \u00bfC\u00f3mo alguien \npuede tener acceso a datos personales y documentos que se \nencuentran en la red? A este respecto, para Flantrmskv (2012), los \nnuevos modelos de la tecnolog\u00eda de la nube son peligrosos, porque al utilizar estos servicios para almacenar los datos personales de clientes se pueden perder los derechos legales. Esto implica que \nlos proveedores de los servicios pueden utilizar toda la data que \ntienen de sus clientes para otros fines.   \n \nWalton (2012) realiz\u00f3  una encuesta acerca de la definici\u00f3n de la \nnube .  Participaron  1,000 estadounidenses  y la mayor\u00eda relacion\u00f3 \nla nube con el clima, no como una nueva tecnolog\u00eda. \nEspec\u00edficamente, se encontr\u00f3 que el 51 % de los encuestados \ncontest\u00f3 que los cambios de clima interfieren con la tecnolog\u00eda de \nla nube ; 29% que la nube es una real y 16 % sab\u00eda realmente lo que \nera la tecnolog\u00eda de la nube. \n \nMather, Kumaraswamy y Latif (2009)  presentaron que la \ntecnolog\u00eda de la nube es utilizada por el 40% (aproximadamente) de las personas a nivel mundial  con un incremento anual de \nusuarios de 10%, lo que significa que al menos tres billones de \npersonas en el mundo tienen y/o han tenido acceso  a esta \ntecnolog\u00eda . Tambi\u00e9n establecen que  los usuarios  carecen del \nconocimiento sobre c\u00f3mo funciona y  c\u00f3mo  ha evolucionado en \nlos \u00faltimos a\u00f1os. Esa carencia de conocer  c\u00f3mo las empresas \nproveedoras en servicios proteg en las fotos, los programas, los \ndatos y /o informaci\u00f3n personal puede conllevar problemas \npersonales y legales.  \n \nEn los \u00faltimos a\u00f1os, la seguridad en la red de la tecnolog\u00eda de la \nnube ha tenido que evolucionar significativamente, desde \nimplementar nuevos algoritmos, programas y aplicaciones pa ra \nproveer seguridad a los datos de sus usuarios, entre otros. En la \u00faltima d\u00e9cada compa\u00f1\u00edas como Sony, Apple y Facebook, han sido atacadas cibern\u00e9ticamente y los servidores han comprometido la \ndata de los clientes. La tecnolog\u00eda de la nube es una forma de  \naumentar la capacidad en forma din\u00e1mica sin invertir en nuevas \ninfraestructuras y licenciar nuevos programas. La tecnolog\u00eda de la nube ha pasado de ser un concepto de negocio prometedor, a uno de los segmentos de r\u00e1pido crecimiento de la industria de TI  \n(Tecnolog\u00eda de la informaci\u00f3n) . Sin embargo, a medida que m\u00e1s y m\u00e1s informaci\u00f3n sobre los individuos y las empresas se colocan \nen la nube, las preocupaciones est\u00e1n empezando a crecer sobre \ncu\u00e1n seguro es su entorno. A pesar de toda la euforia, los clientes \nempresariales siguen siendo reacios a desplegar su negocio en la \ntecnolog\u00eda de la nube (Mather, Kumaraswamy y Latif, 2009).  \n De acuerdo con Gierbolini -Bonilla (2009), la seguridad es uno de \nlos principales problemas que reduce el crecimiento de la tecnolog\u00eda de la nube. Por lo que, las complicaciones con la \nprivacidad de los datos y la protecci\u00f3n de datos afectan al mercado. La tecnolog\u00eda de la nube plantea una amenaza a la  \nseguridad de las tecnolog\u00edas existentes cuando se usa en un entorno de nube. Los usuarios de servicios deben estar atentos a la comprensi\u00f3n de los riesgos de las violaciones en este nuevo \nentorno. Jin, Dai y Zou (2016) exponen que esta es un modelo para \npermitir el acceso conveniente a un grupo compartido de recursos \ninform\u00e1ticos configurables. Por lo que, durante mucho tiempo ha \nestado a la cabeza de una lista de las diez principales tecnolog\u00edas estrat\u00e9gicas.   \nEl mayor  obst\u00e1culo para su desarrollo son los problemas de \nseguridad y privacidad. Para asegurarla, se deben supe rar tres \ndesaf\u00edos principales: La necesidad de un entorno de ejecuci\u00f3n \nseguro para m\u00e1quinas virtuales (VM, por sus siglas en ingl\u00e9s) en la tecnolog\u00eda de la nube; el problema de incoherencia de tiempo y \nestado de las VM; y la necesidad de la alta confiabilidad (Jin, Dai \ny Zou, 2016).  \n La tecnolog\u00eda de la nube promovi\u00f3 un cambio de paradigma de la \ninform\u00e1tica. Las aplicaciones cient\u00edficas y de ingenier\u00eda, la \nminer\u00eda de datos, la financiaci\u00f3n computacional, los juegos y las \nredes sociales, y muchas otras acti vidades computacionales y de \nuso intensivo de datos se beneficiaron de misma . Por ejemplo, en \n2011, Apple anunci\u00f3 iCloud, como una alternativa centrada en la \nred para integrar m\u00fasica, videos, pel\u00edculas e informaci\u00f3n personal. El contenid o que previamente estaba confinado a dispositivos \npersonales, como estaciones de trabajo, computadoras port\u00e1tiles, \ntabletas y tel\u00e9fonos inteligentes, ya no se almacenar\u00eda localmente, \nsino que se compartir\u00eda y acceder\u00eda siempre con el Internet \n(Marinescu, 2 017).  \n La tecnolog\u00eda de la nube se convirti\u00f3 en una realidad t\u00e9cnica y \nsocial. Solamente se pod\u00eda especular la evoluci\u00f3n de la \ninfraestructura y de las aplicaciones. Por otro lado, las \nimplicaciones econ\u00f3micas, sociales, \u00e9ticas y legales ser\u00edan significati vas. Los usuarios confiar\u00edan en los servicios \nproporcionados por los grandes centros, almacenar\u00edan datos privados y utilizar\u00edan software en sistemas que no controlar\u00edan. \nEsto represent\u00f3 un cambio dram\u00e1tico en el dise\u00f1o de sist emas con \ngrandes cantidades de ciclos de computaci\u00f3n y espacio de \nalmacenamiento (Ahmadian, Paya y Marinescu, 2014).  \n El movimiento de la tecnolog\u00eda de la nube no estuvo exento de \nesc\u00e9pticos y cr\u00edticos. Los cr\u00edticos argumentaban que era solo una Vol. 6 - 201916INTER  SCIENTIFIC  \n \n \n t\u00e1ctica de marketing, en donde los usuarios ser\u00edan dependientes de \nsistemas propietarios. Para ellos, el fallo de un sistema tan grande \ntendr\u00eda consecuencias significativas para los que depend\u00edan de la nube para sus necesidades d e computaci\u00f3n y almacenamiento. La \nseguridad y la privacidad eran las principales preocupaciones de los usuarios. Los esc\u00e9pticos cuestionaron lo qu\u00e9 era realmente , \nc\u00f3mo difer\u00eda de otros tipos de sistemas distribuidos a gran escala, y por qu\u00e9 podr\u00eda ser exitosa (Marinescu, Paya y Morrison, 2014).  \n \nLos tres modelos de entrega en la tecnolog\u00eda de la nube, Software \nas a Service (SaaS), Platform as a Service (PaaS) e Infraestructure as a Service (laaS) continuar\u00edan coexistiendo en el fu turo \nprevisible. Los servicios basados en SaaS probablemente ser\u00edan \ncada vez m\u00e1s populares porque eran m\u00e1s accesibles. Mientras que, los servicios basados en laaS ser\u00edan del dominio de las personas \ncon experiencia en inform\u00e1tica. Si el esfuerzo de esta ndarizaci\u00f3n \nfuera exitoso, se podr\u00eda ver que las PaaS estaban dise\u00f1adas para migrar de una infraestructura a otra y superar las preocupaciones relacionadas con el bloqueo de proveedores (Marinescu, 2017).  \n Por lo tanto, lograr una seguridad efectiva de la informaci\u00f3n en la \nnube no fue un proceso trivial. Durante mucho tiempo, esta responsabilidad de la administraci\u00f3n fue un principio fundamental de la buena gesti\u00f3n corporativa durante mucho tiempo.  A menudo, \nlas empresas trataban de demostrar que hab\u00edan log rado la \nseguridad a trav\u00e9s de la garant\u00eda. Esta garant\u00eda, generalmente se \nlogra mediante el cumplimiento de las normas o mediante las \nauditor\u00edas. Sin embargo, una de las dificultades con la tecnolog\u00eda de la nube fueron los m\u00e1s de 30 organismos que trabajar on en los \nest\u00e1ndares de seguridad. A\u00fan se est\u00e1 por ver el desarrollo de un est\u00e1ndar de seguridad completamente integral. Ante estos datos, las preguntas de investigaci\u00f3n fueron las siguientes:  \n 1. \u00bfC\u00f3mo la tecnolog\u00eda de la nube ha evolucionado en los \u00faltimos cinco a\u00f1os?  \n2. \u00bfQu\u00e9 protocolos, configuraciones y encriptaci\u00f3n est\u00e1n disponibles en el mercado para asegurar los datos, las \ninformaciones, los programas y las aplicaciones guardadas \nen la tecnolog\u00eda de la nube de las empresas?  \n3. \u00bfC\u00f3mo las compa\u00f1\u00edas que provee n el servicio de la \ntecnolog\u00eda de la nube protegen la confidencialidad de los usuarios? \n4. \u00bfCu\u00e1ntas capas de seguridad aplican los proveedores de la \ntecnolog\u00eda de la nube en sus servidores?  \n5. \u00bfC\u00f3mo los usuarios identifican la seguridad que proveen las \ncompa\u00f1\u00edas  de servicios de la tecnolog\u00eda de la nube y sus \naplicaciones?  \n6. \u00bfC\u00f3mo se manejan las fotos, datos e informaci\u00f3n personal de \nlas bases de datos en las empresas?  \n7. \u00bfQu\u00e9 personas en las empresas acceden a la informaci\u00f3n de \nlas bases de datos?  \n8. \u00bfQu\u00e9 hacen las em presas con la informaci\u00f3n obtenida en las \nbases de datos?  \n9. \u00bfCu\u00e1les son los beneficios que trae utilizar la tecnolog\u00eda de         la nube?  \nEl Equipo de Investigaci\u00f3n de ESET Latinoam\u00e9rica (2015) \nredact\u00f3 un informe para comunicar el estado actual de las \namen azas inform\u00e1ticas y proyectar la posible evoluci\u00f3n en los \npr\u00f3ximos a\u00f1os. En los datos, se especifica que para el 2011 hubo una consolidaci\u00f3n en cuanto a las redes de computadoras que quedaron a merced de un grupo de ciberdelincuentes. En el 2012, la princi pal tendencia se relacion\u00f3 directamente con las amenazas \ndise\u00f1adas para las plataformas m\u00f3viles. En el 2013 se encontr\u00f3 un crecimiento de c\u00f3digos maliciosos para dispositivos como el mobile3, los cuales son el principal tema de la privacidad en \nInternet. Otra tendencia fue la complejidad de estos c\u00f3digos maliciosos dise\u00f1ados para los dispositivos Android. Este aumento \nde c\u00f3digos al igual que el almacenamiento en la nube ha \nexperimentado una preocupaci\u00f3n por la seguridad de los usuarios.  \nActualmente la tend encia es el uso masivo de la nube en \ncomparaci\u00f3n con otros medios tradicionales.  La Tabla 1 presenta este crecimiento de la nube en algunas regiones del mundo y la cantidad de datos almacenados ( Equipo de Investigaci\u00f3n de ESET \nLatinoam\u00e9rica, 2015) . \n Tabla  1. Crecimiento del tr\u00e1fico en la nube por regiones  \n \nRegi\u00f3n  2012  2013  2014  2015  2016  2017  Crecimiento  \nAL 77 117 159 203 249 298 31% \nAP 319 505 736 1042  1415  1876  43% \nECO  69 101 140 191 253 325 36% \nOMA  17 31 51 77 112 157 57% \nNA 469 691 933 1211  1526  1826 32% \nEO 225 311 400 501 623 770 28% \n(AL: Am\u00e9rica Latina; AP: Asia Pac\u00edfico; ECO: Europa Central y Oriental; \nOMA: Oriente Medio y Africa; NA: Norteam\u00e9rica; EO: Europa \nOccidental) (Equipo de Investigaci\u00f3n de ESET Latinoam\u00e9rica, 2015 ) \n \nM\u00c9TODOS \n \nEl estudi o se enmarc\u00f3 en una investigaci\u00f3n con un enfoque \ncuantitativo. La poblaci\u00f3n (N= 500) fueron las organizaciones que utilizan la nube tecnol\u00f3gica en los pueblos de Arecibo, Hatillo y Barceloneta. El muestreo fue no probabil\u00edstico, ya que no se basa \nen el uso  de t\u00e9cnicas de aleatorizaci\u00f3n para seleccionar los \nmiembros (Creswell y Creswell, 2017). Para esto, se entreg\u00f3 la \ncarta para autorizar la administraci\u00f3n del instrumento. Al recibir la autorizaci\u00f3n, se obtuvo una muestra (n=113) de sujetos con \npuestos en u niversidades y comercios. Los participantes en la \ninvestigaci\u00f3n fueron seleccionados sobre el criterio de que \ntendr\u00edan algo que decir sobre el tema, est\u00e1n dentro del rango de \nedad y residen en los pueblos de Arecibo, Hatillo y Barceloneta. Los criterios de  inclusi\u00f3n son ser mayor de 21 a\u00f1os, tener como \nm\u00ednimo un grado asociado, y al menos un a\u00f1o de experiencia en la tecnolog\u00eda de la nube.  \n \nLos participantes fueron informados del prop\u00f3sito del estudio considerando la confidencialidad y el anonimato expuesto  en la \nHoja de Consentimiento Informado.   En esta hoja se requiri\u00f3 la Vol. 6 - 201917INTER  SCIENTIFIC  \n \n firma del participante. Al aceptar de manera libre y voluntaria su \nparticipaci\u00f3n en el estudio, se hizo entrega del cuestionario. La \nparticipaci\u00f3n en este estudio solo conllev\u00f3 riesgos m \u00ednimos, \ncansancio, dejadez o aburrimiento. La investigaci\u00f3n cuantitativa incorpor\u00f3 el respeto a la diversidad cultural en el estudio del fen\u00f3meno.  Se inst\u00f3 a la eliminaci\u00f3n de los riesgos en el estudio con actitudes respetuosas y democr\u00e1ticas sin juzgar m oralmente \nlas vivencias y experiencias de los participantes. El investigador elimin\u00f3 los riesgos con interacciones que reflejaron los buenos \nmodales, el tacto y la sensibilidad a las narraciones de los \nparticipantes. El respeto por la dignidad humana se integr\u00f3 cuando el investigador tuvo una moralidad alta, posee valores y conoce todos los aspectos legales de la investigaci\u00f3n con seres humanos. Las variables en una investigaci\u00f3n deben ser medibles u \nobservables. Es necesario definir las variables conceptua lmente \npara poder compararlas y llegar a conclusiones. Las definiciones \nconceptuales provienen de los diccionarios, enciclopedias y libros especializados.  Las definiciones de algunas de las variables son las siguientes:  \n \n1. Tecnolog\u00eda de la nube - Modelo de la inform\u00e1tica que accede \ninformaci\u00f3n y datos personales por medio del Internet \n(Fearne, 2015).  \n2. Seguridad en la tecnolog\u00eda de la nube - subraya restricciones \ny establece la no violaci\u00f3n de la integridad de las le yes de \nconfidencialidad (Chang y  Ramachandran , 2015 ). \n3. Protocolos- reglas que permiten a las entidades tener un \nsistema de comunicaci\u00f3n para transmitir informaci\u00f3n (Raya y Raya, 2008 ).  \n4. Configuraciones- elementos considerados como externos e \ninternos que forman parte de un ordenador con caracter\u00edstica s \nespec\u00edficas (Raya y  Raya, 2008 ).  \n5. Encriptaci\u00f3n- medida de seguridad basada que codifica la \ninformaci\u00f3n de forma indescifrable a simple vista (Carbonell, 2015).  \n \nEn resumen, la variable dependiente es la evoluci\u00f3n y seguridad \nde la tecnolog\u00eda de la nube.  Las variables independientes incluyen \nlos protocolos, configuraciones, encriptaci\u00f3n, confidencialidad, \ncapas de seguridad, adiestramientos y beneficios en el uso de la tecnolog\u00eda de la nube para las empresas. El instrumento fue un cuestionario estilo Escala Likert creado por el investigador. El \ncuestionario fue revisado por 7 expertos con grado doctoral, de \nacuerdo con sus recomendaciones fue distribuido en empresas de \nla zona norte de Puerto Rico donde se haya verificado que utilizan la tecnolog\u00eda de la n ube para brindar servicios. Antes de la \nadministraci\u00f3n del cuestionario, se obtuvo la autorizaci\u00f3n de la organizaci\u00f3n, y los participantes firmaron el documento de \nconsentimiento informado, el cual se discuti\u00f3 en forma breve de \nc\u00f3mo ha evolucionado la tecnolog\u00eda de la nube. La primera parte de cuestionario incluy\u00f3 los datos demogr\u00e1ficos como g\u00e9nero, preparaci\u00f3n acad\u00e9mica, a\u00f1os en la compa\u00f1\u00eda, puesto que ocupa en la compa\u00f1\u00eda y tiempo que lleva usando la tecnolog\u00eda de la nube. \nLa segunda parte present\u00f3 48 pre misas relacionadas al uso y la seguridad de la tecnolog\u00eda de la nube. Cada premisa tuvo opciones \nde contestarse de acuerdo con la escala Likert: Totalmente en \nDesacuerdo, En Desacuerdo, Ni en desacuerdo ni en Acuerdo, De \nAcuerdo, Totalmente en Acuerdo. Par a obtener la puntuaci\u00f3n \npromedio general, deber\u00e1n sumarse las puntuaciones de los \ncriterios espec\u00edficos y dividirse entre el n\u00famero de \u00edtems en total (Hern\u00e1ndez, Fern\u00e1ndez y Baptista, 2010) .  \n La investigaci\u00f3n cont\u00f3 con la participaci\u00f3n de 39 profesionales  \ndel g\u00e9nero femenino (65.5%) y 39 varones (34.5%). Concerniente a la escolaridad, 59 (52.2%) de los 113 participantes te n\u00edan un \ngrado universitario de bachillerato. El restante se distribuy\u00f3 en: 23.9% maestr\u00eda, 10.6% un doctorado, 8.8% grado asociado, 3.5%  \nposeen cr\u00e9ditos doctorales, y un .9% no contest\u00f3 la premisa. \nRespecto a sus a\u00f1os en la compa\u00f1\u00eda, un 49% lleva de 1 a 5 a\u00f1os, \notro 16.8% contest\u00f3 de 6 a 10 a\u00f1os y un 15.9% lleva m\u00e1s de 21 \na\u00f1os. Otro 13.3% contest\u00f3 11 a 15 a\u00f1os y el restante 4.4% de 16 a 20 a\u00f1os. En el puesto de los participantes se destaca que un 32.7% \nno contest\u00f3; un 15.9% son educadores; 13.3% trabajan en ventas y la misma cantidad se desempe\u00f1an como Net Developer.  \n \nRESULTADOS \n \nDe acuerdo con el an\u00e1lisis estad\u00edstico, la mayor\u00eda de los \nparticipantes contestaron estar de acuerdo en que la tecnolog\u00eda ha \nevolucionado con los a\u00f1os en expansi\u00f3n, flexibilidad, y reduciendo los gastos operacionales. Contestaron estar de acuerdo en que provee menos costos en la seguridad, y herramientas adecuadas p ara la empresa. Se reflej\u00f3 un rango de 4 y medias entre \n3.32 hasta 4.32. La desviaci\u00f3n fluctu\u00f3 entre .975 hasta 1.23 ( Ver \nTabla 2).  \n \nTabla 2.  Evoluci\u00f3n de la nube tecnol\u00f3gica  \n \n n Rango  Media  Desv.Est.  \nHa evolucionado en los \n\u00faltimos a\u00f1os  113 4 4.30 1.025  \nSe ha expandido sin \ncontrol  112 4 3.32 1.133  \nHa aumentado su \nflexibilidad 113 4 3.98 1.052  \nHa reducido los gastos  112 4 3.84 .945 \nProvee menos costos  112 4 3.45 1.161  \nProvee herramientas  112 4 4.15 1.015  \nn es la muestra  \n Para la segunda pregunta: \u00bfQu\u00e9 protocolos, configuraciones y \nencriptaci\u00f3n est\u00e1n disponibles en el mercado para asegurar la data, la informaci\u00f3n, programas y aplicaciones guardadas en la nube de las empresas?; se utilizaron las 6 premisas. De acuerdo a las \nestad\u00edsticas, la moda fue 5 ( Totalmente de acuerdo) en todas las \npremisas. La mediana fluctu\u00f3 entre 3.96 hasta 4.32 (Ver Tabla 3) . \n \nPara contestar la pregunta: \u00bfC\u00f3mo las compa\u00f1\u00edas que proveen el  Vol. 6 - 201918INTER  SCIENTIFIC  \n \n \n servicio de la tecnolog\u00eda de la nube protegen la confidencialidad \nde los usuarios?, se int egraron 5 premisas en el apartado  nombra -\ndo confidencialidad.  \n \nTabla 3. Protocolos de la tecnolog\u00eda de la nube  \n n A B C D E \nv m \nLa empresa en \nla que laboro \ntiene reglas  111 2 4.32 .105 5.00 5 1.105  \nEl protocolo de \nla empresa instruye  112 1 3.96 .117 4.00 5 1.237  \nEl protocolo exige  113 0 4.22 .099 5.00 5 1.050  \nLa empresa \ntiene un conjunto  113 0 4.25 .099 5.00 5 1.057  \nLa empresa usa \nla encriptaci\u00f3n  111 2 4.20 .101 5.00 5 1.060  \nLa empresa se \nrige por un protocolo  113 0 4.32 .092 5.00 5 .975 \nv: va lid, m: missing , A: media; B: error est\u00e1ndar de la media; C: \nmediana; D: moda; E: desviaci\u00f3n est\u00e1ndar  \n \nDe acuerdo con las estad\u00edsticas, las personas est\u00e1n de acuerdo en que la organizaci\u00f3n protege la confidencialidad, la informaci\u00f3n personal de las bases de datos es protegida por la empresa en la que laboran y las personas que acceden a la informaci\u00f3n de las \nbases de datos firman acuerdos de confidencialidad. Por el \ncontrario, est\u00e1n en desacuerdo en que en el trabajo se pueden acceder los datos sin ninguna seguridad tecnol\u00f3gica y que pudiera \nperjudicar la confidencialidad (Ver Tabla 4).  Tabla 4. Confidencialidad \n \n n Media  Desv.Est.  B \nLa organizaci\u00f3n \nprotege la \nconfidencialidad  111 4.24 1.011  .096 \nEn el trabajo se \npueden acceder  113 2.20 1.383  .130 \nEl \ntrabajo\u2026pudiera \nperjudicar la \nconfidencialidad  113 2.65 1.420  .134 \nLa informaci\u00f3n \npersonal\u2026es protegida  112 4.26 1.046  .099 \nLas personas que acceden\u2026  111 4.05 1.056  .100 \nB: error est\u00e1ndar de la media  \n \nEn la pr\u00f3xima pregunta: \u00bfCu\u00e1ntas capas de seguridad apli can los \nproveedores de la tecnolog\u00eda de la nube en sus servidores?, se  obtuvo que los participantes no est\u00e1n de acuerdo ni en desacuerdo  \n(Ver Tabla 5).  En relaci\u00f3n con la pregunta: \u00bfC\u00f3mo los usuarios identifican la \nseguridad que proveen las compa\u00f1\u00edas de s ervicios de la tecnolog\u00eda \nde la nube y sus aplicaciones?; los participantes contestaron estar \nde acuerdo. Los participantes aseguraron que la organizaci\u00f3n tiene protocolos para asegurar la data, la informaci\u00f3n, programas y \naplicaciones guardadas en la nube ; corrige r\u00e1pidamente cualquier \npeligro de seguridad tecnol\u00f3gica, aunque resulte costoso; considera los protocolos de seguridad; realiza inspecciones de seguridad tecnol\u00f3gica; investiga los problemas de seguridad tecnol\u00f3gica; provee el equipo de seguridad tecnol\u00f3gica para realizar las tareas y los mantiene informado de los riesgos a los que est\u00e1n expuestos al realizar su trabajo. Por otro lado, no est\u00e1n \nde acuerdo ni en desacuerdo en que los/las especialistas de \nseguridad tecnol\u00f3gica siempre est\u00e1n disponibl es cuando se \nnecesitan (Ver Tabla 6). \n Tabla 5.  Capas de Seguridad  \n \n La empresa cuenta con \nmas de tres Las capas de seguridad\u2026  \nValid  112 111 \nMissing  1 2 \nMedia  3.76 3.85 \nB 0.099  0.096  \nMediana  4.00 4.00 \nModa  3 3a \nDesv. \nEst. 1.050  1.011  \na. M\u00faltiples moda s existen. Se muestra el valor menor.  \nB: error est\u00e1ndar de la media \n Tabla 6.  Identificaci\u00f3n de la seguridad  \n \n \nn Media  Desv. Est.  B \nLa organizaci\u00f3n \ntiene protocolos  111 4.13 1.001  .095 \nLa organizaci\u00f3n \ncorrige 110 4.09 1.045  .100 \nLa organizaci\u00f3n \nconsider a 112 4.17 0.939  .089 \nLos especialistas \nde seguridad\u2026  112 3.86 0.994  .094 \nLa organizaci\u00f3n \nrealiza  111 3.90 1.035  .098 \nLa organizaci\u00f3n \ninvestiga 112 4.02 1.004  .095 \nLa organizaci\u00f3n \nprovee  112 4.07 0.975  .092 \nLa organizaci\u00f3n \nnos mantiene  111 4.04 1.044  .099 \nB: error est\u00e1ndar de la media  \n En la pregunta: \u00bfC\u00f3mo se manejan las fotos, datos e informaci\u00f3n  \npersonal de las bases de datos en las empresas?; se obtuvo que los participantes no est\u00e1n de acuerdo ni en desacuerdo en cuanto a Vol. 6 - 201919INTER  SCIENTIFIC  \n \n poder acceder a fotos, da tos y/o informaci\u00f3n personal en las bases \nde datos. Los participantes est\u00e1n de acuerdo en que se utilizan \nprotocolos en las bases de datos y que las fotos son protegidas por \nlas empresas. Por \u00faltimo, est\u00e1n completamente de acuerdo en que \nlos datos son prot egidos por las empresas (Ver Tabla 7). \n \nTabla 7.  Manejo de Datos  \n \n n A B C D E R \nv m \nPuedo \nacceder \nfotos  112 1 3.06 .131 3.00 2 1.390  4 \nSe utilizan \nprotocolos  112 1 4.13 .092 4.00 4\u00aa 0.978  4 \nLas fotos \nson \nprotegidas  112 1 3.91 .099 4.00 4 1.045  4 \nLos datos \nson protegidos  112 1 4.15 .093 4.00 5 0.988  4 \na. M\u00faltiples modas existen. Se muestra el valor menor.  \nv: vali d, m: missing , A: media; B: error est\u00e1ndar de la media; C: \nmediana; D: moda; E: desviaci\u00f3n est\u00e1ndar; R: rango \n Tabla 8.  Acceso a la in formaci\u00f3n  \n \n n Media  Desv.Est.  B \nLas personas \nacceden  113 2.27 1.376  .129 \nLa informaci\u00f3n \nobtenida 112 4.10 1.048  .099 \nEl acceso a la \ninformaci\u00f3n esta regulado 112 4.13 1.009  .095 \nEl acceso a la \ninformaci\u00f3n esta en continua \nrevision 112 4.08 0.978  .092 \nEl acceso a la \ninfromacion \nincluye claves segurdas 112 4.18 0.922  .087 \nLas claves  113 4.04 1.077  .101 \nB: error est\u00e1ndar de la media  \n El an\u00e1lisis de datos para la pregunta: \u00bfQu\u00e9 personas en las empresas acceden a la informaci\u00f3n de las bases de datos?; rev el\u00f3 \nque los participantes est\u00e1n en desacuerdo en que las personas acceden sin ninguna seguridad a la informaci\u00f3n en las bases de datos. Por otro lado, est\u00e1n de acuerdo en que la informaci\u00f3n obtenida es para uso de la organizaci\u00f3n; el acceso a la informaci\u00f3 n \nen las bases de datos est\u00e1 regulado; est\u00e1 en continua revisi\u00f3n; y que incluye claves seguras. La misma tendencia se expres\u00f3 en cuanto a que las claves para la informaci\u00f3n en las bases de datos \nson reemplazadas constantemente (Ver Tabla 8). \n \nEn la pr\u00f3xima  pregunta: \u00bfQu\u00e9 hacen las empresas con la \ninformaci\u00f3n obtenida en las bases de datos?; los participantes \ncontestaron estar de acuerdo en que la informaci\u00f3n es para uso exclusivo de la empresa. Por lo que, est\u00e1n en desacuerdo en que la informaci\u00f3n es compar tida con otras empresas, que est\u00e9 \naccesible para todas las personas de la empresa y que provenga de \notras empresas. No est\u00e1n en desacuerdo ni de acuerdo en que est\u00e1 \nprohibido compartir la informaci\u00f3n con otras empresas (Ver Tabla \n9). \n En el \u00faltimo apartado  utilizado para contestar: \u00bfCu\u00e1les son los \nbeneficios que trae el utilizar la tecnolog\u00eda de la nube?; los \nparticipantes indicaron estar de acuerdo en que la empresa se ha \nbeneficiado con la tecnolog\u00eda de la nube. La misma tendencia se observ\u00f3 en cuanto a q ue la tecnolog\u00eda de la nube agiliza las \noperaciones. No est\u00e1n en acuerdo ni desacuerdo acerca de la tecnolog\u00eda de la nube sea costosa, imprescindible, f\u00e1cil y se utilice \ndiariamente (Ver Tabla 10). \n \nTabla 9.  Uso de la informaci\u00f3n  \n \n n Media  Desv.Est.  B \nLa informaci\u00f3n \nes para uso  112 4.02 1.107  .105 \nLa informaci\u00f3n \nes compartida 113 2.70 1.401  .132 \nLa informaci\u00f3n \nest\u00e1 accesible  112 2.70 1.381  .130 \nEst\u00e1 prohibido  113 3.41 1.406  .132 \nLa informaci\u00f3n \nproviene 112 2.76 1.364  .129 \nB: error est\u00e1ndar de la media  \n Tabla 10.  Beneficios  \n \n n Media  Desv.Est.  B \nLa empresa se ha \nbeneficiado  110 4.00 1.040  .099 \nLa tecnolog\u00eda \nagiliza 112 4.17 0.958  .090 \nLa tecnolog\u00eda no \nes costosa 110 3.47 1.106  .105 \nLa tecnolog\u00eda es \nimprescindible 111 3.79 1.019  .097 \nLa tecnolog\u00eda e s \nutilizada \ndiariamente 111 3.95 1.021  .097 \nLa tecnolog\u00eda es \nf\u00e1cil 112 3.83 1.073  .101 \nB: error est\u00e1ndar de la media  \n Vol. 6 - 201920INTER  SCIENTIFIC  \n \n \n DISCUSI\u00d3N \nEl an\u00e1lisis estad\u00edstico estableci\u00f3 que los participantes reconocen \nque la tecnolog\u00eda de la nube ha evolucionado en los \u00faltimos a\u00f1os, \nprovee herramientas adecuadas para la empresa y que se tienen \nreglas en sus sistemas de informaci\u00f3n. El protocolo de la empresa instruye a qu\u00e9 hacer cuando termina la sesi\u00f3n de conexi\u00f3n y exige \nestrategias para asegurar la seguridad. La empresa tiene  un \nconjunto de los elementos internos y externos para asegurar la \ndata; usa la encriptaci\u00f3n para asegurar la data y se rige por un \nprotocolo para el acceso a la informaci\u00f3n.  \nSe pudo establecer que los participantes est\u00e1n de acuerdo en que la tecnolog\u00eda d e la nube se ha expandido sin control. Esta ha \nevolucionado con los a\u00f1os en expansi\u00f3n, flexibilidad, y \nreduciendo los gastos operacionales. La tecnolog\u00eda de la nube \nprovee menos costos en la seguridad, y herramientas adecuadas para la empresa. Por lo que l as organizaciones y/o empresas \nprotegen la confidencialidad, la informaci\u00f3n personal de las bases \nde datos es protegida por la empresa en la que laboran y las  \npersonas que acceden a la informaci\u00f3n de las bases de datos \nfirman acuerdos de confidencialidad. Estas empresas tienen \nprotocolos para asegurar la data, la informaci\u00f3n, programas y \naplicaciones guardadas en la nube.  Adem\u00e1s,  corrigen r\u00e1pidamente \ncualquier peligro de seguridad tecnol\u00f3gica, aunque resulte costoso; consideran los protocolos de seguridad;  realizan \ninspecciones de seguridad tecnol\u00f3gica; investigan los problemas de seguridad tecnol\u00f3gica; y proveen el equipo de seguridad tecnol\u00f3gica para realizar las tareas. Las empresas mantienen \ninformados a sus empleados acerca de los riesgos a los que est \u00e1n \nexpuestos al realizar su trabajo; utilizan protocolos en las bases de \ndatos y protegen las fotos. En cuanto a la informaci\u00f3n, se corrobor\u00f3 que es para uso de la organizaci\u00f3n. El acceso est\u00e1 regulado, en continua revisi\u00f3n e incluye claves seguras. Las cl aves \npara la informaci\u00f3n en las bases de datos son reemplazadas \nconstantemente y son para uso exclusivo de la empresa.  \nEl estudio se limit\u00f3 a obtener informaci\u00f3n de 113 profesionales \ndel \u00e1rea norte de Puerto Rico en el tema de la evoluci\u00f3n de la seguridad en la nube tecnol\u00f3gica. Estos profesionales residen en \nel \u00e1rea norte de Puerto Rico en pueblos como Arecibo, Barceloneta y Hatillo. No obstante, los hallazgos en esta investigaci\u00f3n deben ser tomados en consideraci\u00f3n por las \nempresas para establecer pol\u00edtic as y pr\u00e1cticas institucionales que \naporten a la seguridad en la tecnolog\u00eda de la nube. Adem\u00e1s, se \nrecomienda aplicar este estudio en otros escenarios para confirmar \nlos hallazgos aqu\u00ed presentados, ampliar la muestra que sea m\u00e1s \nsignificativa, y contribuir a la identificaci\u00f3n de las necesidades espec\u00edficas que puedan afectar a las empresas. Finalmente, se recomienda en futuros estudios simila res se considere lo siguiente: \nrealizar estudio con una muestra m\u00e1s alta y en diferentes tipos de \nempresas; capacitar a las empresas sobre la seguridad en la \ntecnolog\u00eda de la nube y ofrecer charlas o conferencias a las empresas acerca de la seguridad en la tecnolog\u00eda de la nube.   Aunque las nubes son cada vez m\u00e1s populares, se ha podido \nobservar que algunas cosas pueden \"salir mal\" cuando se conf\u00eda \nen un proveedor de nube con sus datos. Proporcionar defensas \npara estos es un \u00e1rea activa de investigaci\u00f3n. Se presentaron los \ndatos de una encuesta de las situaciones que pueden ocurrir en las \nempresas. Sin embargo, estas solu ciones son, en este momento, \nacad\u00e9micas. Todav\u00eda hay preguntas sobre qu\u00e9 tan bien estas protecciones pueden funcionar en la pr\u00e1ctica y, adem\u00e1s, qu\u00e9 tan f\u00e1ciles de usar pueden ser. Por \u00faltimo, todav\u00eda hay que ver qu\u00e9 tan \npopular ser\u00e1 el almacenamiento de da tos en las nubes, y qu\u00e9 \nprotecciones los usuarios elegir\u00e1n usar. \nEn muchos escenarios de aplicaciones, como los de empresas u \norganizaciones, el acceso de los usuarios a los datos suele ser \nselectivo y altamente diferenciado. Diferentes usuarios disfrutan \nde diferentes privilegios de acceso con respecto a los datos. \nCuando los datos se subcontratan a la nube, es fundamental la aplicaci\u00f3n de un acceso a datos seguro, eficiente y confiable entre una gran cantidad de usuarios. Tradicionalmente, para controlar la \ndiseminaci\u00f3n de datos sensibles a la privacidad, los usuarios \nestablecen un servidor confiable para almacenar datos localmente \nen forma clara, y luego controlan ese servidor para verificar si los usuarios solicitan a los usuarios una certificaci\u00f3n adecu ada antes \nde permitirles acceder a los datos. Desde el punto de vista de la seguridad, esta arquitectura de control de acceso ya no es aplicable \ncuando se subcontratan datos a la nube. Debido a que los usuarios \nde datos y los servidores en la nube no se encuentran en el mismo dominio de confianza, es posible que ya no se conf\u00ede plenamente en el servidor como un monitor de referencia omnisciente para \ndefinir y aplicar pol\u00edticas de control de acceso y administraci\u00f3n de \ndetalles del usuario. En caso de compromiso del servidor o \nposibles ataques internos, los datos privados de los usuarios podr\u00edan incluso estar expuestos.  \nUna implicaci\u00f3n del estudio es desarrollar un enfoque para \nimponer el acceso a los datos sin depender de los servidores de la \nnube y cifrar lo s datos de una manera diferenciada y divulgar las \nclaves de descifrado correspondientes solo a los usuarios \nautorizados. Sin embargo, este enfoque generalmente adolece de graves problemas de rendimiento y, especialmente cuando un gran n\u00famero de usuarios ba jo demanda desean un control de acceso a \ndatos detallado. Se insta a las empresas a trabajar en c\u00f3mo realizar un dise\u00f1o de control de acceso detallado que aproveche al m\u00e1ximo \nla riqueza de recursos de la tecnolog\u00eda en la nube. De esta forma, \nlos usuarios d e datos podr\u00edan delegar de forma segura a la nube \nlas cargas de trabajo de administraci\u00f3n de datos, el manejo frecuentes actualizaciones de privilegios de acceso de usuarios en \ngrandes sistemas din\u00e1micos, al tiempo que se preserva la confidencia lidad de lo s datos subyacentes.  \nREFERENCIAS \nAhmadian, M., Paya, A., & Marinescu, D. C. (2014, May). \nSecurity of applications involving multiple organizations and Vol. 6 - 201921INTER  SCIENTIFIC  \n \n order preserving encryption in hybrid cloud environments.  \nPresented at 2014 IEEE International  Parallel  & Distributed \nProcessing Symposium Workshops , Phoeniz, AZ.  \nAndrew, R. (2014). Cloud: The 60 -Year -Old Hot Topic. Cloud \nComputing World, 1, 22-23. \nCarbonell, M. (2015). Bitcoin: m\u00e1s que una tecnolog\u00eda o una \nmoneda, una revoluci\u00f3n .  Recuperado de \nhttp://sobrebitcoin.com/bitcoin- mas-una-tecnologia-una -moneda -\nuna-revolucion/ \nChang, V., & Ramachandran, M. (2015 ). Towards achieving data \nsecurity with the cloud computing adoption framework. IEEE \nTransactions on Services Computing , 9(1), 138 -151.  \n Creswell, J. W. , & Creswell, J. D. (2017).  Research design:  \nQualitative, quantitative, and mixed methods approaches . \nCalifornia: Sage publications.  Equipo de Investigaci\u00f3n de ESET Latinoam\u00e9rica (2015). Tendencia 2014: El desaf\u00edo de la privacidad en Internet . \nRecuperado  de http://www.eset-la.com/pdf/tendencias_ \n2014_el_desafio_de_la_privacidad_en_internet.pdf  \nFearne, D. (2015). The Internet of Things. Cloud Computing \nWorld , 4, 22-24. \nFlantrmskv, H. (2012). La computaci\u00f3n en nube y el cambio del \nuniverso inform\u00e1tico.  Pens amiento y Cultura, 15 , 1, 88 -93. \nFurht, B., &  Escalante. A. (2010). Handbook of cloud computing . \nNY: Springer.  \nGierbolini-Bonilla, J. (2009). Estudio de consulta sobre \nPrescripci\u00f3n y Jurisdicci\u00f3n por medios cibern\u00e9ticos en caso de \nresponsabilidad civil extracontractual contra corporaciones \nfor\u00e1neas; como aportaci\u00f3n al Derecho Inform\u00e1tico en Puerto Rico. Facultad de Derecho. Universidad Interamericana de Puerto \nRico.  \nHern\u00e1ndez, R., Fern\u00e1ndez, C.,  y  Baptista, P. (2010).  Metodolog\u00eda \nde la investigaci\u00f3n.  M\u00e9xi co: McGraw -Hill.  \nJin, H., Dai, W., & Zou, D. (2016). Theory and methodology of \nresearch on cloud security.  Science China Information \nSciences , 59(5), 050105 -1. \nMarinescu, D. C. (2017).  Cloud computing: theory and practice . \nCambridge, MA, Estados Unidos:  Morgan Kaufmann.  Marinescu, D. C., Paya, A., & Morrison, J. P. (2014). Coalition \nformation and combinatorial auctions; applications to self -\norganization and self -management in utility computing.  arXiv \npreprint arXiv:1406.7487 . \nMather, T., Kumaraswamy, S . & Latif, S. (2009). Cloud security \nand privacy an enterprise perspective on risks and compliance . \nSebastopol, CA: O\u2019Reilly.  \nNepal, S., &  Pathan, M. (2014). Secutiry, privacy and trust in \ncloud systems . NY: Springer.  \nPaczkowski, J. (2009). Another one  of these clouds computing \nrants and you\u2019ve got yourself a stand -up routine, Larry. \nRecuperado de http://allthingsd.com/20091002/another -one-of-\nthese-cloud -computing -rants-and -you%E2%80%99ve -got-\nyourself -a-stand-up-routine-larry/ \nRaya, J., &  Raya, L. (200 8). Redes locales . Cuarta edici\u00f3n. \nM\u00e9xico: Alfaomega grupo.  \nWalton, Z. (2012). Americans Think Cloud Computing Comes \nfrom Actual Clouds . Recuperado de \nwww.webpronews.com/americans-think-cloud -computing -\ncomes -from -actual -clouds -2012 -08. \n \nAUTOR /AUTHOR  \n \nAlex ander Nieves M\u00e9ndez . Estudiante de l programa \ndoctoral en Proyectos con Especialidad en Investigaci\u00f3n  de \nTecnolog\u00edas de la Informaci\u00f3n y Comunicaci\u00f3n (TIC) de la \nUniversidad Internacional Iberoamericana (UNINI) en Puerto Rico. Puede ser contactado al correo  electr\u00f3nico:  \na_nieves2@hotmail.com  \n \nStudent of the doctoral degree in Project with specialization in \nresearch in information technology reserach and communication \nat the International Iberoamerican University (UNINI) in Puerto \nRico. May be contacted via email: a_nieves2@hotmail.com  \n \n \n \n \n  Vol. 6 - 201922INTER  SCIENTIFIC  \n \n Methicillin -resistant Staphylococcus aureus and the effectiveness of \nvancomycin in hospitals and nursing h omes \n \nStaphylococcus a ureus resistente a la meticilina y la efectividad de la vancomicina                              \nen hospitales y hogares de ancianos  \n \n \nSoto -Balseiro, R. M., P\u00e9rez-Albino, I., Mel\u00e9ndez- Vel\u00e1zquez, D., Torres -Bugar\u00edn, O.  \n \nUniversidad Aut\u00f3noma de Guadalajara , Jalisco, M\u00e9xico, School of Medicine  \n \nABSTRACT \n \nStaphylococcus aureus is an opportunistic pathogen, frequently found in the human body asymptomatically. Methicillin -resistant \nStaphylococcus aureus (MRSA) are resistant to methicillin and essentially all ot her beta -lactam antibiotics. The objective of this \nmanuscript is to present the effectiveness of vancomycin  in the treatment of MRSA as well as the prevalence in hospitals and \nnursing homes in the United States ( US) and Mexico. The present study shows high  incidence of MRSA in different hospital \nareas  and nursing homes  as well as by  population and nationality. It is important that  medical researchers and scientists can \ncreate awarenes s of this problem and promote more research on the creation of new antimic robials.  \n \nRESUMEN \n Staphylococcus aureus  es un agente pat\u00f3geno oportunista  que con frecuencia se encuentra en el cuerpo humano de forma asintom\u00e1tica. \nStaphylococcus  aureus resistente a meticilina (MRSA, por sus siglas en ingl\u00e9s) es resistente a meticilina y esencialmente a todos los \nantibi\u00f3ticos betalact\u00e1micos. El objetivo de este manuscrito es dejar de manifiesto la efectividad de la vancomicina en el tratamiento de \nMRSA, as\u00ed como su prevalencia en hospitales y hogares de ancianos en los Estados Unidos ( E.U.) y M\u00e9xico. El presente estudio muestra \nuna alta incidencia de MRSA en las diversas zonas hospitalarias  y hogares de ancianos  al igual que por  poblacionales y nacionalidad. \nEs importante que los investigadores m\u00e9dicos y los  cient\u00edficos cre en conciencia  de este problema y prom uevan m\u00e1s  investigaci ones para \nla creaci\u00f3n de nuevos antimicrobianos. \n \nKEYWORDS MRSA,  antimicrobial, vancomycin  \n PALABRAS CLAVE MRSA, antimicrobiano, vancomicina \n \nINTRODUCTION \n \nResistance to antibiotics is the new challenge of medica l \nresearchers, and consequently the search for new antibiotics as a \nresult of the resistance presented by microorganisms specifically Staphylococcus  aureus resistant to penicillin. In this manuscript \nwe evaluate  it in the north a merican and mexican state \npopulations. T here are several problems with antibiotics ; diseases \nin the present are often not diagnosed in time and it is becoming more difficult to treat them because some antibiotics are losing effectiveness due to their excessive or improper use (Agenc ia \nEFE, 2017).  \n In search of new antibiotics, the World Health Organization  \n(WHO) tries to promote research around dangerous bacteria. The critical priority group s include multi -resistant bacteria, which are  \nespecially dangerous in hospitals, nursing home s and among \npatients who need to be treated with devices such as ventilators    and intravenous catheters. These include the (ESKAPE) group, Enterococcus faecium , S. aureus , Klebsiella pneumoniae , \nAcinetobacter baumannii , Pseudomonas aeruginosa , and  \nEnterobacter  species, which can cause serious and often lethal \ninfections (Agencia EFE, 2017). \n \nSince the discovery of penicillin in 1928,  techniques have been \ndeveloped to study the effectiveness of antibiotics in different species of bacteria . One of these tests is the disk diffusion test that \nhas been used for more than 70 years in microbiology l aboratories \n(Soto, Gonzalez, &  Ortiz, 2015).  By 1959, methicillin, the first \nsemisynthetic penicillin was obtained by altering the chemical structure of natural  penici llin, which was rapidly reaching 90% \nresistance levels. Methicillin became the agent of choice for the treatment of infection by this beta -lactamase producing bacteria \ndue to its ability to evade the acti ons of beta -lactamases (Murillo - Vol. 6 - 201923INTER  SCIENTIFIC  \n \n Llanes, Gonz\u00e1lez -Ibarra, Velarde -Felix, & Alejo -Armenta, 2016).  \n \nMRSA are prevalent bacterial pathogens that cause both health \ncare and community -associated infections. Increased resistance to \nthe prescribed antibiotics has made MRSA a serious threat to \npublic health worldwi de (Murillo et al., 2016). This review article \nis focused in the emergence resistance of MRSA and the use of Vancomycin  as a treatment . The presence of MRSA is demarcated \nin hospitals and nursing homes in two countries with a large \npopulation in the E .U. and Mexico. This study shows a high \nincidence of MRSA in the different hospital areas, nursing homes  \nas well as by population and nationality.   \n \nAntibiotic treatment for MRSA \n \nMRSA is a common cause of infection in community and he alth \ncare setting s (Batina, Crnich, Anderson, &  Dofter, 2016) .  In the \npast, before the origin of the antibiotics, infections from common \nopportunistic pathogens such  S. aureus had a higher risk of \nmortality rates. Although, new antibiotic can provide a temporary \nsolution, they are  prone to the development of resistance profiles. \nThe pattern of antibiotic resistance with respect to age of patients \ndepended on the antibiotic mode of action . This resistance \nmutation rates can be significantly altered for a given antibiotic in their co ncentration, us e or misuse (Garcia, Delorme &  Nasr, \n2017).  \n The use of methicillin in medicine has been replaced by newer \nantibiotics. In clinical practice, MRSA indicates resistance to \noxacillin and analogue of methicillin and cefoxitin a second \ngeneratio n cephamycin. A few antibiotics that also present \nresistance besides vancomycin  are: fluoroquinolone, rifampin, \ntetracycline and sulfamethoxazole -trimethoprim . Being \nfluoroquinolone resistance the one that displayed a gradual and steady increase among age patients . S ulfamethoxazole -\ntrimethoprim maintain a low resistance percentage across all age \nclasses (Batina et al., 2016) . \n There are various alternatives to vancomycin  in MRSA treatment. \nA glycopeptide with a similar mode of action is teicoplanin. It is a bactericidal antibiotic, it inhibits bacterial cell wall synthesis by \nthe blockage of glyc opeptide polymerization (Lee &  Howden, \n2015). With higher and appropriate dosing, it can be compared \nwith Vancomycin , this was shown by recent  data and meta -\nanalysis . Teicoplanin is associated with lower rate of adverse \nevents. On the contrary, in patients with MRSA pneumonia and \nbacteremia treated with higher teicoplanin MICs have been associated with increased mortal ity and poor clinical ou tcomes \n(Holmes, Tong, Davi s, & Van, 2015) . \n Another good alternative is memisynthetic lipopoly peptide \nanalogues of   vancomycin , which are dalbavancin, oritavancin and \ntelavancin. They have a heptapeptide core, which enables the \ninhibition of cell wall synthesis. They are also bact ericidal and destabilize cell membrane (Lee &  Howden, 2015). These \nsemisynthetic lipopolypeptide have a prolonged half -life and \nincreased activity against gram -positive cocci due to its lipophilic \nside chain. S. aureus  membrane barrier function is affected  by \ntelavancin and oritavancin. These three drugs also present activity \nagainst v ancomycin  -resistant S. aureus  (VRSA) (Holmes et al., \n2015).  \n Telavancin compared with vancomycin  has a 10 -fold more \npotency. This antibiotic shows in vitro  activity against \nvancomycin intermediate Staphylococcus aureus  (VISA), MRSA, \nlinezolid nonsusceptible and daptomycin non -susceptible S.  \naureus . Compared with linezolid and vancomycin , telavancin \ndemonstrated superior bactericidal activity shown in in vitro  \nstudies of hV ISA clinical strains. Various concerns were raised \nbecause there was no additional benefit over vancomycin , \nincreased QT prolongation, potential increased nephrotoxicity compared with vancomycin  and possible impurities in the \nmanufacturing of the drug (Holmes et al., 2015).  \n \nIn the United States telavancin is used for hospital acquired \npneumonia due to gram -positive bacteria in which alternate \ntreatments (Holmes et al., 2015). This medication has a black box warning due to the its negative effects to the kidney s. Other \nadverse side effects were thrombocytopenia and an elevated \nserum creatinine.  \n \nAnother antibiotic that is a lipoglycopeptide derived from  \nteico planin is dalbavancin. This medication can be administered \nonce a week due to its increased terminal half -life up to 250 hours. \nDalbavancin compared with daptomycin and vancomycin  has an \n8 to 16 -fold more activity against  VISA and  MRSA  (Holmes et \nal., 2015). In a study dalbavancin was equal and there were few adverse effects mainly gastrointestinal complicati ons and pruritus \n(Holmes et al., 2015).  Oritavancin is a bactericidal antibiotic with extensive tissue \ndistribution with an increased half -life up to 393. Studies to \ncompare its potency are not clear since the drug sticks to to plastic \ntubes and microdilu tion wells. It affects VISA, VRSA and MRSA. \nFor the treatment of bacteremia, endocarditis and invasive infection there are no clinical trials. Oritavancin showed non -\ninferiority compared with vancomycin  for the primary composite \nendpoint of early clinical evaluation at 48 to 72 hours (Holmes et \nal., 2015).  \n Anti-MRSA cephalosporins, ceftaroline and ceftobiprole, show in \nvitro  activity against MRSA. This antibiotic is bactericidal and \ninhibit bacterial wall synthesis and activation of autolysis due to inacti vation of penicillin -binding proteins (Lee & Howden, \n2015).  Compared with Vancomycin  or glycopeptides, \u00df -lactams \nare associated with improved clinical outcomes.  \n \nCeftaroline , an anti-MRSA  and VISA  cephalosporin , is approved  Vol. 6 - 201924INTER  SCIENTIFIC  \n \n  in the U.S.  for the treatment  community -acquired pneumonia \n(CAP) and acute bacterial skin and skin structure inf ections \n(ABSSSI). In patients with incessant MRSA bacteremia, salvage \ntherap y and ceftaroline was effective. Several adverse side effects \nwere reported: rash, headache s and infusion-related symptoms. \nAlso, formation of urinary crystals, elevation in liver \ntransaminases and creatinine kinase. Ceftaroline resistance has \nbeen reported in MRSA, and other (VISA, hVISA, daptomycin \nnonsusceptible and linezolid nonsusceptible S. aure us) laboratory \nisolates. These strains of S. aureus have mutations in PBP2a, this \nleads to reduced efficacy, lower binding affinity and higher ceftaroline MICs (Holmes et al., 2015).  Another anti -MRSA cephalosporin is ceftobiprole. It has larger \nspectrum of activity than ceftaroline. It retains activity against \nmore resistant S. aureus  strains. In a study, patients with MRSA \npneumonia treated with ceftobiprole saw microbiological eradication and favorable rates of clinical cure . (Holmes et al., \n2015). Adve rse side effects are similar to does showed by other \ncephalosporins. \n \nDaptomycin is a bactericidal cyclic lipopeptide antibiotic. It has a rapid membrane depolarization and efflux of potassium, due to its calcium-dependent binding to the cytoplasmic membra ne \n(Holmes et al., 2015). This antibiotic shows concentration -\ndependen t bactericidal activity (Lee &  Howden, 2015). \nDaptomycin leads to rapid cell death because it arrests  protein \nsynthesis, RNA and DNA. One of the disadvantages is that daptomycin is inact ivated by pulmonary surfactant and cannot be \nused in used in pneumonia. In cerebrospinal fluid, this antibiotic has poor penetration which can improve the setting of inflamed \nmeninges (Holmes et al., 2015).  It shows  activity against MRSA \nand VRSA. If vanco mycin  therapy fails daptomycin is used as a \nprimary choice, especially in infections with high Vancomycin  \nMICs. Daptomycin resistance has been linked with previous use \nof vancomycin  and retained prosthetic devices. The Infectious \nDiseases Society of America guidelines for MRSA infections recommends that if the patient suffering from complicated \nbacteremia has been treated with Vancomycin  and failed, if \ndaptomycin is to be used it has to be combined with another agent (Holmes et al., 2015).  \nLinezolid is ano ther antibiotic used against MRSA, it is \nbacteriostatic. It is an oxazolidinone that prevents the formation \nof the 70s -initiation complex and shows activity against MRSA. \n(Holmes et al., 2015).  Tedizolid is an oxazolidinone engineered to \nimprove efficacy and bioavailability and to decrease its toxicity compared with linezolid. In contrast to linezolid it needs to be \nadministered once daily and it 4 to 16 times greater potency. This \nantibiotic shows activity against linezolid nonsusceptible S. \naureus . Tedizo lid shows less gastrointestinal problems a nd \nmyelotoxicity than linezolid. One problem that can arise is that at \nclinical relevant doses, the risk of serotonergic syndrome is \nnegligible due to lack of monoxidase inhibition (Holmes et al.,  2015).  \n \nQuinupris tin/dalfopristin (QD) is an antibiotic that combines two  \nsemisynthetic streptogramin. This antibiotic inhibits bacterial protein synthesis by binding to the 50s -bacterial ribosome in two \nsequential steps. The combination of quinupristin /dalfopristin is synergistic and bactericidal, each drug alone is bacteriostatic \nagainst susceptible gram -positive organisms including MRSA. In \nanimal trials QD showed mixed results, rapid bactericidal activity \nin a S. aureus  mouse endocarditis but showed decreased results to \nVancomycin  in MRSA rabbit endocarditis model and both rabbit \narthritis model (Holmes et al., 2015). \n Tigecycline is an antibiotic derived from minocycline, a parenteral \nglycylcycline. In 30 to 40% of treated patients with tigecyc line \nshowed vomiting and nausea. Tigecycline is highly active against \nMRSA isolates in in vitro . In a MRSA rat thigh infection model, \ntigecycline has activity sim ilar to Vancomycin  against MRSA. \nThis antibiotic is similar to teicoplanin in rabbit osteomyelitis \nmodel. In 2010 , the FDA issued a safety warning and in a 2013 a \nblack box warning, due to an increased risk of mortality in patients \nin treatment with tigecycline compared with other antibiotics (Holmes et al., 2015).  As a summary, we list some of the most importants antibio tics \nmentioned above with their characteristics (Table 1). All the antibiotics mentioned were acquired from (Holmes et al., 2015).  \n Vancomycin  treatment for MRSA  \n \nIn the early 1950\u2019s recognition of emerging antibiotic -resistant \nstrains of S. aureus began (Lee &  Howden, 2015).  As a response, \npharmaceutical companies began screening programs for \nantibiotics with high specificity and activity against staphylococci. The most common antibiotics used against MRSA are vancomycin  and daptomycin (Hassoun, Linden an d Friedman, \n2017). Vancomycin  is produced by Streptococcus orientalis  and \nis a tricyclic glycopeptide antibiotic. It is used in hospital, to combat infections by Gram -positive bacteria including MRSA, \npenicillin- resistant pneumococci and in patients that are allergic \nto cephalosporins and penicillin (Bruniera et al., 2015). Its administration is intravenously since little is absorbed in the \ngastrointestinal tract. \n \nVancomycin  became the standard treatment for MRSA infection s \nfor decades after its developme nt. In 1958 due to studies reporting \nadverse effects of vancomycin  including infusion reaction, \nototoxicity and nephrotoxicity, its clinical use was limited due to \nthese effects (Lee & Howden, 2015). Vancomycin  \u2019s utility is \nrestricted by its low tissue penetration, decreased bactericidal \nactivity and escalating reports of treatment failure and  resistance \n(Hassoun, Linden &  Friedman, 2017). In the 1970s it was \ndetermined that some of the adverse effects were due to impurities \nthat were eliminated. Vancomyci n became a regular treatment for  Vol. 6 - 201925INTER  SCIENTIFIC  \n \n  S. aureus in 1980s.  \n \nTable 1. List of antibiotic treatments for MRSA  \n \nAntibiotic  Characteristics  \nVancomycin  Is produced by Streptococcus orientalis  and \nis a tricyclic glycopeptide antibiotic. It\u2019s \nused in hospital, to co mbat infections by \nGram positive bacteria including MRSA  \n \nTeicoplanin  Is a bactericidal antibiotic, it inhibits \nbacterial cell wall synthesis by the blockage \nof glycopeptide polymerization. \n \nDalbavancin  \nOritavancin \nTelavancin  Analogues of Vancomycin , the y have a \nheptapeptide core, which enables the \ninhibition of cell wall synthesis  \n \nCeftaroline  Is an Anti -MRSA cephalosporin? Has high \nactivity against daptomycin nonsusceptible \nS. aureus , MRSA, MSSA, hVISA and \nVISA.  \n \nCeftobiprole  Anti-MRSA cephalosporin. Retains \nactivity against more resistant S. aureus \nstrain including ones with increased \nVancomycin . \n \nDaptomycin  Is a bactericidal cyclic lipopeptide \nantibiotic.  \n \nLinezolid  Is a bacteriostatic, prevents the formation of \nthe 70s -initiation complex and show \nactivity against MRSA.  \nTedizolid  Is an oxazolidinone engineered to improve \nefficacy and bioavailability and to decrease its toxicity compared with linezolid.  \n \nQuinupristin/  \nDalfopristin \n(QD) Inhibits bacterial protein synthesis by \nbinding to the 50s - bacterial ribosome in \ntwo sequential steps. Each drug alone os a bacteriostatic against susceptible gram - \npositive organism including MRSA.  \n \nTigecycline  Is derived from minocycline, a parenteral \nglycylcycline.  \n  Due to mecA , a gene that encodes modified pe nicillin-binding \nprotein (PBP) 2a, MRSA exhibits \u03b2-lactam resistance. It allows \nongoing cell wall synthesis with PBP 2a as a surrogate transpeptidase, due to its significant reduced binding affinity to \u03b2-\nlactam antibiotics. The worldwide spread of MRSA is due to the carriage of mecA  on a mobile genetic element, staphylococcal \nchromosomal cassette mec (SCC mec) (Lee &  Howden, 2015).  \n \nIn the 1990s an epidemiological discriminator between the \nlocation of MRSA acquisition (community or hospital)  was a \ndistinct molecular group. In the 2000\u2019s, relationship bet ween the \nmolecular characteristics and locat ion of disease onset \ndiminished. Different isolates disseminated in the community and \nwere implicated in nosocomial outbreak  (Lee &  Howden, 2015).  \n The first clinical strain of S. aureus  that showed reduced \nsusce ptibility to vancomycin  (MIC 8 \u00b5g/ml)  was identified  in \n1997. It was named Mu50 and classified as Vancomycin  -\nintermediate S. aureus  (VISA). Later another strain of S. aureus , \nMu3, was isolated that was identical to Mu50 on pulse field gel \nelectrophoresis. Mu3 showed subpopulations that grew within the \nintermediate range with a vancomycin  MIC of only 3 \u00b5g/ml, \nsusceptible at that time. The isolates that demonstrate this became \nknown as heteroresistant VISA (hVISA). In 2006 the Clinical \nLaboratory Standards I nstitute (CLSI) in US decreased the \nvancomycin  MIC breakpoints for S. aureus  due to the evidence \nthat failure of vancomycin  therapy was associated with strains of \nhVISA and VISA (Lee & Howden, 2015).  \n In 2002 was reported the first clinical report of VRS A of high \nlevel, MIC 1024 \u00b5g/ml. This high level VRSA was isolated from a dialysis catheter tip. The patient was treated with rifampicin and vancomycin  for chronic diabetic foot ulcers and a prosthetic, \narteriovenous graft -associated MRSA bacteremia. From both sites \nwere isolated VRSA and Vancomycin  -resistant Enterococcus . \nThe enterococcal vancomycin  resistance element vanA mediated \nthe resistance in both organisms. DNA sequencing was performed \nin both organisms and it was identical ; this suggested that ther e \nwas a transfer of locus from Enterococcus  to S. aureus . Studies \nlater on determined that the transfer was transposon mediated (Lee and Howden, 2015).  \n \nDue to the uncertainties and adverse side effects of vancomycin  \nmore studies were performed. In which n ephrotoxicity was \ncorrelated when the common doses of vancomycin  were used for \nMICs ranging from 0.5 to 2 \u00b5g/ml . S. aureus strains with an MIC \nof 2 \u00b5g/ml treated twice a day with vancomycin  2 g had a \nprobability of target accomplishment of 57% and \u2265 35 % \nprobability of nephrotoxicity. To attain a likelihood of target \nattainment of at least 80%, with a predictable 10% minimum risk \nof nephrotoxicity in a MIC of 1 \u00b5g/ml a daily dose of \u2265 3 g was imperative when a creatinine clearance wa s in the lesser range of \nnormal. (Lee and Howden, 2015).  \n Research from 1996 to 2011 showed that independent from the MIC methodology or the source of infection treatment failure was greatly  associated with vancomycin  MIC. Increased mortality risk \nis associated with a MIC of \u2265 2 \u00b5g/ml for MRSA. An independent \npredictor of mortality was found to be a vancomycin  MIC of > 1.5 Vol. 6 - 201926INTER  SCIENTIFIC  \n \n \u00b5g/ml in a study of 532 pat ients with S. aureus  bacteremia. There \nare various indirect predictors of mortality: hospital onset \nbacteremia and age (Lee and Howde n, 2015).   \n Vancomycin  with combined therapy has been in use since the \n1970s. Accelerated development of rifampicin resistance is the \nresult of monotherapy against S. aureus , this is one of the various \nreasons for r ecommending combination therapy. Rifampi cin is \nrecommended as an adjunctive in device -associated infection for \nits biofilm activity and tissue penetration. The treatment for MRSA prosthetic valve endocarditis is vancomycin  and \ngentamicin, according to Clinical  Practice Guidelines by the \nInfectio us Disease Society of America for the Treatment of MRSA \nInfections in Adults and Children . Rifampicin dosage should also \nhave added to the treatment. This guideline also suggests the \naddition of rifampicin to vancomycin  for central nervous system \ninfection s and to vancomycin  or daptomycin in osteomyelitis (Lee \nand Howden, 2015).  \n \nNonetheless, recent studies suggest that these combination \ntherapies predispose a reduction of glycopeptide susceptibility and \ntreatment failure (Lee and Howden, 2015). In a recen t study in \nwhich v ancomycin  was compared to vancomycin  plus rifampicin \nfor MRSA treatment in Intensive Care Unit, the failure of vancomycin  against emerging rifampin resistance was clearly \nshowed (Lee and Howden, 2015). This study had issues: the trough level of vancomycin  was not the recommended and design \nissues, which questions the study (Lee and Howden, 2015). A 34% of the patients who received vancomycin  plus rifampicin \ndeveloped rifampicin resistance . Fourteen days into the study, \nboth subgroups devel oped poor clinical cure rate.  \n Telavancin is a new lipoglycopeptide antibiotic that has good \nactivity against MRSA. It has shown activity against vancomycin  \nresistance, VISA, hVISA and its dosage is a once a day \nadministration (Keynan &  Rubinstein, 2013 ). \n \nMRSA prevalence in hospitals  \n \nIn the present, MRSA  is a major global cause of morbidity and \nmortality, increasingly a cause of nosocomial and community \nonset infection with unknown national scope and magnitude. To \nmid-1990s, MRSA was largely a healthca re associated pathogen, \ncausing infection predominantly in people with frequent or recent \ncontact with healthcare facilities (healthcare associated MRSA [HA-MRSA]). In general hospital in US, MRSA carriage with both asymptomatic and symptomatic is estimate d at 6 -12% patient \npopulations by other side estimated 9 -24% (Hudson et al., 2013) \nin intensive care units (ICUs).     \n Furthermore, community associated MRSA (CA -MRSA), which \noften causes infections among healthy children and young adults with no exposure  to the healthcare setting, has become \nincreasingly prevalent across the globe, particularly in the US. CA-MRSA has caused outbreaks in the hospital setting since 2003 \n(Hudson et al., 2013), often in pediatrics and obstetrics where \n(HA-MRSA) prevalence is low and community influx of patients \nwithout prior healthcare exposure is common.  \n The National Hospital Discharge Survey  used data to calculate the \nnumber of US hospital discharges listing S. aureus  specific \ndiagnoses. From 1999 to 2000, an estimated 125, 969 \nhospitalizations with a diagnosis of MRSA infection occurred \nannually, including 31,440 for septicemia, 29,823 for pneumonia, \nand 64,706 for other infections, accounting for 3.95 per 1,000 hospital discharges (Hudson et al., 2013).  \n S. aureus is a major cause of infection in both healthcare and \ncommunity settings. S. aureus is also a frequent cause of \ncommunity associated infections, particularly skin and soft tissue infections. Although most community onset infections are treated in the outpatient set ting, some invasive infections, including \nbacteremia, septic arthritis, toxic shock syndrome, osteomyelitis, and endocarditis, have devastating complications and may require \nhospitalization specifically in United States (Kuehnert et al., \n2005).   \n In the l ast 20 years, MRSA has spread throughout the world in \nhealthcare settings, leading to an increased reliance on \nvancomycin  for empiric treatment (Kuehnert et al., 2005). \nRecently, S. aureus resistance to vancomycin , the last commonly \nused antimicrobial drug  to which this organism was considered \nuniformly susceptible, has emerged (Chang et al., 2003).  \n  \nMRSA strains are prevalent bacterial pathogens that cause both \nhealth care and community associated infections. Increased \nresistance to the prescribed antibiotics has made MRSA a serious threat to public health worldwide (Murillo et al., 2016).  \n To mention some findings that are already exposed in our review article we can say that in general hospitals or specialties such as \nthe intensive care unit both in Mexico and the United States exhibit show S. aureus  strains resistant to antibiotics. I n Mexico, \na study of more than 1,500 samples  collected from July 30, 2004 \nto July 4, 2007  including different areas of the hospital, such as: \ngeneral surgery, internal medicine, neurosurgery and in the \nintensive care unit  has been done . (Murillo et al., 2016).  Of a total \nof 1,511 samples 206 (13.63%) were positive for S. aureus ; 27 \n(13.10%) of central venous catheter, 36 (17.47%) of wound and \nulcers, 70 (33.98%) of sputum, 32 (15.53%) of blood cultures, 13 \n(6.31%) of third space fluid (cerebrospinal fluid, ascitis, pleural fluid, pericardial or peritoneal fluid), foley catheter 24 (11.65%) \nand other sites 4 (1.94%) (Murillo et al., 2016).  The proportion of \npositive cultures for S. aureus according to the service was 52 of \n374 (13.9%) samples from the intensive care unit (ICU), 58 of 415 \n(13.79%) from general surgery, 75 of 550 (13.63%) from internal medicine and 21 of 172 (12.20%) of neurosurgery. Of the sites of \ninfection wi th positive cultures for S. aureus in the ICU, 4 (7.69%) Vol. 6 - 201927INTER  SCIENTIFIC  \n \n were central venous catheter, 2 (3.85%) for sores and wounds, 33 \n(63.46%) sputum, 10 (19.23%) for blood cultures, 2 for the third \nspace fluid and 1 for foley tip (Murillo et al., 2016).  \n S. aureus  was identified in sputum samples in 63.43% of cases, \nand of these, 73.52% were methicillin resistant. In their study, they tried to find antimicrobial resistance patterns in tracheal aspirates of patients with ventilator -associated pneumonia in an \nintensive care unit of a hospital in Mexico. They found a \nfrequency of S. aureus of 24% and in turn reported a frequency of \n70% methicillin resistan ce. (Murillo et al., 2016).  \n  Recently, community and hospital acquired infections with S. \naureus have increased and r aised antibiotic resistant isolates. A \ntotal of 1,116 S. aureus isolates were produced and MRSA to 21% \nof all S. aureus isolates between 2009 and 2014. According to the \nresults of susceptibility tests of all isolates of S. aureus , they have \nbeen identified  as sensitive to vancomycin , daptomycin, linezolid, \nand levofloxacin. The highest percentage of methicillin resistance was determined as 30% in 2009, and the resistance was \ndetermined to have decreased in subsequent years (20%, 16%, \n13%, 19%, and 21%) comp ared to the rates during 2010 -2013 (p \n< 0.01); no statistically significant difference was found in MRSA isolates between 2009 and 2014 (p > 0.05). (Ragbetli,  Parlak, \nBayram, Guducuoglu, & Ceylan, 2016).  \n S. aureus  presents a historical sequence as one of the most  \nsuccessful and adaptable human pathogens. Its advantageous ability to acquire resistance to antibiotics has contributed to its \nappearance as an important pathogen in a variety of environments. \nIn the pre -antibiotic era, S. aureus  infections wer e associated with \na very high mortality rate throughout history (Table 2) (Sampathkumar., 2007).  \n By the 1980s, MRSA had been firmly established in US hospitals and rates of infection with MRSA have continued to increase. In the big US hospitals MRSA rates (the proportion of all isolates of \nS. aureus  that are MRSA) increased from 4% in the 1980s to 50% \nin the late 1990s. According to the Surveillance Data National \nNosocomial Infections, the increase in MRSA rates in the intensive care units was even higher , reaching 60% in 2003. \nCurrently, the 5 main MRSA clones represent approximately 70% \nof the MRSA isolates in hospitals in the United States, South \nAmerica and Europe (Sampathkumar., 2007).  \n \nTraditional risk factors for MRSA acquisition include prior hospi talization, use of antibiotics, residence in long -term care \nfacilities, and long -term hemodialysis. The increased use of \nVancomycin  to treat MRSA led to the emergence of S. aureus with \nintermediate resistance to vancomycin  (VISA) and then to S. \nAureus vancomycin  -resistant  (VRSA) in the 1990s. Fortunately, \ninfections VISA and VRSA have been sporadic, and intensive infection control measures have ensured that they do not circulate \nwidely in healthcare settings (Sampathkumar., 2007).  Tabl e 2. Timeline of S. aureus infections.  \n \nYear  Event  \n1940  Penicillin introduced  \n1942  Penicillin-resistant S. aureus appears  \n1959  Methicillin introduced; most S. aureus \nstrains in both hospital and community \nsettings are penicillin resistant  \n1961  MRSA  appears  \n1963  First hos pital outbreak of MRSA  \n1968  First MRSA strain in US hospitals  \n1970s  Clonal spread of MRSA globally, very high \nMRSA rates in Europe  \n1982   4% MRSA rate in the United States  \n1980s, early  Dramatic decreases in MRSA rates due to \nsearch -and- destroy programs  in Northern \nEurope \n1990s  By 1999, <1% MRSA rate in the \nNetherlands; that rate has been sustained to date despite increasing MRSA rates in other \nparts of the world  \n1996  Vancomycin  -resistant S. aureus (VRSA) \nreported in Japan  \n1997  Approximately 25% MRSA  rate in US \nhospitals; Vancomycin  use increases; \nVancomycin -intermediate S. aureus  \n(VISA) appears; serious community -\nacquired MRSA (CA -MRSA) infections \nreported; pediatric deaths reported  \n2002  First clinical infection with VRSA in the \nUnited States  \n2003  MRSA rates continue to increase; \napproximately 60% MRSA rate in intensive \ncare units; outbreaks of CA - MRSA \n(predominantly EE.UU. 300   clone) \nreported in numerous community settings \nand also implicated in hospital outbreaks                    \n2006  >50% o f staphylococcal skin infections \nseen in emergency departments caused by \nCA-MRSA HA MRSA rate continues to increase Distinction between HA -MRSA \nand CA -MRSA on epidemiological basis \nbecomes increasingly difficult  \n2007  The Year of MRSA? Report of active, \npopulation- based surveillance for invasive \nMRSA done in 2004 -2005 estimates 95,000 \ninvasive MRSA infections and 19,000 \ndeaths from MRSA per year Continued \nreports in the medical literature and the lay \npress about severe CA -MRSA infections \nSeveral states pas s or are considering Vol. 6 - 201928INTER  SCIENTIFIC  \n \n legislation regarding control of MRSA and \npublic reporting of MRSA rates Strategies \nto control MRSA, including public \nreporting of MRSA infections, are hotly \ndebated; \u201cstaph\u201d and MRSA become \nhousehold words  \n \n There is a difference bet ween HA -MRSA and CA -MRSA in the \neditorial article of (Sampathkumar., 2007) . The strains HA -\nMRSA and CA -MRSA carry different types of genetic complexes \nknown as staphylococcal chromosome cassette  (SCC mec), which \ncontain the mecA gene that confers resistance  to methicillin. \nMRSA strains acquired in healthcare have SCC mec types I, II and \nIII and tend to be multiresistant. Thus, causing infections in the blood and postoperative wounds along with nosocomial \npneumonia in hospitalized patients.  \n \nOn the other hand,  strains of CA -MRSA that have SCC mec type \nIV and V and generally cause skin and soft tissue infections in children and adults living in communities. The most common clinical presentations are boils, superficial abscesses and boils that \nare often mistakenly  attributed to spider bites. In some \nmetropolitan areas, CA -MRSA accounts for 80% of all S. aureus \ninfections observed in emergency services (Sampathkumar., \n2007).  \n \nOther researchers conducted a study of MRSA and SCC mec in \nbacteria along the mexican border  in southern Texas. Between \nSeptember and December 2008, 375 samples from previous nares \nwere collected by students attending the University of Texas -Pan \nAmerican  (UTPA) and cultivated for MRSA. The easy access of \nthe Texas border community to antibiotics in Mexico without a \nprescription, and the strong partition in SCC mec types between \nMRSA and non -S. aureus  bacteria suggests that this border region \nof Texas may be especially suitable for the study of emerging \nSCCmec  types, their horizontal transfer and pe rhaps other aspects \nof antibiotic resistance in bacteria. It has been shown that an \nincrease in antibiotic resistance occurs in the presence of SCC mec. \nFifty -seven bacterial isolates from 375 nasal swabs were \nmaintained for further analysis that included the suspicion of \nMRSA and other bacteria containing SCC mec (Ammons et al., \n2009).  \n \nPrevalence of S. aureus in skin and nose was evaluated in  a  \npopulation study during 2001 -2002 in the United States . \n(Sampathkumar., 2007) It showed  nasal colonization with S. \naureus and MRSA in 31.6% and 0.84%, respectively, that is, \napproximately 2.3 million people colonized by MRSA in the \nUnited States. United. On the other hand, it is shown that women, \npeople over 65 years, people with diabetes mellitus or those who have been in long -term care in the last year are more likely to be \ncolonized with MRSA. Insulin -dependent diabetes mellitus, long -\nterm dialysis, intravenous drug abuse, repeated allergy injections, liver cirrhosis, liver transplantation, human immunodeficiency virus infection and people undergoing hospitalization are the most \nexposed to MRSA (Sampathkumar., 2007).  \n \nRegarding prevention and epidemiology in hospitals, a study of \n50 hospitals in the United States found no significant differences \nin the rates of S. aureus bacteremia between the medium size \nhospitals (58% of S. aureus  susceptible to methicillin [MSSA]; \n42% of MRSA ) and large hospitals. However, the proportion of S. \naureus bacteremia caused by MSSA was higher in medium sized \nhospitals and did not correlate with MRSA bacteremia. (Fakih et al., 2018).  Also, they sought to determine whether bacteremia by \nHospital-Onset MRSA or Hospital -Onset S. aureus (HO-MRSA) \nor (HO - S. aureus ) would better reflect the presence of invasive S. \naureus  in a large health syst em, specifically depending on the size \nof the hospital. Hospital initiated MRSA bacteremia has been used \nas a substitute for invasive MRSA acquired at the hospital.   \n \nHistorically, MRSA bacteremia has been the focus of research and has been associated with  poorer outcomes and higher mortality; \nHowever, MSSA bacteremia may be more frequent in hospitals. \nBy measuring only bacteraemia by HO -MRSA, a significant \nportion of patients at risk of damage by S. aureus  can be \noverlooked (Fakih et al., 2018). S. aureus  bacteremia initiated in \nthe hospital may provide a better measure to assess the risk of \ninvasive S. aureus  in the hospital setting and could mitigate the \nprevalence factor of MRSA. These findings are important for policy decisions related to the definition of a condition acquired \nin the hospital (Fakih et al., 2018).  \n \nThe impact of MRSA in colonized patients is more likely to \ndevelop colonized infections with methicillin -sensitive S. aureus \n(MSSA). MRSA infections prolong hospital stays (by an average of 10 days) and are associated with a 2.5 times higher mortality \nrate and an increase in medical care costs. A diagnosis of S. aureus  \ninfection represents an estimated 292,000 hospitalizations per year in the United States. In 2005, approximately 94,000 people were diagnosed with invasive (ie, serious) MRSA infections, and \nan estimated 19,000 died. Of these MRSA infections, 86% were acquired health services and 14% were acquired in the community.1 The annual cost of treating MRSA in hospitalized patients in the United States is estimated at between $ 3.2 and $ 4.2 billion (Sampathkumar., 2007).  \n \nMRSA represents a serious threat to the health of hospitalized \npatients. Attempts to reduce the spread of MRSA have largely depended on hospital hygiene and patient isolat ion. Although S. \naureus is asymptomatic in 30% of healthy adults (the vast \nmajority is MSSA), it is an important cause of invasive disease \namong hospitalized patients. In this situation, MRSA is limited to \n\"epidemic\"  behavior; long periods without MRSA are  marked by \nshort outbreaks of infection, often traceable to imported cases. In other places, similar approaches have failed and an endemic state is reached (ie, MRSA is continuously present) (Cooper et al., \n2004).  Vol. 6 - 201929INTER  SCIENTIFIC  \n \n A study by Gerber and colleagues, 2009 con sidered hospitalized \nchildren.  It was a  6-year study  from  January 1, 2002 to December \n31, 2007 (Gerber, Coffin, Smather, and Zaoutis, 2009), 5,794 \nchildren with S. aureus infection were identified ; 29,309 (51%) of \nwhom had MRSA infection. The mean age of p atients with S. \naureus  infection was 3.1 years, and less than one third of these \npatients had chronic and complex medical conditions. Over time, \nthere was a significant increase in cases of MRSA infection (from 6.7 cases per 1000 admissions in 2002 to 21.1  cases per 1000 \nadmissions in 2007; P p .02, per trend test). The incidences of skin and soft tissue infection, pneumonia, osteomyelitis and bacteremia caused by S. aureus i ncreased with time, and were exclusively \nMRSA. The mortality rate of hospitalized children with MRSA infection was 1% (360 of 29,309 children). There has been a \nrecent increase in the number of hospitalized children with MRSA \ninfection (Gerber et al., 2009).   \n \nThey established that for many years, cases of MRSA were limited to hospitaliz ed patients , but the recent emergence of MRSA (CA -\nMRSA) infections associated with the community has widened \nthe scope of MRSA infections to include  S. aureus  infections with \nan epidemiology fundamentally different from that of MRSA \ninfections (HA - MRSA) associated with the hospital. CA -MRSA \ninfections often occur in people with no history of exposure to medical care and, most often, they manifest as skin and soft tissue \ninfections. S. aureus  infections in the skin and soft tissues are \ntreated in the US emergency services. In the same way, skin and \nsoft tissue infections that start in the community are the cause of most MRSA infections in children. The rate of MRSA infection \nin the community should generate an increase in the frequency of \nhospitalization due  to MRSA infection (Gerber et al., 2009).  \n Like any disease there is a mode of transmission and control. for MRSA is not the exception , to the contrary, medical attention is \nprevailing since it is transmitted from patient to patient mainly through the hands of health professionals (Sampathkumar., 2007).  \nGood hand hygiene practices will limit the transmission from \nperson to person and decrease the number of people who are \ncolonized.  In health care settings, active surveillance cultures \nhave been proposed to  identify patients with MRSA, contact \nprecautions (use of gowns and gloves while caring for these patients) and good environmental cleansing as additional \nstrategies to limit the transmission of MRSA.  \n \nStudies have implicated S. aureus as the main cause of septicemia \nin the metropolis of Tamale in Ghana. The high multidrug resistance of MRSA in hospital environments in Ghana reinforces the need for efficient and routine cleaning of hospital door \nhandles. Additional research is needed to understand if S. au reus \nfrom the door handles could be the possible cause of nosocomial \ndiseases in hospitals. There is a need for regular monitoring and monitoring of S. aureus  and MRSA in the hospital environment, \nas well as regular and effective cleaning of door rails and  contact \nsurfaces in Ghanaian hospitals (Saba, Amenyona, and Kpordzih,   2017).  \n Physicians can help control the spread of CA -MRSA in \ncommunities by promoting hand hygiene, maintaining a high degree of suspicion of MRSA as an etiologic agent when treating skin and soft tissue infections, knowing local rates of CA -MRSA \n(public health departments may be able to provide this data), emphasizing the importance of patients with MRSA and discouraging the exchange of personal items such as towels and \nrazors. Flu vaccines (especially in children) may be useful in \nreducing the risk of post influenza bacterial pneumonia with MRSA (Sampathkumar., 2007).  \n MRSA has traditionally been regarded as a nosocomial pathogen, \nbut more recently, MRSA infections have appeared in com munity \nsettings. The clones typically responsible for hospital - and \ncommunity -acquired MRSA infections have been classified as \nhealthcare associated MRSA (HA -MRSA) and community -\nassociated MRSA (CA -MR - SA), respectively. These clones can \nbe distinguished b ased on specific microbiologic and genetic \ncharacteristics, and often have different epidemiologic, clinical \nand therapeutic characteristics (Table 3) (Rodr\u00edguez and Seas, 2010). Occasionally, hospital -acquired infections may be derived \nfrom CA -MRSA strains, and infections acquired in the \ncommunity may carry healthcare associated risk factors. \nDefinitive HA -MRSA and CA -MRSA designations for individual \nclones, therefore, rely on microbiologic and genetic \ncharacterization, and the terms \u2018health - care-acquired \u2019 and \n\u2018community -acquired\u2019 refer to the location at which the infection \nwas acquired (Rodr\u00edguez and Seas, 2010).  \n \nMRSA clones are genetically diverse, but they often share \ncommon genes encoding multidrug resistance to lactams, erythromycin, chloramphenicol  and clindamycin, and variable \nresistance to rifampin, the fluoroquinolones and trimethoprim-\nsulfamethoxazole  (TMP -SMX). Three classes of antimicrobials, \nincluding glycopeptides, oxazolidinones and the new tigecycline \nderived from tetracycline, are uniform ly active against these \nclonal variants in the region (Rodr\u00edguez and Seas, 2010).  \n \nIn Latin America, pandemic clones are common in hospitals in the region, and infections associated with the community are growing \nin number. Clones circulating in the region  show genetic diversity, \nalthough common genes encoding resistance to multiple drugs to \nantimicrobials. Improved pathogenic properties, including the production of biographies and the production of enterotoxins, have been described for certain clones, and the ability of \nnosocomial and community clones to exchange genetic material \nhas also been identified (Rodr\u00edguez and Seas, 2010).  \n \nRodr\u00edguez and Seas conclude that r egional surveillance protocols \nare required, using central reference laboratories and inform ation \nfrom health centers with different complexities, if we want to \nunderstand more about the development of MRSA infections in Vol. 6 - 201930INTER  SCIENTIFIC  \n \n Latin America and design better treatment and prevention \nstrategies (Rodr\u00edguez and Seas, 2010).  \n \nTable 3. S aureus clone charac teristics including  microbiologic \nand genetic characteristics, as well as  epidemiologic, clinical and \ntherapeutic characteristics  \n \nCharacteristic                                                   CA-MRSA  HA-MRSA                                                  \nYear of \ndiscovery  1961  1980s  \nPopulation at \nrisk Patients having \nprevious \nhospitalization, surgery, residence in \nlong-term care \nfacilities, dialysis, permanent indwelling \ncatheters, intensive \ncare unit  \n Children, \nhomeless, men who have sex with men,  \nathletes, military recruits, jail inmates, native \nAmericans, \nPacific Islanders, adult emergency department patients  \nMain clinical \nsyndromes  Bacteremia, HAP, \nVAP, catheter - and \nprosthetic-related infections  SSTI, necrotizing \nCAP, bacteremia, osteomyelitis  \nAntibiotic \nresistance \nprofile Multidrug resistant; \nincluding b -lactams, \nmacrolides, TMP -\nSMX, lincosamides, \ntetracyclines, rifampin, quinolones  \nGrowing resistance to glycopeptides also Resistant to b -\nlactams. Variable \nsusceptibility to \nmacrolides, TMP -\nSMX, tetracyclines, \nlincosamydes  \n \nSCC mec type \nassociated with \nstrains causing \ninfection  I, II and III  IV and V  \nExpression of \nPVL  Rare  Common  \nHAP: hospital -acquired pneumonia; VAP: ventilator -associated \npneumonia; SSTI: skin and soft tissue infection; CAP: community -\nacquired pneumonia; TMP -SMX: trimethoprim- sulfamethoxazole; \nSCCmec: staphylococcal chromosomal cassette mec; PVL: Panton -\nValentine leukocidin; PFGE: pulsed -field gel electrophoresis.  \n \nMRSA  prevalence in nursing homes  \n \nEven though S. aureus is known to cause severe infection in the  \nelderly, colonization and infection are increased among nursing home residents ; most facilities have been concerned primarily \nwith antibacterial -resistant strains of staphylococci, specifically \nMRSA. This interest d eveloped because of  MRSA outbreaks in \nacute care facilities in the late 1970s and early 1980s. Several epidemic strains of MRSA were widely disseminated to patients \nin large tertiary acute care facilities, particularly those in intensive \ncare units. Delays  in the initiation of appropriate treatment \noccurred because of the lack of clinical awareness and unavailability of accurate antimicrobial testing. As a result, many patients died of their MRSA infection. In  this way, nursing homes \nbecame identified as a potential source of MRSA that could be \nintroduced into acute care hospitals. Once introduced, the subsequent spread of MRSA between patients would create a \nreservoir of MRSA within a nursing home, providing the potential \nfor an outbreak and further hospita l outbreaks when affected \nnursing home residents require hospital treatments (Hughes, Tunney, and Bradley, 2013).  \n \nMRSA causes an estimate  of  80,461 invasive infections and 11, \n285 deaths per year in the United States and leading Healthcare \nassociated infections. 80% of the MRSA infections occur outside hospitals, within more than 60% of cases occurring within 12 weeks after hospital discharge. Approximately 4 million individuals receive care in 15,600 nursing homes each year in \nUnited States.  While, numb er of mathematical models have been \nused to describe the dynamic of MRSA in acute care settings and \nto predict the role of nursing homes in the regional spread of MRSA, their use in describing the dynamic of MRSA within the nursing homes remain limited (Grigg et al., 2018).  \n Above all, a number of factors could influence the dynamic of MRSA within nursing homes.  Some of the risk factors known to increase the risk of MRSA colonization and common among older \npeople include:  \n \n- Chronic illness and debilitation  \n- Multiple exposure to antibiotics  \n- Presence of pressure ulcers  \n- Indwelling devices  \n \nAlthough some of these risk factors may apply to younger \nresidents (less than 65 yrs.) most residents in nursing homes are \nolder than this. Furthermore, epidemiological work has indicated \nthat there is and increased relative risk of dying within six months in nursing homes residents who carry MRSA compare to non -\ncarriers (Hughes, Tunney, and Bradley, 2013).  \n \nFurthermore,  a study based on how MRSA could be eliminated \nor reduce d on the nursing home settings affirm that the elimination \nof MRSA  from nursing homes in the U.S. is highly rare. This \nintuitive finding is similar to the finding of the other modeling \nstudy, which conclude that MRSA would persist in the nursing \nhomes for as long as colonized residents continue to enter the \nfacilities (Batina, Crnich, Anderson, and Dopfer, 2016).  \n \nOn the other hand, another matter in this article is the relationship between MRSA with treatments such as vancomycin  in the \nnursing home settings. The antibiotic treatment of choice for Vol. 6 - 201931INTER  SCIENTIFIC  \n \n MRSA is vancomycin . However, this antibiotic treatment in the \nrecents years has increasingly resulted in treatment failure and \npoor for clinicals outcomes (Heinze et al., 2018).  \n \nEven though, the hospitals are the  main environments for the \nMRSA and VRSA co -colonization in infected individuals, studies \nsuggest that other health care\u2019s such nursing facilities present a unique pattern for the dissemination of resistance. Patients are admitted to these facilities for rehabilitation following discharge \nfrom acute care hospitals, and they have high rates of bacterial \ncolonization based on several factors, including impaired functional status, widespread antibiotic use, and frequent long -\nterm use of indwelling devices such  as urinary catheters and \nfeeding tubes (Heinze et al., 2018).  \n \nLastly, further studies are needed to investigate the benefits of \nidentifying the high risk of the individuals and implementing specific infection prevention measures, such as collecting surveillance cultures, utilizing proper contact and isolation \nprecautions also, hand hygiene is very important on patient\u2019s co -\ncolonization rates (Heinze et al., 2018). Little attention has been given to infection prevention and control in nursing homes with respect to MRSA, unlike the situation in the hospital setting an \ninstitutional setting. Visitors, staff and residents constantly come and go, thereby increasing the risk of transmission (Hughes, \nTunney, and Bradley, 2013).  \n \nThe nursing home environment is highly conductive to the  \nacquisition and spread of infection, with susceptible residents \nsharing sources of air, food, water and health care within an \ninstitutional setting. Visitors, staff and residents constantly come \nand go, thereby increasing the risk of transmission (Hughes, \nTunney, and Bradley, 2013). The quality of care provided to older people in nursing homes has been of concern for many years and in this context, infection prevention and control is related issue that has not been adequately addres sed (Hughes, Tunney, and \nBradley, 2013). There may be many factors that contribute to this \nsituation, such as the ownership status of nursing homes, lack of \nformal infection prevention, control advice to nursing homes and staffing levels.  \n The US has adopt ed an adversarial approach to nursing home \nregulation through the Omnibus, which exerts its effects through \nregulation, inspection and sanctions. Constant reminders to staff \nwill be required to ensure adherence to an infection prevention and control protoc ol, and this may be difficult to achieve in setting \nwhere there are staff shortages and rapid staff turnover (Hughes, Tunney, and Bradley, 2013). Most staff had no previously thought \nabout protecting themselves from MRSA. Nonetheless, staff and \nadministrat ors suggested several strategies to reduce MRSA \ntransmission including staff education and changing practice (Albrecht et al., 2018).  \n \nDISCUSSION  In our review article, we compar e the prevalence of MRSA in both \nhospitals and nursing homes in the US and Me xico. Since late \n1980s, there has been a gap in the discovery of new antimicrobial \ndrugs and their introduction to combat staphylococcal infections, \nthe latter being the lipopeptide daptomycin in 1987 (Sampathkumar., 2007). It is clear that S. aureus has an \nextraordinary ability to develop resistance to any antibiotic to which they have been exposed (Foster, 2017). There have been pronouncements that the end of the antibiotic era is near and that \nit has been widely publi shed in the media. In certain infecti ons, \ntreatment options are running low (Aminov, 2010; Segung, \nKeshavjee, and Rich, 2015). It is still possible to treat most of S. \naureus  infections caused by changing medications or employing \ndifferent combinations, considering that the persistent bactere mia \nand endocarditis are very difficult to treat because underlying \ndiseases can lead to an immunocompromised state; and the ability \nof bacteria to avoid antibiotics. Since the development of new \ndrugs is feasible, better administration should prolong thei r \nactivity and, together with a more informed use of the combinations, should guarantee the continuous ability to treat \nmany MRSA infections (Foster, 2017).  \n \nThe burden of MRSA in nursing homes is less well studied compared to hospital settings. In additi on, nursing homes may \nhave unique risk factors  (Murphy et al., 2012). Social interaction \nbetween residents distinguishes nursing homes from acute care settings, and has an unknown impact upon MRSA acquisition (Murphy et al., 2012). However, a recent study states that in \nnursing homes in comparison to hospitals, the burden and \npredictors of MRSA are not well understood (Murphy et al., \n2012).  \n The quality of care provided to older people in nursing homes has been of concern for many years and in this context , infection \nprevention and control is a related issue that has not been adequately addressed. Person to person transmission plays a central role in the spread of MRSA in healthcare settings. MRSA \nis a common cause of colonization and infection for patients  in \nhospitals and nursing homes, causing significant excess \nmorbidity, mortality and cost (Albrecht, Croft, Morgan and Morgan, 2018).  \n \nEven though S. aureus is commonly seen in the hospital onset it \nhas been proved that the prevalence and impact in the nu rsing \nhomes has been relatively increasing in the past years. Nursing \nhome residents have a 10% risk of MRSA infection within the first month of arrival, with risks as high as 40% within one year (Lee et al., 2014). These infections are costly and often result in hospital \nreadmission of patients (with MRSA infection, 20 \u201340% were \nrecently in nursing homes ) (Lee et al., 2014). It is likely that the \nprevalence of MRSA within nursing homes is increasing as a \nresult of the increased prevalence of MRSA within hos pitals, \nwhich may have been compounded by the considerable movement Vol. 6 - 201932INTER  SCIENTIFIC  \n \n of patients from long -stay hospitals to community -based nursing \nhomes.  \n \nOn the other hand, nursing homes can influence hospital infection \ncontrol by several means. First, nursing homes can  \nmultiply/magnify the effects of a hospital outbreak on other hospitals. A nursing home can link two hospitals that were not otherwise strongly linked, acting as a bridge for infectious pathogens to spread from facility to facility. Secondly, outbreaks \noriginating a nursing home can affect multiple hospitals in a \nregion, even those geographically distant. Even if a hospital keeps \nits own MRSA levels low, it is at risk for an outbreak if nursing homes in the same region do not maintain effective infection control (Lee et al., 2014). \n \nAs already discussed there has been much debate about how to \nprevent and control the transmission of MRSA. Since many hospitals report high MRSA colonization rates among elderly patients, and because it has been shown that  S. aur eus colonization \nincreases with advancing age, there are concerns about the \nintroduction of MRSA into nursing homes by MRSA positive \npatients discharged from hospital. Nursing homes provide an ideal environment for the acquisition and spread of MRSA, since  \nresidents have an increased risk of colonization due to chronic illness and debilitation, multiple exposures to antimicrobial \nagents, and the presence of pressure ulcers and indwelling devices. \nFurthermore, epidemiological work has indicated that there is  an \nincreased relative risk of dying within six months in nursing home residents who carry MRSA compared to non -carriers (Hughes, \nTunney and Bradley, 2013).  \n \nThe selection of initial antibiotic regimens should be guided by \nthe local prevalence of MRSA, the presence of risk factors associated with medical care, and the severity and type of clinical presentation. For severe infections, intravenous Vancomycin  \nshould be included in the initial empirical therapy. Microbiological data and antibiotic sensitivity tests should be used \nto guide subsequent therapy. Approved for the first time in 1958, Vancomycin  became a standard therapy for MRSA in the 1960s. \nIts advantages include its good safety profile, long experience with its use and its relatively infrequent dosing regimen. Disadvantages include the need for intravenous administration \nand monitoring of levels in critically ill patients and in those with \nchanging renal function. Recently, there have been reports of \nVancomycin  insufficiency due to relative resista nce to \nVancomycin  or MRSA infections at sites that have little \nVancomycin  penetration (Sampathkumar., 2007). The clones of S. \naureus  have a history of resistance to antibiotics that began 4 years \nafter the introduction of penicillin in clinical practice, a nd by \n1944, penicillin resistant S. aureus  clones had been isolated. In \nlater years, S. aureus become resistant to all natural penicillins. \nThe first clones of MRSA had genetic properties similar to those of S. aureus (MSSA) susceptible to methicillin that  were epidemic \nin Europe (Rodr\u00edguez and Seas, 2010).  The spread of MRSA and other drug -resistant organisms may be \nlimited by infection control measures. It is time for us, as health professionals, to incorporate proven infection control measures, \nsuch as hand hygiene and the use of appropriate personal \nprotective equipment (gowns and gloves) in our daily patient care \nroutines. The next influenza pandemic may or may not occur in our lives. The MRSA pandemic is constantly present. Patient orientation to this  we refer to the patient medical relationship and \nthe worldwide orientation a unification of efforts of both medical \nresearchers and scientific researchers to inform in a conclusive \nway the problem that addresses us in this 21st century with the resistance and the exams of antibiotics. Raise awareness and \npromote more informative investigations that encourage and invite more scientists to investigate the creation of new \nantimicrobials. \n \nACKNOWLEDGMENTS   \n \nWe are more than grateful with the Universidad Aut\u00f3n oma de \nGuadalajara, especially with the School of Medicine of the \nInternational Program, for allowing us to carry out this work. Our \nthanks also to Dr. Mar\u00eda G. Zavala Cerna and Dr. Olivia Torres Bugar\u00edn, for providing the necessary help for this research work. \nWe greatly appreciate the efforts of all the staff of the Faculty of Medicine who made this work a success.  \n CONFLICT OF INTEREST: None declared  \n \nREFERENCES \nEn busca de nuevos antibi\u00f3ticos. (March 1, 2017). El Nuevo D\u00eda , \n49. \nAlbrecht, J. S., Croft, L., Morgan, D. J., & Roghmann, M. (2017). \nPerceptions of gown and glove u se to prevent mrsa transmission \nin nursing homes. Journal of the  American  Medical Dir ectors \nAssociation , 18(2), 158 -161.  \nAminov R.I. (2010). A brief history of the antibiotic era: les sons \nlearned and challenges for the future. Front iers in  Microbiol ogy; \n1, 134. \nAmmons, D. R., Puttagunta, R., Granados, J. C., Garza, G. D., Eyam be, G. S., & Rampersad, J. (2010 ). An exploratory study of \nmrsaand sccmec elements obtained from a community se tting \nalong the Texas b order with Mexico. Curr ent Microbiol ogy, \n60(5), 321 -326.      \nBatina, N. G., Crnich, C. J., Anderson, D. F., & D\u00f6pfer, D. \n(2016 a). Models to predict prevalence and transition dynamics of \nMRSA in community nursing homes. American  Journal of  \nInfect ion Control , 44 (5), 507 -514.   \nBatina, N. G., Crnich, C. J., Anderson, D. F., & D\u00f6pfer, D. (2016b). Identifying conditions for elimination and epidemic Vol. 6 - 201933INTER  SCIENTIFIC  \n \n potential of MRSAin nursing homes. Antimicrobial Resistance & \nInfection Control ,5 , 32.   \nBatina, N. G., Crnich, C. J., & D\u00f6pfer, D. (2017). Acquisition and \npersistence of strain -specific MRSA and their determinants in \ncommunity nursing homes. BMC Infect ious Dis eases , 17(1), 752 .   \nBruniera, F.R., Ferreira, F.M., Saviolli, L.R,, Bacci , M.R., Feder , \nD., da Luz Gon\u00e7alves Pedreira , M., Sorgini Peterlini , \nM.A., Azzalis , L.A., Campos Junqueira , V.B., & Fonseca , F.L . \n(2015). The use of Vancomycin  with its therapeutic and adverse \neffects: A review. European  Rev iew for  Medical and  \nPharmacol ogical Sciences, 19(4), 694-700.  \nCasanova-Cardiel, L.J., Casta\u00f1\u00f3n -Gonz\u00e1lez , J.A., Le\u00f3n -\nGuti\u00e9rrez, M.A., Becerra -Lara, J.J., Calyeca -S\u00e1nchez , M.V., \nFranco -Contreras, A.E., Polanco -Flores, E., Gonz\u00e1lez -Green , I., \n& Mart\u00ednez -Guti\u00e9rrez, M. (2008). Respiratory tract fluid \nmicrobiology in an intensive care unit. Revista M\u00e9 dica del  \nInstituto Mexicano del  Seguro Soc ial, 46  (3), 329-338.  \nChang , S., Sievert , D.M., Hageman , J.C., Boulton , M.L., Tenover , \nF.C., Downes , F.P., Shah , S., Rudrik , J.T., Pupp , G.R., Brown , \nW.J., Cardo , D., & Fridk in, S.K. (2003). Infection with \nvancomycin -resistant Staphycoccus  aureus containing the vanA  \nresistance gene. New Engl and Journal of Medicine, 348  (14), \n1342 \u20137. \nCooper, B.S., Medley, G.F., Stone, S.P., Kibbler, C.C., Cookson, B.D., Roberts, J.A.,  & Ebrahim, S. (2004). M ethicillin-resistant \nStaphylococcus au reus in hospitals and the community: Stealth \ndynamics and control catastrophes. Proc edings of the National \nAcademy of Sciences of the United States of America.  101(27), \n10223 -8.  \nEmori, T.G., Culver, D.H., Horan, T.C., Jarvis, W.R., White, J.W., Olson, D.R., Banerjee, S, Edwards, JR, Martone, W.J., Gaynes, \nR.P.,  & Hughes, J.M. (1991). National Nosocomial Infections \nSurveillance (NNIS): description of surveillance methods. \nAmerican Journal of Infection Control , 19 (1), 19 -35. \nFakih, M.G., Battjes, R., Sturm , L., Jones, L., Groves, C., \nBufalino, A., & Hendrich, A. (2018). Hospital -Onset \nStaphylococcus  aureus bacteremia is a better measure than MRSA \nbacteremia for assessing infection prevention : evaluation of 50 US \nhospitals. Infect ion Control & Hospital Epide miology, 39(4):476-\n478. \nFoster, T.J. (2017). Antibiotic resistance in Staphylococcus \naureus . Current status and future prospects. FEMS Microbiol ogy \nReview,  41(3), 430 -449.   \nGarcia, A., Delorme, T., & Nasr, P. (2017), Patient age as a factor \nof antibiotic resistance in methicillin -resistant Staphylococcus \naureus.  Journal of  Medical Microbiology, 66 (12), 1782 -1789.  Gerber J.S., Coffin S.E., Smathers S.A., & Zaou tis T.E. (2009). \nTrends in the i ncidence of M ethicillin-Resistant Staphycoloccus \naureus  infection  in children\u2019s hospitals in the United Stat es. \nClinical Infectious Diseases, 49 (1), 65-7. \nG \nrigg, C., Palms, D., Stone, N. D., Gualandi, N., Bamberg, W., \nDumyati, G., & See, I. (2018). Burden of i nvasive Methicillin-\nResistant Staphycoloccus aureus  infection s in nursing home \nresidents . Journal of the  American  Geriatr ic Society,  66(8), 1581 -\n1586.   \nHassoun, A., Linden, P. K., & Friedman, B. (2017). Incidence, prevalence, and management of MRSA bacteremia across patient \npopulations -a review of recent developmen ts in MRSA \nmanagem ent and treatment. Critical Care, 21 (1), 211.  \nHeinze, K., Kabeto, M., Martin, E.T., Cassone,  M., Hicks, L., & \nMody, L. (2019 ). Predictors of Methicillin-Resistant \nStaphycoloccus aureus  and vancomycin  -resistant enterococci co -\ncolonizatio n among nursing facility patients. American  Journal of  \nInfect ion Control,  4, 415-420. \nHolmes, N.E., Tong, S.Y., Davis, J.S., & Van, S.J. (2015). \nTreatment of methicillin -resistant Staphylococcus aureus:  \nvancomycin  and beyond. Semin ars in  Respir atory and  Critical \nCare Med icine, 36 (1), 17-30. \nHudson, L.O., Murphy, C.R., Spratt, B.G., Enright, M.C., Elkins, K., Nguyen, C., Huang, S.S. (2013). Diversity of methicillin-\nresistant Staphylococcus aureus  (MRSA) strains isolated from \ninpatients of 30 hospitals in Orange County, California. PLoS \nONE,  8(4). \nHughes, C., Tunney, M., & Bradley, M.C. (2013). Infection control strategies for preventing the transmission of methicillin -\nresistant Staphylococcus  aureus (MRSA) in nursing homes for \nolder people. Cochrane Database  of Systematic Reviews,  19, \n(11):CD006354  \nKeynan, Y., & Rubinstein, E. (2013). Staphylococcus  aureus \nbacteremia, risk factors, complications, and management. Critical \nCare Clinics, 29 (3), 547-62. \nKuehnert , M.J., Hill , H.A., Kupronis , B.A., Tokars , J.I., S olomon , \nS.L., & Jernigan, D.B. (2005). Methicillin -resistant-\nStaphylococcus  aureus hospitalizations, United States. Emerg ing \nInfect ious Diseases, 11 (6), 868-72. \nLee, B.Y., Bartsch, S.M., Wong, K.F., Singh, A., Avery, T.R., Kim, D.S.,  & Huang, S.S. (2013). The importance of nursing \nhomes in the spread of methicillin-resistant Staphylococcus  \naureus (MRSA) among h ospitals. Medical Care,51 (3), 205 -215.  \nLee, J.Y., & Howden, B.P. (2015). Vancomycin  in the treatment \nof methicillin -resistant Staphylococcus aureus- a clinician's guide Vol. 6 - 201934INTER  SCIENTIFIC  \n \n to the science informing current practice. Expert Review of Anti - \nInfective Therapy, 13 (7), 855-69. \nMurillo-Llanes, J., Gonzalez -Ibarra, F.P., Velarde -Felix, S.,  & \nAlejo- Armenta, L.N. (2016). Antimicrobial resistance patterns of \nStaph ycoccus  aureus in the Intensive Care Unit at a tertia ry \nhospital. Critical Care and Shock, 19, 24-28. \nMurphy, C.R., Quan, V., Kim, D., Peterson, E., Whealon, M., Tan, \nG., & Huang, S.S. (2012). Nursing home characteristics \nassociated with methicillin-resist ant Staphylococcus  aureus  \n(MRSA) Burden and Transmission.  BMC Infectious Diseases, 24, \n12-269. \nRagbetli, C., Parlak, M., Bayram, Y., Guducuoglu, H., & Ceylan , \nN. (2016). Evaluation of antimicrobial resistance in \nStaphylococcus  aureus isolates by years . Interdisciplinary \nPerspect ives on  Infect ious Diseases, http://dx.doi. org \n/10.1155/2016/9171395  \nRodr\u00edguez-Noriega, E., & Seas, C. (2010). The changing pattern of Methicillin-Resistant Staphycoloccus aureus  clones in Latin \nAmerica: i mplications for clinical pra ctice in the region . Braz ilian \nJournal of  Infectious Diseases, 14, Suppl 2: S87 -96. \nSaba, C. K., Amenyona, J. K., & Kpordze, S. W. (2017). Prevalence and pattern of antibiotic resistance of Staphylococcus \naureus  isolated from door handles and other points of contact in \npublic hospitals in Ghana. Antimicrobial Resistance & Infection \nControl,  6, 44. doi:10.1186/s13756 -017-0203 -2. \nSampathkumar, P. (2007). Methicillin -Resistant Staphylococcus \naureus : the latest health scare . Mayo Clin ic Proc eedings , 82 (12), \n1463 -1467 . DOI: https://doi.org/10.1016/S0025 -6196(11)61088 -\n4. \nSeung, K.J., Keshavjee, S., & Rich, M.L. (2015). Multidrug -\nresistant tuberculosis and extensively drug -resistant tuberculosis. \nCold Spring Harb or Perspect ives in Medicine, 5(9), a017863 . \nSoto Balseiro, R.M., Gonzalez Lopez, V., & Ortiz Maldonado, \nJ.R. (2015). Evaluation of the antibacterial properties of garlic \n(Allyum sativum ). Inter Scientific , 2, 32 -36. AUTHORS /AUTORES  \nRomina Soto -Balseiro, Ileanmarie P\u00e9rez -Albino and \nDaziury Mel\u00e9ndez -Vel\u00e1zquez  \nStudents of the Doctorate in Medicine of the Universidad \nAut\u00f3noma de Guadalajara School of Medicine. They developed this research during their second year of studies. \nDr. C. Olivia Torres -Bugar\u00edn can be contacted through her \nmentor at: oliviatorres@hotmail.com \n \nSon estudiantes de la Facultad de Medicina de la Universidad \nAut\u00f3noma de Guadalajara. Desarrollaron esta investigaci\u00f3n durante su segundo a\u00f1o de estudios. Pueden ser contactados a \ntrav\u00e9s de su ment ora la Dra. C. Olivia Torres -Bugar\u00edn al: \noliviatorres@hotmail.com  \n \nOlivia Torres -Bugar\u00edn.  Professor- Researcher, Sistema \nNacional de Investigadores (SNI II), International Program \nin the Faculty of Medicine of the Universidad Aut\u00f3noma de \nGuadalajara. He holds a degree in Dr. C. with a specialty in \nhuman genetics. It can be contacted through the email: \noliviatorres@hotmail.com   \nProfesora -Investigadora, Sist ema Nacional de Investigadores \n(SNI II), Programa Internacional en la Facultad de Medicina de la \nUniversidad Aut\u00f3noma de Guadalajara. Pose\u00e9 un grado de Dr. en C. con especialidad en gen\u00e9tica humana. Puede ser contactada a \ntrav\u00e9s del correo electr\u00f3nico : oliviatorres@hotmail.com  \n \n  \n  \n \n \n \n \n \n   \n \n  Vol. 6 - 201935INTER  SCIENTIFIC  \n \n Adherencia terap\u00e9utica en el adulto mayor que vive con  VIH:        \nbarreras y facilitadores  \n \nTherapeutic adherence in the elderly that lives with HIV:  \nbarriers and facilitators \n \nCabrera Montero, I. \n Universidad Interamericana de Puerto Rico, Recinto de Arecibo, Departamento de Enfer mer\u00eda \n \nRESUMEN \n \nLas personas que tienen el Virus de Inmunodeficiencia Humana (VIH) requieren un r\u00e9gimen terap\u00e9utico complejo a trav\u00e9s de \nsu vida . El seguimiento o adherencia a dicho r\u00e9gimen ha sido motivo de estudio en m\u00faltiples ocasiones. Debido a  la complejidad \nde los tratamientos muchos estudios se han enfocado en la adherencia y no en otros factores que puedan afectar positiva o \nnegativamente dicha adherencia. En este manuscrito consid eramos las deficiniones sobre a dherencia terap\u00e9utica, factore s \nidentificados como barreras o facilitadores de adherencia y enfocamos los hallazgos en la poblaci\u00f3n adulto mayor. Encontramos \nestudios que consideran poblaciones j\u00f3venes y de adultos, pero hay carencia de informaci\u00f3n en relaci\u00f3n al adulto mayor.   \n \nABSTRACT  \n \nPeople with the Human Immunodeficiency Virus (HIV) require a complex therapeutic regime throughout their lives. Adherence to that \nregime has been studied on multiple occa sions. Because of the complexity of the treatments, many studies have been focused on the \nadherence to the treatment and have not considered factors that can affect positively or negatively that adherence. This manuscr ipt \npresents the definitions of therapeutic adherence, factors identified as barriers or facilitators of adherence and the findin gs are focused \non the elderly population. Studies described consider young and adult populations, but information on the elderl y is limited. \n \nPALABRAS CLAVE  VIH, adulto mayor, adherencia terap\u00e9utica  \n \nKEYWORDS  HIV, elderly, terapeuthic adherence   \n \nINTRODUCCI\u00d3N  \nEl Virus de Inmunodeficiencia Humana (VIH)  es considerado una \nenfermedad cr\u00f3nica que requiere un r\u00e9gimen terap\u00e9utico complejo \na lo largo de la  vida (Ball, 2014) . Dicho r\u00e9gimen, se refiere al \nprograma de tratamientos para una enfermedad y sus secuelas.  \nAbarca la terapia farmacol\u00f3gica, los procedimientos m\u00e9dicos, los cambios en los h\u00e1b itos de vida y la adherencia terap\u00e9utica, entre \notros.  Para Varela Ar \u00e9valo y sus colegas (2008) , la adherencia \nterap\u00e9utica en los pacientes con VIH incluye: tomar los \nmedicamentos antirretrovirales, seguir las prescripciones \nm\u00e9dicas, asistir a las citas m\u00e9dicas peri\u00f3dicas y con otros \nprofesionales de la salud. Adem\u00e1s, incluye realizarse los \nex\u00e1menes de control (CD4, carga viral, citolog\u00eda, etc.) , hacer \nejercicio con regularidad , alimentarse seg\u00fan las recomendaciones \nde los m\u00e9dicos y nutricionistas  y controlar su estado emocional \npara evitar emociones que afecten su sistema inmunol\u00f3gico.  \n La adherencia al r\u00e9gimen terap\u00e9utico ha llegado a ser una de las \nl\u00edneas de investigaci\u00f3n m\u00e1s importantes para l os profesion ales de  \nla salud en especial a los que brindan servicios a personas que   \n  padecen VIH  (Cahill y Val ad\u00e9z, 2013; Rodr\u00edgue z Quesad a, 2016;  \nOrtiz, Ortega , Viveros y  Herrera, 2011; Sep\u00falveda Carrillo et al., \n2016) .  Seg\u00fan Abara, Adekeye, Xu, Heiman, y Rust, (2016) , este \ntema es esencial en el adulto mayor que vive con VIH, sin embargo existe una escasez de estudi os dirigidos a la adherencia \nal r\u00e9gimen terap\u00e9utico en dicha poblaci\u00f3n .  \n \nLa investigaci\u00f3n realizada con el adulto mayor que vive con VIH, \npresenta por un lado a un adulto mayor con alto riesgo de no \nadherencia terap\u00e9utica ( Abara, Adekeye, Xu, Heiman, y Rust, \n2016)  por factores relacionados con la complejidad de los \nmedicamentos, los efectos secundarios, los altos costos del \ntratamiento y la falta de conocimiento o informaci\u00f3 n de los \nmismos; adem\u00e1s de la p\u00e9rdida cognitiva, entre otros (Hinkin et al., \n2002;  Pinheiro et al., 2016) . Por  otra parte,  presenta a un adulto \nmayor con \u00edndices altos de adherencia terap\u00e9utica cuando se \ncompara con sus contrapartes j\u00f3venes (Bra\u00f1as et al., 2008;  Negin \ny Cumming , 2010; Newman et al., 2012; Silverberg et al., 2007) . \nEsta contradicci\u00f3n de evidencia aporta a que sea altamente Vol. 6 - 201936INTER  SCIENTIFIC  \n \n \n recomendada  la realizaci\u00f3n de estudios sobre la adherencia en la \npoblaci\u00f3n adulto mayor seg\u00fan  Nachega, Hsu, Uthman, Spinewine, \ny Pham, (2012) . Esta incongruencia, en la manera de visualizar y \nevaluar al adulto mayor con VIH, en relaci\u00f3n con la adherencia al \nr\u00e9gimen terap\u00e9utico es motivo de inter\u00e9s para evaluar otros  \nelementos relacionados con la misma. Por ejemplo, existen varios \nelementos que contribuyen a que el paciente desarrolle o no la adherencia terap\u00e9utica. En la literatura se presentan diversas clasificaciones de estos elementos asociados con la adherencia a l \ntratamiento. Autores como  Knobel y Guelar (2004)  y la OMS \n(2003) indicaron la existencia de factor es que facilitan y otros que \nson barreras en el mencionado proceso.    \n  \nR\u00e9gimen Terap\u00e9utico  \n \nEl r\u00e9gimen terap\u00e9utico es un plan de tratamiento individualizado, \nestructurado para mejorar y mantener la salud.   Una de las  \u00e1reas \nque incluye es,  los medicamentos antirretrovirales . Para los \nadultos mayores al igual que  para los dem\u00e1s pacientes con VIH , \nindependientemente de la cifra de linfocitos CD4 , est\u00e1 plenamente \njustificada la instauraci\u00f3n temprana del tratamiento antirretroviral \n(TAR). Los reg\u00edmenes recomen dados para el tratamiento inicial \nde la infecci\u00f3n por el VIH incluyen una combinaci\u00f3n de tres o m\u00e1s \nmedicamentos antirretrovirales (ARV) pertenecientes por lo menos a dos clases diferentes. Un tratamiento de elecci\u00f3n debe ser \nuna combinaci\u00f3n que incluya do s inhibidores de la transcriptasa \ninversa de an\u00e1logos de nucle\u00f3sidos (ITIAN) asociado s a un \ninhibidor de la transcriptasa inversa de an\u00e1logos no nucle\u00f3sidos (ITINN), un inhibidor de la proteasa potenciado con ritonavir \n(IP/r) o  un inhibidor de la integrasa  (infoSIDA, 2017; Huldrych, \net al, 2014; Sociedad Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda \n(SEGG), 2015 ).  \n \nEn la selecci\u00f3n de tratamiento se debe tener en cuenta las \ncomorbilidades, la interacci\u00f3n entre medicamentos, efectos adversos secundarios y la resistenci a a los medicam entos \n(infoSIDA, 2017; Huldryc h et al, 2014)  ya que el adulto mayor \ntoma como m\u00ednimo cuatro medicamentos diarios adem\u00e1s del \nTAR . Seg\u00fan las gu\u00edas de manejo para los pacientes a dultos \nmayores con VIH (Aitchesen  et al,  2014; ACRIA del 2012: H IV \nClinical Resourse,  2015) se deben incluir el manejo de las \ncomorbilidades, y dos o m\u00e1s enfermedades cr\u00f3nicas como  las \nenfermedades cardiovasculares, diabetes mellitus, enfermedad \npsiqui\u00e1trica, hepatitis viral, fallo renal cr\u00f3nico, neuropat\u00eda peri \nferal,  enfermedad respiratoria y malignidades asociadas y no \nasociadas al VIH.   \n En las visitas iniciales se debe analizar el historial completo de \nsalud (enfermedades pasadas, enfermedades en la familia), \nantecedentes de viajes y vacunas . Tambi\u00e9n se debe reali zar un \nexamen f\u00edsico completo, incluyendo medidas antropom\u00e9tricas \n(peso, estatura y circunferencia abdominal), temperatura, presi\u00f3n arterial, respiraciones por minuto, pulso y dolor ( si est\u00e1 presente),  confirmar el estatus de VIH con un segundo ELISA (o similar) y una prueba confirmatoria (Western Blot ), solicitar carga viral \nplasm\u00e1tica de VIH, solicitar recuento absoluto y relativo de CD4 \n(opcional: CD8 absoluto y relativo), y verificar con laboratorios de referencia para buscar condiciones de salud o f uncionamiento \nde \u00f3rganos internos (conteo total de c\u00e9lulas sangu\u00edneas con diferencial, enzimas hep\u00e1ticas, glucemia, urea, creatinina, colesterol total, HDL, LDL, triglic\u00e9ridos, solicitar VDRL, HAV IgG, HbS Ag, anticore total, Ac HCV, toxoplasma IgG y an\u00e1li sis \nde orina completo).  \n \nEn las visitas de seguimiento, los pacientes deben ser evaluados \npara detectar otras enfermedades de transmisi\u00f3n sexual. Deben ser controlados los factores de riesgo a enfermedad cardiovascular incluyendo tabaquismo, dieta habitual  y peso, determinar riesgo \ncardiovascular con escore de Framingham, solicitar PAP cervical \n(mujeres), el cual debe realizarse cada 6 -12 meses, evaluar \ncondici\u00f3n social y psicol\u00f3gica, administrar vacunas \ncorrespondientes y solicitar PPD. El proceso es uno l argo y \nabarcador , es por e llo que cuando nos  referirnos a la adherencia \nterap\u00e9utica en el adulto mayor debemos evaluar todas estas dimensiones y no solo la adherencia a la terapia antirretroviral \n(GeSIDA, 2017).  \n \nAdherencia al r\u00e9gimen terap\u00e9utico  \n \nEn la li teratura encontramos diferentes t\u00e9rminos para referirnos a \nel concepto adherencia . Los m\u00e1s utilizados son cumplimiento y \nadherencia, sin embargo, han sugerido otros como alianza terap\u00e9utica, seguimiento, observancia, adhesi\u00f3n, concordancia, \ncolaboraci\u00f3n y cooperaci\u00f3n.  Una definici\u00f3n muy utilizada en la \nliteratura es  de Hentinen y King\u00e4s (1992) quienes definen el \nt\u00e9rmino como un proceso activo, intencional y responsable de \ncuidado, donde el paciente trabaja mano a mano con el equipo de \nsalud.   La adherencia  terap\u00e9utica o comportamiento de adherencia puede \nser definido  tambi\u00e9n, como la coincidencia entre el \ncomportamiento de una persona y los consejos sobre salud o \nprescripciones que ha recibido (Martos M e\u0301ndez, Pozo Mu n\u0303oz, \nAlonso Morillejo, y Universidad de Almer i\u0301a, 2010) .  Como es un \nfen\u00f3meno multifac\u00e9tico, cambia con el tiempo: los pacientes \npasan por fases de mayor o menor adherencia, por tal motivo el seguimiento debe ser constante. Seg\u00fan Tashiro et al.,( 2013)  para \nque se d\u00e9 la adherencia se debe promover un nuevo modelo de cuidado de la salud donde las pers onas participen en la creaci\u00f3n \nde su plan de cuidados y desarrollen una relaci\u00f3n de colaboraci\u00f3n con el equipo de profesionales de la salud de manera que las responsabilidades sean compartidas. Si logramos explorar y describir los factores que afectan ya s ea positiva o negativamente \nlas conductas de adherencia, entonces podr\u00edamos elaborar intervenciones m\u00e1s asertivas que llevar\u00e1n a una conducta de adherencia terap\u00e9utica satisfactoria.  \nLa investigaci\u00f3n sobre adherencia al r\u00e9gimen terap\u00e9utico en  Vol. 6 - 201937INTER  SCIENTIFIC  \n \n  el VIH  \n \nLa adherencia al r\u00e9gimen terap\u00e9utico ha sido investigada por m\u00e1s \nde tres d\u00e9cadas, seg\u00fan explican Bosworth, Oddone y Weinbeger (2008) la adherencia terap\u00e9utica ha sido examinada desde varias perspectivas cient\u00edficas y en diferentes culturas, naciones y poblaci ones. Se han realizado estudios con adultos y el VIH, pero \nno se han encontrado espec\u00edficos para la poblaci\u00f3n adulto mayor.  \n \nGarc\u00eda Cedillo y Rodr\u00edguez Delgado ( 2014)  realizaron un estudio \nen la provincia de San Luis Potos\u00ed, M\u00e9xico, con el objetivo de \ncomparar la situaci\u00f3n en que viven y el nivel  de adherencia al \nr\u00e9gimen terap\u00e9utico en una muestra de 29 mujeres y 47 hombres \nque viven con VIH. Realizaron una entrevista semi estructurada y \nlos resultaron mostraron que los hombres tienen mayor \nadherencia . Justificaron  que para  las mujeres es m\u00e1s dif\u00ed cil por \ntodas sus responsabili dades  y el poco apoyo familiar.  Otro estudio \nrealizado en Tamaulipas, M\u00e9xico fue el de Pe\u00f1arrieta et al., \n(2009), el prop\u00f3sito del mismo era conocer la magnitud de la no \nadherencia al tratamiento antirretroviral e identificar los factores \nque intervienen en personas adscritas al programa de VIH de la \nSecretar\u00eda de Salud de Tamaulipas entre junio de 2006 hasta \noctubre del 2008. Se desarroll\u00f3 un estudio de corte transversal, incluyendo a las 117 personas del programa de tratamiento, identificando no adherencia en los cuatro d\u00edas y cuatro semanas \n\u00faltimas prev ias de aplicada la encuesta. Los factores identificados \nen la no adherencia son no guardar el medicamento en un lugar \nespec\u00edfico, percepci\u00f3n insatisfecha de su salud actual y considerar dif\u00edcil el manejo de su tratamiento. Las condiciones reconocidas \nson factibles para ser modificado por el sistema de salud, sobre \ntodo, a ntes del inicio del tratamiento.  \n En el continente africano encontramos los estudios por  Musumari \net al., (2013) , en el Congo. En el mismo se utiliz\u00f3 el m\u00e9todo \ncualitativo de entrevista profundo para explorar los determinantes que facilitaban y cuales serv\u00edan de obst\u00e1culos para la adherencia en un grupo de adultos. Se entrevistaron 28 participantes de l os \ncuales 24 fueron f\u00e9minas con una media de edad en 41 a\u00f1os. Se encontr\u00f3 que la inseguridad de no tener alimentos para ingerir fue la mayor barrera para la adherencia, adem\u00e1s de falta de recursos econ\u00f3micos, olvido, miedo al estigma y creencias religiosas. \nCuriosamente las creencias religiosas tambi\u00e9n figuraron como \nfacilitador.    \n \nKumarasamy y colegas (2003) realizzaron  un estudio cualitativo \nfenol\u00f3gico etnogr\u00e1fico en Chennai, India. Participaron  49 \nhombre s y 11 mujeres. Se realizaron  entrevistas profundas  y \nobservaciones de campo. Los resultados presentaron como \nbarreras el costo de los servicios, el estigma, aislamiento social y \nla inhabilidad de tomar pastillas. Como facilitadores se encontraron los benefi cios del tratamiento y sentir las \nconsecuencias de no adherirse al mismo.  \n \nOtro estudio fue realizado en Kiev, Ucrania, por Mimiaga y  colegas (2010). Estos realizaron un estudio cualitativo utilizando \ngrupos focales. P articiparon 16 personas con una media de edad \nde 31 a\u00f1os y todos estaban en terapia de sustituci\u00f3n para opioides.  \nEl objetivo era utilizar esta informaci\u00f3n para adaptar y ajustar, a \nla cultura ucraniana, una intervenci\u00f3n basada en la evidencia para mejorar la adherencia al TARGA.  Las barreras identificadas \nfueron  acoso y discriminaci\u00f3n por parte de la polic\u00eda , dependencia \nal opio , complejidad del r\u00e9gimen de medicamento , efectos \nsecundarios, olvido , problemas de salud mental  y estigma por \nVIH. Los facilitadores para la adherencia fueron  las indi caciones \npara tomar las p\u00edldoras , apoyo  y recordatorios de familiares, y \namigos , terapia de sustituci\u00f3n de opioides y querer mejorar la \nsalud. Otros factores explorados fueron  conocimiento sobre la \nterapia antirretroviral , almacenamiento de los medicamento s y \nenfermedades de transmisi\u00f3n sexual.  \n En el 2015, Pacifico y Guti\u00e9rrez realizaron un estudio cuantitativo en Lima, Per\u00fa. El prop\u00f3sito de este fue determinar la asociaci\u00f3n entre la informaci\u00f3n sobre la medicaci\u00f3n y adherencia al tratamiento antirretroviral de gran actividad (TARGA) en \npacientes con VIH/SIDA de un hospital de Lima, Per\u00fa. Se realiz\u00f3 \nun estudio de corte transversal anal\u00edtico. Por medio de entrevistas se aplic\u00f3 el cuestionario SIMS ( Satisfaction with Information \nabout Medicines Scale ) para me dir la satisfacci\u00f3n con la \ninformaci\u00f3n recibida sobre los medicamentos y el cuestionario \nSMAQ (Simplified Medication Adherence Questionnaire ) para \ndeterminar la adherencia al TARGA. Mediante la revisi\u00f3n de \nhistorias cl\u00ednicas se recogieron datos sociodemogr \u00e1ficos y \ncl\u00ednicos. Los resultaron reflejaron que la satisfacci\u00f3n con la \ninformaci\u00f3n recibida sobre los medicamentos no estuvo asociada \na la adherencia a TARGA. La satisfacci\u00f3n con la informaci\u00f3n \nrecibida sobre el TARGA se incrementa con la edad y es menor \nen mujeres y el grado de instrucci\u00f3n superior. Hay deseos de mayor informaci\u00f3n sobre las potenciales reacciones adversas al TARGA.  Youngran Yang  (2014), realiz\u00f3 un an\u00e1lisis sistem\u00e1tico sobre el \ntema de la adherencia.  El estudio present\u00f3 una revisi\u00f3n sistem\u00e1tica \nde una intervenci\u00f3n multicomponente para abordar la adherencia al TAR y explor\u00f3 si la intervenci\u00f3n, comparada con la atenci\u00f3n est\u00e1ndar, result\u00f3 en una mejor adherencia al TAR. Se revisaron once estudios de ensayos  controlados aleatorios publicados entre \n1999 y 2008. Siete de \u00e9stos demostraron un efecto beneficioso de \nla intervenci\u00f3n multicomponente, que incorpor\u00f3 principal mente la \neducaci\u00f3n individual y  de una a tres intervenciones adicionales. \nLas intervenciones d irigidas a la mejora de las habilidades de \nmanejo de medicamentos del paciente fueron particularmente \nexitosas. Sin embargo, debido a los resultados incongruentes entre \nlos estudios, no se pudo determinar si la mejora de la adherencia \nse extendi\u00f3 a la mejora virol\u00f3gica o resultados inmunol\u00f3gicos. Existe una necesidad de estandarizaci\u00f3n y un mayor rigor metodol\u00f3gico en la ejecuci\u00f3n de los ensayos de adherencia.     \n    \nFactores relacionados con la adherencia terap\u00e9utica  Vol. 6 - 201938INTER  SCIENTIFIC  \n \n \n La literatura revisada se ha concentrado en el estudio de la \nadherencia terap\u00e9utica relacionada con la terapia de los \nmedicamentos antirretrovirales, dejando a un lado la observaci\u00f3n de los otros factores relacionados con la adherencia terap\u00e9utica sin \nevaluar. Por ejemplo, Haynes (1976,1979, ci tado en Martos \nMe\u0301ndez et al., 2010)  mencion\u00f3 la existencia de m\u00e1s de 200 \nfactores que podr\u00edan relacionarse con la adherencia a las \nprescripciones terap\u00e9uticas.  Estudios como el de Tavares Pinheiro, et al (2016), donde se \ninvestigaba la relaci\u00f3n entre la adherencia terap\u00e9utica en adultos \nmayores con VIH y la perdida de d estrezas cognitivas revelaron \nuna alta prevalencia en la p\u00e9rdida de destrezas cognitivas en el adulto mayor con VIH, no obstante, independientemente de estos resultados su \u00edndice de adherencia terap\u00e9utica se manten\u00eda m\u00e1s \nelevado que el de sus contrapartes j\u00f3venes. En la investigaci\u00f3n de \nBello, et al (2016), el prop\u00f3sito era presentar como m\u00faltiples sind\u00e9micos (syndemic en ingl\u00e9s) factores sicosociales est\u00e1n asociados con la no adherencia terap\u00e9utica en adultos latinos con VIH. Estas variables sicosociales s ind\u00e9micas fueron nombradas \ncomo: depresi\u00f3n, silencio, estigma, abuso de sustancias, \nalcoholismo y discriminaci\u00f3n. Los resultados encontrados fueron \ncomparados con otros estudios realizados en los Estados Unidos de Am\u00e9rica, los mismos fueron consistentes en  presentar una \nrelaci\u00f3n directamente proporcional entre altos \u201codds\u201d de no adherencia terap\u00e9utica a medida que aumentaban los factores sicosociales sind\u00e9micos. \n \nFacilitadores para la adherencia terap\u00e9utica en el adulto \nmayor con VIH  \n \nComo mencionamos anter iormente, son escasos los estudios \nrealizados en adultos mayores, s\u00ed se encontraron varios estudios \nen la poblaci\u00f3n adulta en general.  De los encontrados con adultos mayores tenemos por ejemplo, el estudio de Burgess, Zeuli, y \nKasten, (2015)  quienes mencionan como facilitadores para la \nadherencia, el tener amigos o conocidos que fallecieron por VIH, el uso de recordatorios (llamadas telef\u00f3nicas, textos) educaci\u00f3n e \ninstrucci\u00f3n sobre el uso de los medicamento s, a trav\u00e9s de \nherramientas que facilitan su dosificaci\u00f3n (pastillas o unidades de \nuna sola dosis) la utilizaci\u00f3n medicamentos combinados y la inclusi\u00f3n de familiares o cuidadores.  \n \nPor otra parte, en el estudio de Abara, Adekeye, Xu, Heiman y \nRust (2016)  estos mencionan que el darles seguimiento continuo \na los adultos mayores mantiene unos niveles altos de adherencia \nespecialmente en las f\u00e9minas.  Otros autores como Croome, Ahluwalia, Hughes y Abas (2017), clasificaron estos factores como los que son relacionados a:  proveedores de salud,  trabajar, \nfe en Dios, tener control de su salud, creer en el tratamiento y tener \nbuenos proveedores de salud, creer en la medicaci\u00f3n, en las relaciones interpersonales, la salud mental y el  bienestar general, las creenc ias de salud, creencias sobre el  VIH y su tratamiento, \ncreencias sobre los antirretrovirales, sobre el recogido del medicamento y los factores relacionados al tratamiento. Mientras \nque  Bezabhe y sus colaboradores (2014)  clasificaron estos \nfactores como: factores personales, factores relacionados con los \nprofesionales de la salud,  con los medicamentos y  con los centros \nde servicios de salud. Otros autores como  Davis, Thornton, Oslin, \n& Zanjani, (2014 ) y Williams, Amico, & Konkle -Parker  (2011) \nclasificaron los facilitadores  en: los de apoyo de la familia, de \namigos de pares y personal de salud, la actividad alrededor del \ncuidado, aspectos positivos de las visitas al servicio de cuidados y  percepci\u00f3n de vulnerabilidad a consecuencias negativas como el \nno abandono del tratamiento. De otra parte,  Rasmussenaeh et al., \n(2013)  presenta los factores que benefician la adherencia como: la \nexperiencia de los beneficios del tratamiento y el uso de las redes \nsociales por internet. \n \nLos autores, Vedhanayagan, et al. (2016), encontraron como \nfactores facilitadores: el apoyo familiar, excelentes relaciones entre el paciente y el equipo de salud, el  entendimiento por parte \ndel paciente de la relaci\u00f3n entre la adherencia y los niveles de CD4, disminuci\u00f3n de infecciones y enfermedades oportunistas, disminuci\u00f3n de la frecuencia de dosis, menos pastillas por d\u00eda, \nmenos restricciones en la dieta, ajustar los medicamentos a los \nestilos de vida de cada individuo,  creencias sobre la efectividad de los medicamentos y creencias positivas sobre los beneficios del tratamiento. As\u00ed como los factores facilitadores son varios y clasificados de distintas maneras as\u00ed  tambi\u00e9n las barreras para la \nadherencia terap\u00e9utica.  \n  \nBarreras para la adherencia terap\u00e9utica en el adulto mayor \ncon VIH  \n \nLas barreras en la adherencia terap\u00e9utica han sido uno de los temas \ncon mayor discusi\u00f3n en la literatura, pero aparentemente no han \nsido superadas seg\u00fan Horne, Weinman, Barber, & Elliott, (2005) , \nellos se refieren a  las causas para la no adherencia terap\u00e9utica como multifactoriales y que las mismas pueden ser intencionales como no intencionales.   \nDentro de las no in tencionales podemos mencionar: las \nlimitaciones de capacidad y recursos, como por ejemplo no \nentender las instrucciones o no poder pagar los medicamentos; Por el contrario, entre las intencionadas, donde media la decisi\u00f3n del paciente, pueden estar influen ciadas por sus creencias y \npreferencias. Basett, et al (2017) en un estudio realizado con adultos mayores de 18 a\u00f1os en Durban, \u00c1frica del Sur, present\u00f3 como barreras: esperar mucho tiempo para poder ver a un proveedor servicios, no ser tratado con respeto  por los \nprofesionales de la salud, no ser elegible para la medicaci\u00f3n gratuita o la transportaci\u00f3n, no sentirse tan enfermo, tener otras \nresponsabilidades, servicios inaccesibles entre otros. Croome, \nAhluwalia, Hughes y Abas (2017), clasificaron las barre ras como \nlas relacionadas con: proveedores de salud, trabajar, fe en Dios, tener control de su salud, creer en el tratamiento y tener buenos proveedores de salud, creencias sobre la medicaci\u00f3n, las Vol. 6 - 201939INTER  SCIENTIFIC  \n \n relaciones interpersonales, la salud mental y el bienestar  general, \ncreencias de salud, creencias sobre el VIH y el tratamiento, \ncreencias sobre los antirretrovirales, creencias sobre el recogido \ndel medicamento y los relacionados al tratamiento.  Otros han  \nidentificado como barreras para la adherencia terap\u00e9uti ca; el estr\u00e9s \nfinanciero (SMcallister et al., 2 013);  el estigma (Heckman et al., \n2001)  problemas sociales y de comunicaci\u00f3n m\u00e9dico -paciente \n(Nelsen et al., 2013)l comorbilidades y el proceso de vejez, (Ball, \n2014; Cahill et al., 2013) ; el sistema inmunol\u00f3gico disminuido, \ndisminuci\u00f3n de la habilidad de metabolizar los retrovirales aumentando la toxicidad (Cahill et al., 2013; Ford, et al, 2013 ); \ndesconfianza en los servicios de salud, desinformaci\u00f3n sobre la condici\u00f3n (Ford et al, 2013); depresi\u00f3n y aislamiento (Brennan, \nEmlet, y  Eady, 2011) . Otros autores como Williams, Rivet -Amico \n& Konkle -Parker, (2011) presentan las barreras como: \ncompetencia entre prioridades de familia, el trabajo y los hijos, \naspectos del sistema de cuidado, como la calidad acceso y fragmentaci\u00f3n de los servicios. El estigma, las experiencias negativas como el miedo al abandono, la negaci\u00f3n, la desesperanza y sus creencias sobre el VIH.   Otr o punto de vista \n(Rasmussennaeh, et al, 2013) presenta las barreras como la diferencia entre los costos del tratamiento vs los costos de las necesidades diarias, la pobre infraestructura de las cl\u00ednicas de servicio, el estigma, y pr\u00e1cticas culturales.  \n \nVedhanayagan, et al. (2016), describieron como barreras: el estr\u00e9s \ndel cuidado de los ni\u00f1os, asuntos femeninos, ausencia de soporte \nfamiliar y social, enfermedades asintom\u00e1ticas, alteraciones severas a los estilos de vida, eventos familiares dif\u00edciles, efecto s \nadversos del tratamiento, olvido, una vida estresada, abuso de alcohol y drogas ilegales, depresi\u00f3n, desesperanza y angustia, \ncreencias que el alcohol y las drogas interfiere con el tratamiento, \ndejar de tomar los antiretrovirales para tomar otros medica mentos, \nsentir que los medicamentos los envenenan, problemas de transportaci\u00f3n, olvidar llevarse los medicamentos cuando sale del hogar, problemas de suplido y servicios.  \n \nDISCUSI\u00d3N \n \nEl prop\u00f3sito de esta revisi\u00f3n de literatura integrada era describir \nlos f actores que intervienen en la adherencia terap\u00e9utica de los \nadultos mayores con VIH. Este pretende aportar a un mejor \nentendimiento de la necesidad de realizar estudios sobre el tema \nen esta poblaci\u00f3n. Y a\u00f1adir un recurso a la literatura que est\u00e1 \ndisponibl e. Aunque hemos encontrado gran cantidad de literatura \nrelacionada con el tema de adherencia terap\u00e9utica, queremos resaltar varios puntos (lagunas) donde se necesita profundizar e investigar. \n \nLa adherencia al r\u00e9gimen terap\u00e9utico es un concepto multifactor ial y hasta el momento su estudio se ha centrado en la \nadherencia al uso de los antirretrovirales dejando a un lado componentes importantes para que el proceso de adherencia \nterap\u00e9utica se d\u00e9 y sea efectivo.  Los factores que intervienen con la adherencia terap\u00e9utica pueden ser a favor, facilitando la misma \no puede ser obstaculizadores o barreras de la adherencia . \n Por otro lado, la poblaci\u00f3n adulto mayor con VIH puede ser \nclasificada en tres grupos diferentes (Services and Advocacy for GLBT Seniors, 2016):  sobrevivientes de largo tiempo, los de \ndiagn\u00f3stico reciente y los reci\u00e9n infectados cada uno de ellos con necesidades diferentes y reacciones diferentes. Por lo que deben realizarse investigaciones por los diferentes grupos y culturas. L as \nintervenciones publicadas destinadas a mejorar la adherencia en \npacientes con el VIH de mayor edad son muy escasas y no permiten determinar unas recomendaciones de apoyo espec\u00edficas. Aunque podr\u00eda considerarse la idea de extrapolar las llevadas a cabo en otras patolog\u00edas  como la diabetes o HTA, es necesario \nevaluar su utilidad en poblaciones espec\u00edficas como aquellos \npacientes con el VIH con deterioro cognitivo o con una mayor \nfragilidad f\u00edsica o emocional.  \n \nREFERENCIAS \n \nAbara, W. E., Adekeye, O. A., Xu, J., Heiman, H. J., & Rust, G. , \n(2016). Correlates of combination antiretroviral adherence among \nrecently diagnosed older  HIV-Infected adults between 50 and \n64 years. AIDS and Behavior , 20 (11), 2674 \u20132681. \nhttps://doi .org/10.1007/s10461 -016-1325 -x \n \nAitchesen, P., Brennan -ing, M., Espinosa, R., Pacheco, B., Tax, \nA., & Tieetz, D. (2014). Eight Policy Recommendations for \nImproving the Health and Wellness of Older Adults with HIV . \nDiverse Elders Coalition.  \nAIDS Community Research Initiative of America (ACRIA) \n(2012). Recommended Treatment Strategies for Clinicians: \nManaging Older People, Report .  \nBall, S. C. (2014). Increased longevity in HIV:  caring for older \nhiv-infected adults . Care Management Journal,  15(2), 76 -82. \nhttps://doi.org/http://dx.doi.org/10.1891/1521-0987.15.2.76  \n Bassett, I., Coleman, S., Giddy, J., Bogart, L., Chaisson, C., Ross , \nD., Flash, M., Govender, T., Walensky, R., Freedberg,  K. & \nLosina, E. (2017). Barrier s to care and 1 -year mortality among \nnewly diagnoses HIV- infected people in Durban, South Africa. \nJournal of Acquired  Immune Defic iency Syndr omes , 74 (4), 432-\n38. \nBezabhe, W. M., Chalmers, L., Bereznicki, L. R., Peterson, G.  M., \nBimirew, M. A., & Kassie, D. M. (2014). Barriers and facilitators \nof adherence to antiretroviral drug therapy and retention in care among adult HIV -positive patients: a qualitative study from \nEthiopia. PloS One , 9(5), e97353. https:// \ndoi.org/10.1371/journal.pone.0097353  \n Bosworth, H., Oddone, E. & Weinberger, M. (2008). Patient \nTreatment Adherence Concepts Interventions and Measurement.   Vol. 6 - 201940INTER  SCIENTIFIC  \n \n \n Taylor & Francis e-Library.  \nBra\u00f1as, F., Berenguer, J., S\u00e1nchez -Conde, M., L\u00f3pez-Bernaldo \nDe Quir\u00f3s, J. C., Miralles, P., Cos\u00edn, J., & Serra, J. A. (2008). The \nEldest of Older Adults Living with HIV\u202f: Response and \nAdherence to Highly Active Antiretroviral Therapy. The \nAmerican Journal of Medicine , 121 (9), 820\u2013824. \nhttps://doi.org/10.1016/j.amjmed.2008.05.027  \n \nBrennan, D. J., Emlet, C., & Eady, A. (2011). HIV, sexual health, \nand psychosocial issues among older adults living with  HIV in \nNorth America. Ageing International , 36(3), 313 \u2013333. \nhttps://doi.org/10.1007/s12126-011 -9111 -6 \n \nBurgess, M. J., Zeuli, J. D., & Kasten, M. J. (2015). Management \nof HIV/AIDS in older patients -drug/drug interactions and \nadherence to antiretroviral therapy. HIV/AIDS (Auckland, N.Z.) , \n7, 251 \u201364. https://doi.org/10.2147/HIV.S39655 \n \nCahill, S.,  & Valad\u00e9z, R., (2013). Growing older with HIV/AIDS: \nNew public health challenges. American Journal of Public Health , \n103(3), 7 \u201316. https://doi.org/10.2105/AJPH.2012.301161 \n Croome, N., Ahluwalia, M., Hughes, L. & Abas, M. (2017).  \nPatient -reported barriers and facilitators to antiretroviviral \nadherence in sub -Saharan Africa. AIDS , 31(7),  995-1007 . \nDavis, T., Thornton, A., Oslin, D., & Zanjani, F. (2014). Medication and behavioral adherence among HIV+ older adults . \nClinical Gerontologist , 37 (5), 458 \u2013474. https:// \ndoi.org/10.1080/07317115.2014.937844  \n Documento de consenso de GeSIDA/Plan Nacional sobre e l Sida \nrespecto al tratamiento antirretroviral en adultos infectados por el \nvirus de la inmunodeficiencia humana (Actualizaci\u00f3n enero \n2017). Panel de expertos de GeSIDA y Plan Nacional sobre el \nSida. Consultado en febrero de 2017. Di sponible en: \nhttp://www.gesida-\nseimc.org/contenidos/guiasclinicas/2017/gesida-guiasclinicas-\n2017 -TAR.pdf  \n Ford, C. L., Mulatu, M. S., Godette, D. C., & Gaines, T. L.  (2015)  \nTrends in HIV Testing Among U.S. Older Adults Prior to and \nSince Release of CDC\u2019s Routine HIV Testing Recommendatio ns: \nNational Findings from the BRFSS. Public Health Reports , \n130(5), 514 \u201325.  \n \nGarc\u00eda Cedillo, I. & Rodr\u00edguez Delgado, M., (2014). Situaci\u00f3n en \nque viven y adhesi\u00f3n al tratamiento en mujeres y hombres de San Luis Potos\u00ed con VIH / SIDA. Acta Universitaria , 24(4), 3 \u201315.  \n Hentinen, M. & Kyng\u00e4s, H. (1992). Compliance of young \ndiabetic's with health regimens. Journal of Advanced Nursing, 17 , \n530-536.  Hinkin, C. H., Castellon, S. A., Durvasula, R. S., Hardy, D. J., \nLam, M. N., Mason, K. I. , \u2026 Stefaniak, M. (2002 ). Medication \nadherence among HIV+ adults: Effects of cognitive dysfunction \nand regimen complexity. Neurology , 59 (12), 1944 \u20131950.  \n Horne, R., Weinman, J., Barber, N., & Elliott, R. (2005). Concordance, adherence and compliance in medicine taking. Report for the National Co -Ordinating Centre for NHS Service \nDelivery and Organisation R & D (NCCSDO) , 1\u2013331. \nhttps://doi.org/10.1007/SpringerReference_64584 \n \nKnobel, H., & Guelar, A. (2004). Estrategias para optimizar la adherencia al tratamiento antirretroviral. Intervenciones en la pauta terap\u00e9utica. Enferm edade s Infecc iosas y  Microbiol og\u00eda \nCl\u00ednica , 22 (2), 106 \u2013112. https://doi.org/10.1016/S0213 -\n005X(04)73044 -X \n Kumarasamy, N., Safren, S. A., Raminani, S. R., Pickard, R., James , R., Krishnan, A. K., \u2026 & Mayer, K. H. (2005 ). Barriers \nand facilitator s to antiretroviral medication adherence among \npatients with HIV in Chennai, India: a qualit ative study . AIDS \nPatient Care and STDs , 19(8), 526 \u2013537.  \nMartos M e\u0301ndez, M. J., Pozo Mu n\u0303oz, C.,  & Alonso Morillejo, E. \n(2010). Enfermedades cr o\u0301nicas y adherencia terap e\u0301utica:  \nrelevancia del apoyo social . Universidad de Almer i\u0301a. \n McA llister, J., Beardsworth, G., Lavie, E., Macrae, K., & Carr, A.  \n(2013). Financial stress is associated with reduced treatment \nadherence in HIV -infected adults in a resource -rich setting. HIV \nMedicine , 14 (2), 120 \u2013124. https://doi.org/10.1111/j.1468 -\n1293.2012.01034.x  \n \nMimiaga, M. J., Safren, S. A., Dvoryak, S., Reisner, S. L., Need le, \nR., & Woody, G. (2010). \u201c We fear the police, and the police fear \nus\u201d: structur al and individual barriers and facilitators to HIV \nmedication adherence among injection drug users in Kiev, \nUkraine. AIDS Care , 22 (11), 1305 \u20131313. \nhttps://doi.org/10.1080/09540121003758515  \nMusumari, P. M., Feldman, M. D., Techasrivichien, T., Wouters, E., Ono -Kihara, M., Kihara, M. (2013). \u201cIf I have nothing to eat, \nI get angry and push the pills bottle away from  me\u201d: A qualitative \nstudy of patient determinants of adherence to antiretroviral therapy in the Democratic Republic of Congo. AIDS Care , 25 \n(10), 1271 \u20131278. https://doi.org/10.1080/09540121.2013.7 64391  \n \nNachega, J. B., Hsu, A. J., Uthman, O.  a., Spinewine, A., & Pham, \nP. A . (2012). Antiretroviral therapy adherence and drug \u2013drug \ninteractions in the aging HIV population. Aids, 26, S39 \u2013S53. \nhttps://doi.org/10.1097/QAD.0b013e32835584ea  \n \nNegin, J. & Cumming, R.  (2010). HIV infection among older \nadults in sub -Saharan Africa.  Bulletin of the  World Health Vol. 6 - 201941INTER  SCIENTIFIC  \n \n Organ ization , 88 (11), 847 \u2013853. https://doi.org/  10.2471/  \nBLT.10.076349  \nNelsen, A., Gupta, S., Trautner, B., Petersen, N., Garza, A., \nGiordano, T., \u2026 Rodriguez-Barradas, M. M. C. (2013). Intention \nto adhere to HIV treatment: a patient -centred predictor of \nantiretroviral adherence. HIV Medicine , 14(8), 472 \u2013480. \nhttps://doi.org/10.1111/hiv.12032 \n \nNewman, J., Iriondo -perez, J., Hemingway -foday, J., Freeman, \nA., Akam, W., Balimba, A., \u2026 Atibu, J. (2012). Older Adults Accessing HIV Care and Treatment and Adherence in the IeDEA Central Africa Cohort, 2012. \nhttps://doi.org/10.1155/2012/725713  \n \nOrtiz, G. R., Ortega, E., Viveros, G. R. O., & Herrera, \u00c9. O. \n(2011). Capacidad predictiva de la adherencia al tratamiento en los modelos sociocognitivos de creenc ias en salud. Psicolog\u00eda y \nSalud , 21(1), 79 \u201390. Retrieved from \nhttp://revistas.uv.mx/index.php/psicysalud/article/view/590 \n Pac\u00edfico, J., & Guti\u00e9rrez, C. (2015). Informaci\u00f3n Sobre La Medicaci\u00f3n Y Adherencia Al Tratamiento Antirretroviral De \nGran Actividad En Pacient es Con Vih/Sida De Un Hospital De \nLima, Per\u00fa. (Spanish) . Revista Peruana de Medicina \nExperimental Y Salud Publica , 32(1), 66 \u201372. Retrieved from \nhttp://www.scielo.org.pe/pdf/rins/v32n1/a10v32n1.pdf  \nPe\u00f1arrieta, I. M., Kendall, T., Martinez, N., Ma r\u00eda Rivera, A., \nGonzales, N., flores,  florabel, & del Angel, E. (2009). Adherencia Al Tratamiento Antirretroviral En Personas Con Vih En Tamaulipas, M\u00e9xico.. (Spanish) . Rev Peru Med Exp Salud \nPublica , 26(3), 333 \u201337. Retrieved from \nhttp://sisbib.unmsm.edu.pe/BVRevistas/Medicina_Experimental/v26_n3/pdf/a011v26n3.pdf  \n Pinheiro, C. A. T., Mattos Souza, L. D. de, Motta, J. V. dos S., Kelbert, E. F., Martins, C.  de S. R., Souza, M. S. de, \u2026 Tavares, \nR. (2016). Original article Aging , neurocognitive impairment and adherence to antiretroviral therapy in human immunodeficiency \nvirus-infected individuals. Brazilian Journal of Infectious \nDiseases, 20(6), 599 \u2013604. \nhttps://doi.org/10.1016/j.bjid.2016.09.006  \n \nRasmussenaeh, D. N., Da Silva Teg, D., Rodkjaerc, L., \nOliveiraab, I., Medinag, C., Barfodd, T., \u2026 Wejse, C. (2013). \nBarriers and facilitators to antiretrovi ral therapy adherence among \npatients with HIV in Bissau, Guinea -Bissau: A qualitative study. \nAfrican Journal of AIDS Research\u202f: AJAR , 12((Rasmussenaeh, \nOliveiraab, Aabyaf, Sodemannae, Wejseai) Bandim Health \nProject, Indepth Network, Apartado 861, 1004 Bissau codex, Guinea -Bissau), 1 \u20138. https://doi.org/10.2989/16085906.  2013.  \n815405  \n Rodr\u00edguez Quesada, P. (2016). TESIS DOCTORAL: Estudio de \nfactores de riesgo influyentes en el adherencia al tratamiento antirretroviral y desarrollo de un modelo predictivo en pacientes \nVIH positivos . Retrieved from http://eprints.ucm.es/ \n36230/1/T36928.pdf  \n \nSep\u00falveda Carrillo, G., Mauricio Z\u00fa\u00f1iga, \u00c1., Alejandra Amaya, G., Lorena Ar\u00e9valo, W., Arias, J., Andrea Carrillo, P., \u2026 Ivonne S\u00e1nchez, S. (n.d.). Carac ter\u00edsticas Sociodemogr\u00e1ficas Y \nDeterminantes De Adhesi\u00f3n Terap\u00e9utica Antirretroviral En Pacientes Con Vih/Sida En Dos Instituciones De Bogot\u00e1 Sociodemographic Characteristics And Determinants Of Antiretroviral Therapy Adherence In Hiv/Aids Patients In Two Institutions In Bogot\u00e1. Retrieved from \nhttps://www.minsalud.gov.co/salud/Documents/observatorio_vih\n/documentos/literatura_interes/caracteristicas_sociodemograficas\ny adh al tar en colombia.pdf  Silverberg, M. J., Leyden, W., Horberg, M.A., DeLorenze, G.N., \nKlein, D., & Quesenberry, C.P . (2007 ). Older Age and the \nResponse to and Tolerability of Antiretroviral Therapy. Archives \nof Internal Medicine , 167(7), 684. https://doi.org \n/10.1001/archinte.167.7.684 \n \nServices & Advocacy F or GLBT Elders (2016). Growing o lder  \nwith the e pidemic: HIV and Aging.  http://www.gmhc.org/files                   \n/editor/file/a _pa_aging10_emb2.pdf  \n Tashiro, J., Shimpuku, Y., Naruse, K., Maftuhah, Matsutani, M., \nVermeire, E., \u2026 Ortiz, G. (2013). Concept analysis of reflection \nin nursing professional development. Japan Journal of Nursing \nScience , 10(2), 170\u2013 179. https://doi.org/10.1111/j.1742-\n7924.2012.00222.x  \n \nVarela Ar\u00e9valo, M. T., Salazar Torres, I. C., Correa S\u00e1nchez, D., Luc, D., Nore, G., & Luzinski, C. (2008). Adherencia al \ntratamiento en la infecci\u00f3n por vih/sida. Consideraciones te\u00f3ricas \ny metod ol\u00f3gicas para su abordaje. Acta Colombiana de \nPsicolog\u00eda , 11(2), 101 \u2013113. \nhttps://doi.org/10.1097/NNA.0b013e3182378a71  \n \nVedhanayagam, M., Rajagopalan, R., Rajedran, B., Sengodan, S. \n& Sengodan, S. (2016). Factors associeted with anti -retroviral \ntherapy adherence among peopl e living with HIV visiting IRT \nPerundurai medical college hospital link ART centre,  Perundurai, \nTamilnadu, India. International Journal Of Advancesin Medicine , \nNov: 3(4); 982 -988 \nWilliams, B., Amico, K. R., & Konkle -Parker, D. Qualitative to \nassessment of barriers and facilitators to HIV treatment. The \nJournal of the Association of Nurses in AIDS Care\u202f: JANAC , \n22(4), 307 \u201312. https://doi.org/10.1016/j.jana.2010.11.001  \n Vol. 6 - 201942INTER  SCIENTIFIC  \n \n \n Yang, Y. (2014). State of the Science: The efficacy of  a \nmulti component in tervention for Art adherence among people \nliving with HIV. J Assoc Nurses AIDS Care.  25(4):297 -308. doi:  \n10.1016/j.jana.2013.0 8.003.  \n \nAUTOR/AUTHOR \nIsaida Cabrera Montero. Catedr\u00e1tica Auxiliar de la \nespecialidad de medico -quir\u00fargico del Departamento de \nEnfermer\u00eda de la Universidad Interamericana de Puerto \nRico, Recinto de Arecibo. Puede ser contactada a trav\u00e9s del correo electr\u00f3ni co: icabrera@arecibo.inter.edu  \n \nAssitant profesor in the medical -surgical field at the Nursing \nDepartment of the Inter American UNiversity of Puerto Rico, \nArecibo Campus. May be contacted at: icabrera@arecibo.inter.edu \n \n \n \n  \n Vol. 6 - 201943INTER  SCIENTIFIC  \n \n OTRAS  INVESTIGACIONES  EN EL CAMPUS / OTHER RESEARCH ON CAMPUS  \n \nResumen de otras investigaciones realizadas por nuestros estudiantes en el R ecinto durante el a\u00f1o \nacad\u00e9mico 2018-2019 en los campos de farmacolog\u00eda y bioqu\u00edmica , ecolog\u00eda y  qu\u00edmica. \nSummary of other research conducted on campus by our students during the academic year 2018-2019 i n the \nfields of pharmacology and biochemistry, ecology and chemistry. \n \nFARMACOLOG\u00cdA -BIOQU\u00cdMICA / PHARMACOLOGY -BIOCHEMISTRY  \n1-A Time- course analysis o f PANC -1 cells viability after exposure to phytochemicals and evaluation \nof the pharmacological interactions with synthetic compounds  \nLinette Cruz Romero, Jos\u00e9 Ra\u00fal Rivera Cordero, Melanie Cuba no Santiago, Michael Soto Cintr\u00f3 n and \nKaren Woolcock Rodr\u00edguez  \n \nPancreatic Cancer is the 3rd leading cause of cancer -related death in the United States and has the lowest \nfive-year survival rate of any major cancer . Gemcitabine is the most common treatment for pancreatic \ncancer, but the effic acy is not fully satisfactory. Possible intracellular circuits that can be targeted with \nalternate treatments are those that regulates proliferation, induces apoptosis, and reduce the capacity of invasion and metastasis. Rac is a monomeric G -protein, membe r of the Rho family that regulates the \nmentioned circuits and can be inhibited by EHop -16. In the present study a time -course analysis of the \neffect of 6-shogaol , EHop -16 and Bortezomib on PANC -1 cells viability was done. Also, the pharmacological \ninteract ion among natural compounds and chemical compounds was characterized. Results show that 6-\nshogaol  and EHop -16 reduced the percentage of PANC -1 cells viability in a dose -dependent manner. \nBortezomib produced a time and dose dependent reduction of cell viability. The treatments with highest \npotency were Ehop- 16 + 6-shogaol  (GI\n50 = 3.8 nM) and Bortezomib (GI 50 = 52.8 nM). It was observed that \nEhop -16 + 6-shogaol and Bortezomib + 6-shogaol  caused 80% of cell mortality. The combination of EHop -\n16 with 6-shogaol resulted in a potentiation among them. In conclusion, PANC-1 cells are sensitive to Rac \ninhibition, and Unfolded Protein Response (UPR) since administration of EHop -16 and Bortezomib \nproduced a reduction (30%) of cell viability. All tested compounds and combinations were more efficient \nthan gemcitabine in reducing PANC -1 cells viability. Combinations of natural and synthetic  compounds can \nbe a logical approach to be established in clinical practice.  \n1-B Apoptosis induction and detection of E -cadherin expres sion on PANC -1 cells after treat ment \nwith EHop-16 and 6-shogaol \nNatalia Acevedo, Isabeliz Seijo, Cristopher Marrero, Kevin Ongay and Karen Woolcock   \nPancreatic ductal adenocarcinoma is an aggressive type of cancer and the fourth leading cause of cancer -\nrelated deaths in the United States. Common treatments for pancreatic cancer include a broad range of \nchemotherapeutic drugs, with the major disadvantage being the development of chemoresistance to the \npharmacological action of these drugs. Therefore, the evaluation of alternative treatments including synthetic and natural compounds, that decrease the metastasis and invasion activity of pancreatic cancer cells and reduces their ability to avoid apoptosis are important to improve patient prognosis and life expectancy in the future. Since it has been shown that synthetic (Bortezomib, E -Hop016) and natural ( 6-\nshogaol ) compounds could possess anticancer activity, the objectives of this project were to: 1) Evaluate \nthe efficacy of natural compounds ( 6-shogaol ) and chemical compounds (Ehop -16) to induce apoptosis on \npancreatic cancer cells in vitro, and 2) To evaluate cellular morphological  changes and E -cadherin \nexpression of PANC -1 cells after exposure to gemcitabine, EHop -16 and 6-shogaol . Results demonstrate Vol. 6 - 201944INTER  SCIENTIFIC  \n \n \n that Bortezomib (100 \u00b5M) and 6-shogaol (100 \u00b5M) induced Caspase 3/7 mediated apoptosis in 46 % and \n26% of cells respectively, when were exposed for 48 hours. The activity was reduced at 72 hours. \nMorphological studies revealed that EH op-16 seems to induce Mesenchymal -Epithelia Transition, as \ndemonstrated with the increased expression of E -cadherin in the cell membrane. Moreover, improved cell -\ncell adhesion was observed. 6-shogaol  improved cytoskeletal structure which may reduce the inv asion \ncapability of the cell. These effects suggest that the combination of EHop -16 with 6-shogaol could be \nconsidered as treatment protocol for pancreatic cancer. \n \nECOLOG \u00cdA/ ECOLOGY  \n2-A Bacterial (16S) and Symbiodiniaceae (ITS2) metagenomic analyses in th e endangered coral \nDendrogyra cylindrus  (Scleractinia: Meandrinidae) from north central and southwestern Puerto \nRico \nG\u00e9nesis P\u00e9rez Cartagena , Edwin De Le\u00f3n Perez, Norberto Rodriguez, Maria Pagan, Arlyn Perez, Lizbeth \nRomero, Alex Veglia, Daniel Toledo, Ernesto F. Weil, Nikolaos V. Schizas, and Mathew Lucas \n Scleractinian corals associate with a diverse microbiome (bacteria, archaea, viruses, fungi, algae), deemed the \u201ccoral -holobiont\u201d. Symbiosis with the photosynthetic dinoflagellates (family Symbiodiniacea e) has been \nfundamental to their evolutionary success. Thermal stress increases susceptibility to pathogens and destabilizes the coral microbiome, often leading to disease and mortality. The gap in our understanding of the mechanisms by which the coral microbiome supports coral health and increases resistance needs attention. Listed as endangered, Dendrogyra cylindrus is a widespread, but low abundance species due to low juvenile survivorship, and recent mortalities by bleaching, disease, hurricanes and local environmental \ndegradation. This species is a good candidate to examine the diversity, symbiotic associations and potential \nmanipulations that could enhance survivorship. This study aims to understand the effect of local environment, thermal history, and  coral host (mitochondrial lineages) on the bacterial and Symbiodiniaceae \nassociations in D. cylindrus  from two contrasting environments, the north central, oceanic and rough coast \n(Arecibo), and the calm, southwestern (Parguera) coast of Puerto Rico. We are currently using PCR and \nsequencing in D. cylindrus colonies in two mitochondrial DNA regions. Bacterial (16S rRNA) and \nSymbiodiniaceae (ITS2) diversity will be characterized using high -throughput sequencing (Illumina \nplatform). Multivariate statistics w ill be used to explain sequence data in colonies sampled from different \nenvironments. Collectively, microbial communities play important roles in ecological resilience. These data will serve as an important baseline on the microbial contributions, both bac terial and Symbiodiniaceae, for \nfuture studies in D. cylindrus . Further understanding the role of the coral holobiont, their environmentally -\nrelated differences, and their influence on future coral resistance and adaptation are important for species conservation and coral reef management. \n \nQu\u00edmica/  Chemistry \n \n3-A S\u00edntesis de nanopart\u00edculas de plata, caracterizaci\u00f3n y efectos bactericidas \nJohan Salv\u00e1 -Mart\u00ed y Gloria Herrera Sandoval  \n Las nanopart\u00edculas de plata son reconocidas por un amplio rango de aplicaciones.  Se ha encontrado que \ntienen una vasta aplicaci\u00f3n en la industria biom\u00e9dica, m\u00e9dico -farmace\u00fatica, electr\u00f3nica, industria textil, \npinturas, cosm\u00e9ticos, bactericidas, biofungicidas, y alimentaria.  Sus aplicaciones antimicrobianas y \nfungicidas han sido reconocidas y estudiadas desde la \u00e9poca antigua. Actualmente en el mercado hay disponibles para la venta generadores de plata coloidal (nanopart\u00edculas de plata) para su uso como antibi\u00f3tico natural, para la curaci\u00f3n del cuerpo, especialmente de quemadura s, infecciones y da\u00f1os en los Vol. 6 - 201945INTER  SCIENTIFIC  \n \n tejidos blandos (m\u00fasculo y cart\u00edlago). Uno de los objetivos de esta investigaci\u00f3n fue llevar a cabo la s\u00edntesis \nde nanopart\u00edculas de plata por m\u00e9todos electroqu\u00edmicos y por reducci\u00f3n qu\u00edmica.  El m\u00e9todo \nelectroqu\u00edmico consisti \u00f3 en el uso de un equipo comercial disponible en el mercado, para la s\u00edntesis del \ncoloide de plata que las personas consumen.   El m\u00e9todo de reducci\u00f3n fue un m\u00e9todo de qu\u00edmica verde o ecoamigable, donde se hizo uso del extracto de hojas de guan\u00e1bana para c onvertir iones plata a \nnanopart\u00edculas de plata a trav\u00e9s de la reducci\u00f3n.   Se llev\u00f3 a cabo la caracterizaci\u00f3n de las nanopart\u00edculas a trav\u00e9s del uso de t\u00e9cnicas como espectroscopia ultravioleta - visible y espectroscopia infrarroja.  Las \nnanopart\u00edculas fueron analizadas por el m\u00e9todo Kyrbi -Bauer para evaluar los efectos bactericidas de las \nnanopart\u00edculas de plata en las bacterias Gram -positivo y Gram -negativo, como lo son la Escherichia Coli , \nPseudomonas Aeruginosa  y Staphylococcus Aureus . \n \n3-B Obtenci\u00f3n de biodiesel por medio de aceite de cocina usado \nDannytza B. Reyes-Hermina y Gloria Herrera Sandoval  \n \nUno de los problemas ambientales m\u00e1s grandes en los cuerpos de agua y en el suelo es producido por la mala disposici\u00f3n de aceites de cocina usados. En est e trabajo, se investig\u00f3 la obtenci\u00f3n de Biodiesel a \npartir de aceite de cocina usado.  Se convirti\u00f3 el aceite a biodi\u00e9sel haciendo uso de qu\u00edmica org\u00e1nica, por medio de una reacci\u00f3n de trans -esterificaci\u00f3n. Esta reacci\u00f3n se realiz\u00f3 con dos tipos de aceite:  un aceite \ncon poco uso y uno que hab\u00eda sido utilizado en varias ocasiones. La reacci\u00f3n de trans -esterificaci\u00f3n \nconsiste en la reacci\u00f3n del aceite con metanol y empleando un catalizador b\u00e1sico, en este caso, hidr\u00f3xido de sodio.  El proceso de producci\u00f3n de  este biocombustible requiere de varias etapas y t\u00e9cnicas qu\u00edmicas \ntales como: filtraci\u00f3n, titulaci\u00f3n, reacci\u00f3n de trans-esterificaci\u00f3n, decantaci\u00f3n; posteriormente, el biodiesel \nes lavado y finalmente secado. Para caracterizar el producto final obtenido s e llev\u00f3 a cabo la determinaci\u00f3n \nde propiedades importantes en el biodiesel tales como la densidad, viscosidad, punto de neblina y un an\u00e1lisis espectrosc\u00f3pico infrarrojo. La comparaci\u00f3n de los datos obtenidos con el Diesel comercial reflej\u00f3 que, si se llev\u00f3 a cabo la conversi\u00f3n de aceite a biodiesel, teniendo los resultados de sus propiedades en \nlos par\u00e1metros esperados seg\u00fan la literatura.  \n \n  Vol. 6 - 201946INTER  SCIENTIFIC  \n \n \n POL\u00cdTICAS EDITORIALES /EDITORIAL POLICIES  \nInter Scientific es una revista acad\u00e9mica de publicaci\u00f3n anual del Decana to de Asuntos \nAcad\u00e9micos, Recinto de Arecibo de la Universidad Interamericana de Puerto Rico. Persigue \nel prop\u00f3sito de fomentar y divulgar investigaciones y art\u00edculos especializados del campo \ncient\u00edfico de las Matem\u00e1ticas, Ciencias Naturales, la Salud y la  Tecnolog\u00eda. Publica art\u00edculos \nin\u00e9ditos de la facultad, estudiantes y especialista extramuros enmarcados dentro de alguna \nde las siguientes categor\u00edas:  \n \n1. Art\u00edculo de investigaci\u00f3n cient\u00edfica y tecnol\u00f3gica   \n2. Art\u00edculo de revisi\u00f3n   \n3. Art\u00edculo corto   \n4. Ensayos  \n \nPuede descargar la  gu\u00eda completa de pol\u00edticas editoriales al igual que  la plantilla para la \npreparaci\u00f3n y presentaci\u00f3n de art\u00edculos a trav\u00e9s del siguiente enlace: \n http://www.arecibo.inter.edu/publicaciones/  \n \n \n \n \nInter Scientific is an annual academic publication of the Office of the Dean of Academic Affairs of the \nArecibo Campus of Inter American University of Puerto Rico. Its goal is to promote and disseminate \nresearch and scholarly article s in the scientific fields of Mathematics, Science, Health and Technology. \nIt publishes original articles of faculty, students, and extramural specialists framed within one of the \nfollowing categories: \n \n1. Article on scientific and technological research  \n2. Review article  \n3. Brief article  \n4. Essays  \n \nThis complete guide of editorial policies as well as the template for  the preparation and submission of \narticles is available at: \n \n            http://www.arecibo.inter.edu/publicaciones/Inter  amer Ican  unIversI ty of Puerto  rIco\narecI bo camPus", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}